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In this general introduction we provide information about the rationale of this PhD 
thesis followed by the general aim and main research questions and a description of the 
structure of the thesis.
1.1 Prevalence of cardiovascular diseases
Cardiovascular diseases (CVD), including ischemic heart disease, ischemic stroke, 
peripheral arterial disease and aortic aneurysm, remain a major cause of death worldwide. 
There are an estimated 422 million prevalent cases of CVD and 18 million people died 
from CVD (one-third of all deaths in 2015) globally, with projections showing an 
increase to 23.3 million in 2030.1,2 In Europe alone, 4 million people died of CVD in 
2015.3 Twenty-five percent of these CVD events happen in individuals with a previously 
established CVD, and after initiation of cardiovascular risk management.4 Factors 
associated with higher risk of recurrence include: older age, lower socio-economic status, 
presence of co-morbidities, and lack of adherence to secondary prevention medication.2 
Both acute interventions after an event and best medical treatment, including 
cardiovascular risk management, are important in improving the long-term outcome of 
hospitalized patients.1
1.2 Risk factors for cardiovascular diseases
Most CVD occur when an atherosclerotic plaque ruptures and a thrombus occludes 
the artery. Atherosclerosis is a process that develops slowly over many years 5, and is 
the result of multiple, interacting risk factors. These are the well-known risk factors as 
hypertension, dyslipidemia and diabetes, which in turn are influenced by behavioural 
factors such as smoking, sedentary lifestyle with low physical inactivity, and bad 
eating habits.6 Although there has been continued research to other risk factors, the 
conventional risk factors still account for more than 90% of the attributable risk of 
CVD. 7 Reduced exposure to these risk factors has a significant impact on the occurrence 
and re-occurrence of a CVD.8 
1.3 Management of cardiovascular risk reduction
According to the World Health Organization (WHO), effective reduction of 
cardiovascular morbidity and mortality should be based on three key points: surveillance 
(mapping and monitoring the epidemic of CVDs), prevention (reducing exposure 
to risk factors) and management (equitable health care for people with CVD).9 This 
thesis focuses on the secondary prevention for patients with manifest CVD. Secondary 
prevention aims to reduce the impact of a disease that is already manifest and so 
prevent more severe problems. Cardiovascular secondary prevention aims to reduce the 
recurrence of cardiovascular disease and to improve long-term prognosis10 Secondary 
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prevention in CVD is predominantly based on lipid and blood pressure lowering 
treatment, inhibition of platelet aggregation and lifestyle interventions on smoking 
behaviour and eating habits.1 Applying the recommended guidelines for the secondary 
prevention of CVD has been estimated to be responsible for one-half of the overall 50% 
reduction in mortality in CVD over the past twenty years.11 A prerequisite to achieve 
this reduction is that patients adhere to their prescribed medication. Medications do not 
work in patients who do not take them. This true statement highlights the importance 
of medication adherence.12 Nevertheless, only 60% of people who use cardiovascular 
medication, are fully adherent to their cardiovascular medication.13 About ten percent of 
all CVD events may even be attributed to poor adherence to medication alone.13
2 Medication adherence
2.1 Medication adherence
Medication adherence is defined by the WHO as ‘the degree to which the person’s 
behaviour corresponds with the agreed recommendations from a health care provider’.9 
Patients may be poor adherent during different stages of their treatment. They may 
decide not to collect their prescriptions at the pharmacy and/or not start their treatment 
at all. Patients may use the prescribed medication at the wrong time or in a wrong 
way. They may also discontinue treatment prematurely, especially when the underlying 
disease is asymptomatic.14 Failure to comply with cardiovascular medication in the 
context of secondary preventive care in CVD results on average in worse outcomes after 
four years. 15 A large observational study in patients with established CVD showed that 
nonadherence with any of the cardiovascular medication is independently associated 
with an increased risk of adverse clinical outcomes including all-cause mortality and 
cardiovascular mortality.15 Patients who were nonadherent to any evidence-based 
secondary prevention medication at 1-year follow-up demonstrated a 19% higher risk of 
cardiovascular death/myocardial infarction/stroke at 4 years compared to patients who 
were adherent. 15 High levels of adherence to statins (80% adherence levels or higher) are 
associated with reductions in all-cause mortality and fatal and nonfatal cardiovascular 
events.16 To achieve full benefit of medication in cardiovascular patients, it is necessary 
to assure a lifelong adequate adherence to this treatment.
2.2 Determinants of medication adherence
Many studies have addressed the complexity of adequate adherence to treatment 
and tried to identify causal or related factors.17 The WHO determined a conceptual 
framework containing five sets of determinants that influence nonadherence: social 
and economic-, health system-, condition-, therapy- and patient related determinants.9 
This thesis focuses mainly on the patient related determinants of nonadherence. 
These are potentially modifiable within the existing management of cardiovascular 
risk management (CVRM). Patient related determinants can be grouped into 




there is an increasing recognition of patients’ beliefs about their illness and treatment 
as determinants of adherence. Patients seek to balance perceived treatment necessity 
and concerns with a minimum use of prescribed medication. They then can make an 
active decision to be adherent or not.17 This decision is evaluated by knowledge (or lack 
of ) regarding prescribed medication and the effect on risk reduction, patients’ beliefs, 
perception and management of their illness or medication. These beliefs are influenced 
by illness related factors as not accepting the illness or underestimating its severity.18,19 
Cardiovascular medication in particular may be perceived by patients as not providing 
benefit because they do not feel better by taking the drugs.20 Also, past experiences, social 
and cultural norms, and received information from various sources can lead to doubts 
about the efficacy or necessity of the medication.17,18,21,22. Unintentional nonadherence 
can be determined by more practical barriers that prevent patients from following 
their decision to be adherent. These unintentional barriers can be related to cognitive 
problems (e.g. forgetting instructions or forgetting to the take medication) or more 
practical skills. These practical skills can relate to difficulties in opening medication 
containers or being unaware how to refill a prescription at the pharmacy (knowledge).17 
Of course, intentional and unintentional determinants can influence each other or be 
simultaneously present in an individual.9
2.3 Adherence enhancing interventions
There is substantial research in adherence-enhancing strategies. Most interventions 
have limited effect at best, are mostly complex and require significant investment due 
to the ongoing support of allied health professionals. They provide intensive training, 
counselling or daily treatment support (or both), sometimes with support from 
family or peers.23,24 Consequently, implementation of these interventions into daily 
practice has not routinely taken place.25 Evidence suggests that interventions should 
be based on patients’ perspective, target patients’ capacity and practical barriers, and 
address their beliefs and perceptions regarding illness and medication.14,17 In CVD, 
life-long adherence is important, which implies that interventions should improve 
patients’ intentions to take medication, as well as solve emergent practical barriers. To 
incorporate and address the different and complex determinants that lead to medication 
nonadherence, a theory that addresses behavioural change in general is often lacking.26 
However, to develop an intervention which can be effective in research and can be scaled 
into daily practice, there are some challenges to be met. These challenges for research in 
medication adherence are similar to those for the improvement of other health-related 
behaviours, such as smoking cessation, exercise and diet: how to influence and change 
behaviour of patients on a long-term basis. Interpreting research results on the effect of 
adherence-enhancing interventions is difficult because of the multi-faceted determinants 
which lead to nonadherent behaviour.27,28 To interpret research results and scale them 
to daily practice interventions are likely to benefit from a taxonomy to categorize the 
used behaviour change techniques.27  There is some specific guidance regarding research 
which evaluates (new) interventions to improve patient behaviour. A process evaluation 
is highly recommended because it helps to understand the relationship between how 
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well an intervention was delivered, the different elements of an intervention and the 
main outcomes of a trial.29,30 It furthermore improves the validity and interpretation of 
these outcomes and gives information so the intervention can be replicated.31 
2.4 Measurement of adherence
Another challenge in medication adherence is to make an accurate estimate of the degree 
of adherence of patients. There are many methods for measuring levels of medication 
adherence, but each method has its strengths and limitations. Currently none of the 
available methods can be considered as a gold standard and a combination of methods 
is recommended.32 The methods used can roughly be divided into two groups: objective 
and subjective measurements. Pill counts, electronic monitoring, database analysis 
of pharmacy refill dates and biochemical measures are considered objective methods. 
Subjective measures involve those requiring provider’s or patient’s evaluation of their 
medication taking behaviour33. Self-reported questionnaires and assessments are 
two examples of subjective measurements. Patients’ overestimation of their adherent 
behaviour to get approval from their healthcare provider is the main disadvantage of 
all tools. All methods are circumstantial and some are very expensive. Also, improved 
patient adherence around clinic visits is a well-known phenomenon when applying 
adherence measurements.33 Ideally, patients should not be aware that their adherence is 
monitored which is impossible when using subjective measures. 
3 Aim and outline of this thesis 
3.1 Aim
The overall aim of this thesis was to develop and evaluate an intervention to enhance 
medication adherence in cardiovascular patients. The aim for the intervention was set for 
three levels; it should change patients’ adherence behaviour, it should change patients’ 
perceptions and beliefs and the intervention should successfully improve the clinical 
outcome by achieving target levels in cholesterol and blood pressure. An intervention to 
enhance medication adherence in CVD patients was developed.
3.2 Usual care and population
The existing cardiovascular risk management program was the starting point for our 
intervention. The Radboud university medical center applies a hospital-wide screening 
program on cardiovascular risk factors in patients with an established cardiovascular 
disease (acute coronary syndrome, peripheral arterial disease, an aneurysm of the aorta or 
stroke/TIA).6 This screening program is situated at the cardiovascular outpatient clinics. 
Patients referred to the departments of Vascular Surgery, Neurology or Cardiology with 
a manifestation of CVD are included in the screening program. A cardiovascular risk 
profile is assessed including an automated lifestyle questionnaire34, blood lipid levels, 
blood pressure, waist circumference, BMI, blood level of glucose and a family history 




plan of care based on this assessment. During follow-up, a nurse-led lifestyle intervention 
program, including a brief tailored behavioural feedback procedure is offered. This 
is in line with nurse coordinated programs which are recommended in the guideline 
on cardiovascular disease prevention. Also, the best medical treatment is offered.6,35 
This includes the prescription (or continuation) of plated aggregation inhibitors, 
antihypertension agents and lipid modifying agents. 
3.3 Outline of the thesis
Chapter 2 describes the management of the cardiovascular risk screening at Radboud 
university medical center. In patients with established cardiovascular disease, a 
cardiovascular risk profile was assessed, and lifestyle was evaluated by using an automated 
questionnaire. A multidisciplinary team proposed an integral individualized plan of care 
based on these assessments. During follow-up, a nurse-led lifestyle intervention program 
and the best medical treatment were offered. The impact of this structured screening 
and nurse-based intervention on cardiovascular risk factors are evaluated in this chapter.
Chapter 3 provides an overview of available e-health interventions and the extent to 
which they can improve medication adherence. E-health interventions, health-related 
information and interventions that are supported by the internet, may have a positive 
effect on medication adherence. These interventions aim to bring about a positive 
change or to increase knowledge, awareness and understanding. This is done by offering 
health-related information and using internet-based interactive components.
Chapter 4 describes the rationale and design of the MIRROR-trial, a nurse- and web-
based intervention to improve medication adherence. The theory used to develop the 
intervention is the Health Belief Model. Also, both intentional and non-intentional 
determinants of nonadherence are considered in the development of the intervention.
In chapter 5 the process and effect of a nurse-led, web-based intervention to improve 
medication adherence in patients with cardiovascular disease are evaluated. This 
intervention program aimed to improve patient’s necessity beliefs about medication, 
which is expected to lead to better adherent behaviour in cardiovascular patients. A 
process evaluation of this intervention program was also included. A process evaluation 
helps to understand the relationship between how well an intervention was delivered, the 
different elements of an intervention and the main outcomes of the trial. It furthermore 
improves the validity and interpretation of these outcomes and gives information, so the 
intervention can be replicated.
Chapter 6 describes in a retrospective cohort study the existing levels of medication 
adherence of participants and non-participants prior to inclusion in a randomized 
controlled study. It is suggested that patient recruitment methods in randomized 
controlled trials (RCTs) to improve patient adherence to medication may influence 
outcome. An important observation is that patients participating in RCTs generally 
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have higher adherence rates at baseline than could be expected based on observational 
studies. In this study we evaluated this hypothesis.
In chapter 7 a cluster analysis was performed. By combining and clustering well-known 
risk factors of CVD (such as high blood pressure, high cholesterol levels and an unhealthy 
life style ), patient groups who are at risk of non-adherent behaviour, might be better 
determined. Identifying these high risk groups could enable developing an intervention 
and target patients more appropriately 
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The aim of this study was to evaluate the impact of a structured screening and nurse-based 
intervention on cardiovascular risk factors. In patients with established cardiovascular 
disease, a cardiovascular risk profile was assessed, and lifestyle was evaluated by using an 
automated questionnaire. A multidisciplinary team proposed an integral individualized 
plan of care on the basis of these assessments. During follow-up, a nurse-led lifestyle 
intervention program and the best medical treatment were offered. A total of 328 
outpatients were included. After screening, a follow-up term of at least 1 year was 
reached in 176 patients (59.9%). Low-density lipoprotein cholesterol and systolic blood 
pressure were significantly reduced. A reduction in the amount of smoking, alcohol 
consumption, and unhealthy eating habits was observed. However, the amount of 
physical activity was unaffected, and body mass was increased. A structural evaluation of 
cardiovascular risk factors and an integrated nurse-led approach can successfully reduce 
risk in cardiovascular patients.




Cardiovascular disease (CVD) is a major cause of morbidity and mortality in the 
Netherlands and other industrialized countries and is taking the lead in developing 
countries.1 In 2013, 39,000 Dutch people died because of CVD, which is almost 
one third of the total mortality.2  Most CVD occurs in the presence of well-known 
risk factors, including hypertension, dyslipidemia, and type 2 diabetes, which in turn 
are influenced by behavioral factors such as smoking, alcohol consumption, physical 
activity, and eating habits. 3 Early recognition and treatment of these risk factors reduce 
the morbidity and mortality of any cardiovascular event and improves the short- and 
long-term preventive effects of conservative and interventional treatment.3 Thus, 
cardiovascular risk management, including interventions on lifestyle, can enhance the 
prognosis of CVD.4 Health care professionals, such as nurses, are increasingly more 
involved in executing cardiovascular prevention protocols and advising patients to 
improve their lifestyle behavior. Although the role of nursing professionals in improving 
lifestyle is less-clearly defined, there is reasonable evidence that smoking cessation advice 
and/or counseling given by nurses to patients can be effective. Suggested success rates 
range from 5% to 29% in the general population.5
Lifestyle behavioral interventions are not routinely monitored as part of standard 
outpatient practices. Not all patients are asked about their tobacco and alcohol use, 
nutritional habits, and physical activity level, nor are patients given advice and counseling, 
combined with reinforcement and structured follow-up, to incorporate behavioral 
lifestyle changes. Recently, we introduced a structured lifestyle inventory with a brief 
individually tailored behavioral feedback procedure as part of usual care for patients with 
manifest CVD or elevated cardiovascular risk.6  This is in line with nurse-coordinated 
programs which are also recommended in the latest European Society of Cardiology 
(ESC) guideline on cardiovascular prevention.7 However, we focus on a broader patient 
population than only coronary patients, targeting multiple risk factors. Previous research 
has measured the combined impact of lifestyle factors on CVD and indicated that even 
modest differences in lifestyle can have a substantial impact on reducing mortality.8,9 
However, changing cardiovascular risk in the long term has been shown difficult.10 In 
addition, it is necessary to understand the effect of an intervention on various risk 
factors, including lifestyle behavior, to prioritize clinical health efforts.
This study was performed to evaluate the magnitude of change in various modifiable 
cardiovascular risk factors, such as body mass index, waist, blood pressure, lipid levels, and 
lifestyle parameters, during short- and long-term follow-up, in an outpatient population 
presenting with CVD. This was accomplished by an implemented multidisciplinary 






Patients above the age of 18, who were referred with a manifest atherosclerotic vascular 
diseases (cardiac, cerebral, or peripheral diseases) to one of the participating departments 
(i.e., Cardiology, General Internal Medicine, Neurology, or Vascular Surgery) of our 
hospital, routinely participated in an outpatient care program, if their physical and 
mental state allowed. This care program, in which cardiovascular risk factors and 
lifestyle factors were evaluated on a structural basis, was led by specialized nurses (nurse 
practitioners), and patients immediately followed this program after hospitalization due 
to a cardiovascular event.
The changes in observed risk factors (including lifestyle) of these patients were 
retrospectively evaluated. From January 2010, consecutive patients were enrolled in this 
evaluation until a predefined number of 110 patients per department was achieved. 
Patients presenting with only an elevated risk for CVD but without manifestation of 
CVD (primary prevention) did not participate in this study. Furthermore, patients with 
missing baseline values were excluded from further analysis. Informed, written consent 
was obtained from all patients who visited the university hospital outpatient clinic 
regarding the use of their data for retrospective analysis of regular care outcome.
Risk Profile Identification
At baseline (before the intervention), a complete vascular risk profile of each patient 
was conducted by a nurse practitioners, all of which have extensive experience (more 
than 3 years) with Cardiovascular risk management (CVRM). Data were collected 
using a structured overall questionnaire, which consisted of information on general 
sociodemographic factors, anthropometric variables, lifestyle habits, a problem-oriented 
medical his- tory, drugs therapy, and family history of CVD (first degree relatives). In 
addition, anthropometry (body mass index [BMI], waist circumference) and a standard 
physical exam were performed, in which systolic and diastolic blood pressure was recorded 
as a mean of three measurements with an automatic blood pressure monitor in sitting 
position after 5 min of rest.12 Furthermore, fasting glucose and lipid profiles, creatinine 
level and urine analysis, as well as electrocardiography were routinely performed.
After collecting and storing all data in an electronic patient file, a dedicated 
Multidisciplinary Advice Group, consisting of an internist and a cardiologist, and four 
nurse practitioners from participating departments (Neurology, Cardiology, Vascular 
Surgery, and Internal Medicine), dis- cussed these data weekly to optimize secondary 
prevention. Finally, a team- wise integral recommendation was proposed to reduce the 
amendable risk factors and lifestyle factors corresponding to the Dutch guideline for 
cardio- vascular risk management.11,12
Nurse-Led Multidisciplinary Intervention to Improve Cardiovascular Disease Profile of Patients
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Results from the Multidisciplinary Advice Group were reported back to the patient, after 
which interventions were planned (Figure 1). Finally, an individually tailored treatment 
plan, combining both medical treatment and lifestyle interventions, was initiated.
 
Figure 1. Organogram the Vascular Centre of the Radboud University Medical Centre (solid lines), in which the flow of 




The lifestyle of each patient was evaluated using an online lifestyle questionnaire, which 
was also available for patients to use at the outpatient clinic, and comprised a compilation 
of existing validated questionnaires regarding smoking, physical activity, eating habits, 
and alcohol consumption.13 The questionnaire consisted of the following sections:
A total of 11 questions were asked about smoking. Five general questions regarding pack 
per year, mean number of cigarettes, and type of tobacco smoked as well as six items 
of the Fragerström Test for Nicotine Dependence to evaluate the degree of nicotine 
dependency of each patient.14
Seven questions about habitual physical activity were asked, including intensity and 
frequency of physical activity per week. The questions were consistent with the short 
version of the International Physical Activity Questionnaire.15
A total of 28 questions about eating habits were asked, using three separate questionnaires, 
which were validated in a Dutch eating habit study concerning fat, fiber, vegetable, and 
fruit intake.16 Fourteen questions evaluated total and saturated fat intake as a percentage 
of total energy intake, eight questions measured fiber intake in grams per kilocalorie, 
and six questions measured vegetables and fruit  intake in grams per day.
Ten questions about alcohol drinking behavior were asked using the Alcohol Use 
Disorders Identification Tests (AUDIT).17 The AUDIT measured the frequency, 
quantity, and psychosocial problems concerning alcohol consumption. Three questions 
were regarding frequency and amount of alcohol consumption, three regarding alcohol 
dependency, and four regarding possible psychosocial problems.
The automated questionnaire generated a summary of lifestyle issues, which were 
visualized in smileys. A green, orange, and red smiley referred to a healthy, a not really 
harmful but could be improved, and an unhealthy life- style, respectively.
Nurse-Led Intervention Program
After feedback of the screening results was provided to the patient, best medical 
treatment and a lifestyle intervention program to reduce smoking, alcohol use, body 
weight, or to increase healthy nutrition could be initiated and conducted by a nurse 
practitioner of each department using hospital proto- cols. An individual care plan 
including information of the intervention steps was available online for patients and 
nurses via an electronic interactive file, integrated in the hospital website.
Best medical treatment was tailored by the nurse practitioner to the patient clinical 
situation. In general, in all patients, not on oral anticoagulant therapy or platelet 
aggregation inhibitors, for example, acetylsalicylic acid 80 mg once daily (o.d.) was 
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initiated. Furthermore, a statin-based cholesterol lowering therapy was initiated 
(simvastatin 40 mg o.d. or atorvastatin 20 to 80 mg o.d.), or the statin dosage was 
adjusted in case of preexisting us. Also angiotensin converting enzym (ACE) inhibitor 
(lisinopril 5-10 mg o.d.), or thiazide diuretic–based (chlortalidone 12.5-25 mg o.d.) 
blood pressure lowering medication was started when systolic blood pressure was on 
average above 140 mmHg after the standardized measurement. Medication was adapted 
by the internist and cardiologist in case of side effects, in elderly age, or with preexisting 
hypertension, or existing vascular complication, for example, carotid stenosis, or renal 
artery stenosis. The treatment targets to be achieved during follow-up for low-density 
lipoprotein (LDL) cholesterol was 2.5 mmol/l and for blood pressure 140/90 mmHg.
In case of smoking, excessive alcohol consumption, lack of exercise, or an unhealthy diet 
or obesity, a nurse-led lifestyle intervention program was initiated based on motivational 
interviewing according to Prochaska and DiClemente’s Transtheoretical Model 18, 
matched with the determined readiness for behavioral change. 19 All nurse practitioners 
have followed at least 10 training sessions in motivational interviewing and continued 
to increase their skills by discussing results together. Nurse practitioners could start their 
intervention by using the visualized screening results, including motivation to change 
scores. An intervention lasted 3 months and individual care plan and obtained results 
were structured recorded in the patient record. The intervention targets to be achieved 
during follow-up are “nonsmoking,” “alcohol intake below 3 (for men) and 2 (for 
women) standardized units daily for 5 days or less a week,” “at least 30 min of moderate 
exercise per day” and “a diet with less than 35% of the total caloric intake as fat; more 
than 3 g of fiber per day; more than 200 g of vegetables per day and at least 2 servings 
of fruit per day.”
Feedback of the screening results was provided during a 1-hr visit, after which an 
intervention was performed during 3 to 4 follow-up visits of 30 to 45 min. In individual 
cases, additional visits of 30 min were scheduled for additional support. In case of extended 
follow-up due to complex care (e.g., follow-up of an growing abdominal aneurysm), 
CVRM was combined with regular care for these presenting CVDs. Cardiovascular risk 
management was transferred back to first line care (i.e., general practitioner) as soon 
as possible after treatment and lifestyle intervention were initiated, except for patients 
who needed a follow-up for their actual CVD or those with complex cardiovascular risk 
profiles, who did not reach the predefined target values.
Follow-Up
After the initial treatment of the presenting vascular disease, a patient’s follow-up was 
determined by the severity of their clinical symptoms. Generally, a follow-up was 
terminated after 3 months, after which patients were referred to their general practitioner. 
Only in a situation of complex care it was continued  for a longer period. In this study, 
only patients with follow-up period for at least 9 months were included. BMI, waist 
circumference, blood pressure, and LDL-cholesterol were monitored during each face-
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to-face follow- up visit and evaluated at 3 to 6 months (short-term follow-up) and after 
9 to 15 months (long-term follow-up). In contrast to the initial data collection, in 
which data were obtained using a lifestyle questionnaire, follow-up data were collected 
from each individual patient file using predefined parameters, namely, smoking habits, 
alcohol use, physical activity, eating habits, LDL- cholesterol, systolic blood pressure, 
BMI, and waist circumference. When lifestyle changes or risk factor reductions were not 
recorded, these data were defined as missing values.
Data Analysis
Statistical analyses were performed using SPSS (version 18.0). Differences in parameters 
between specialties were tested by univariate ANOVA test. The effect of interventions 
on risk factors (follow-up vs. baseline) was tested by a paired t test, or chi-square test 
in case of normal distribution, or non parametric tests (Wilcoxon signed rank test), in 
case of skewed distribution. For evaluation of the effects of the intervention on alcohol 
use, physical activity and eating habits, the number of patients in the healthy category 
were compared with the sum of patients in the “could be improved” category and 
“unhealthy” category. Alpha was set at the 0.05 level for all statistical comparisons , with 
data reported as means and standard errors of the means (±), unless stated otherwise as 
standard deviation (SD).
Outcomes
Patients. From January 2010 until July 2010, 328 patients who were referred to the 
Radboud University Medical Centre were included in this analysis (Figure 1). Out of these 
patients, 34 were excluded due to missing values at the start of the study (i.e., baseline). 
A follow-up of at least 3 months till a maximum of 15 months after inclusion into this 
study was performed for 59.9% of the total patient population (N = 294). Therefore, 
176 follow-up data were available for analyses. At the department of cardiology, a total 
of 103 patients were included, of which 74.8% had a follow-up longer than 3 months. 
Similar results were observed at the department of vascular surgery and neurology, 
where, respectively, 92 and 99 patients were included, of which 66.3% and 38.4% had 
a follow-up longer than 3 months through the outpatient clinic (Figure 1). In 40.1% 
of the total study population, no follow- up was achieved, primarily due to patient 
referral back to either a general practitioner or primary hospital after the treatment of 
the cardiovascular event (~70%). In addition, 10.0% of the patients did not meet the 
predefined inclusion window for follow-up (3-15 months), predominantly caused by 
the course of their vascular disease. About 13% of the patients refused interventions and 
follow-up, and in about 7% of the patients, follow-up data were incomplete.
Baseline characteristics. Tables 1 and 2 represent the baseline characteristics for the total 
study population and for each department separately. It illustrates the large number of 
patients who did not meet the recommended level of risk factors according to the Dutch 
guideline at baseline, that is, before commencing their individual health program. In this 
patient population, 65.0% were male, with a mean age of 65.1 ± 11.9 years. Furthermore, 
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29.3% of the patients were regular smokers and 15.6% consumed unhealthy amounts 
of alcohol prior to the intervention. The average value of the Fragerström test score for 
nicotine dependence was 3.1 ± 2.6 for the total population and 2.0 ± 2.6, 4.0 ± 2.2 and 
3.3 ± 2.5 for cardiology, vascular surgery, and neurology, respectively. In addition, 39.8% 
of the population performed less than aver- age amounts of physical activity and 19.5% 
had unhealthy eating habits. BMI ≥ 25 kg/m2 or a waist circumference ≥ 94 cm (males) 
or ≥ 88 cm (females) was observed in the 55.7% and 31.2% of patients,  indicating 
that most patients were overweight. Furthermore, high systolic blood pressure (³140 
mmHg) as well as a high LDL-cholesterol level (≥ 2.5 mmol/L) was observed in 41.8% 
and 41.8% of the patients (Table 1).
Table 1. Baseline Characteristics of the Study Population.













n (%) n (%) n (%) n (%)
Male gender 191 (65.0) 76 (73.8) 63 (68.5) 53 (53.5) <.001
Smoking habits
Actual smoking 86 (29.3) 23 (22.3) 51 (55.4) 12 (12.1) <.001
Nonsmoking 208 (70.7) 80 (77.7) 41 (44.6) 87 (87.9)
Alcohol use
Healthy 191 (65.0) 61 (59.2) 51 (57.3) 79 (79.8) <.001
Could be improved 57 (19.4) 22 (21.4) 21 (22.8) 15 (15.2)
Unhealthy 46 (15.6) 20 (19.4) 20 (21.7) 5 (5.1)
Physical activity
Healthy 145 (49.3) 62 (60.2) 42 (45.7) 41 (41.4) .09
Could be improved 32 (10.9) 5 (4.9) 13 (14.1) 14 (14.1)
Unhealthy 117 (39.8) 37 (35.9) 37 (40.2) 44 (44.4)
Eating habits
Healthy 13 (4.4) 4 (3.9) 5 (5.4) 4 (4.1) n.s.
Could be improved 223 (76.1) 73 (70.9) 73 (79.3) 78 (78.6)
Unhealthy 57 (19.5) 26 (25.2) 14 (15.2) 17 (17.3)
Note. n.s. = not significant.
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(N = 294) (n = 176) Change (n = 176) Change
n (%) % % p Value % % p Value
Smoking habits
Nonsmoking 208 (70.7) 71.2 +0.5 n.s. 77.4 +6.7 <.0001
Smoking 86 (29.3) 28.8 22.6
Alcohol use
Healthya 191 (65.0) 71.9 +6.9 .002 76.7 +11.7 <.0001
Could be improved 57 (19.4) 18.0 13.7
Unhealthy 46 (15.6) 10.1 9.6
Physical activityb
Healthyc 145 (49.3) 53.6 +4.3 n.s. 45.2 −4.1 n.s.
Could be improved 32 (10.9) 33.0 44.0
Unhealthy 117 (39.8) 13.4 10.7
Eating habitsd
Healthye 13 (4.4) 64.2 +59.8 <.0001 85.7 +81.3 <.0001
Could be improved 223 (76.1) 34.6 11.1
Unhealthy 57 (19.5) 1.2 3.2
Note. n.s. = not significant.
a. Alcohol intake below 3 (for men) and 2 (for women) standardized units daily for 5 days or less a week.
b. Results obtained in n = 175 patients.
c. At least 30 min of moderate exercise per day.
d. Results obtained in n = 159 patients.
e. Diet with less than 35% of the total caloric intake as fat; more than 3 g of fiber per day; more than 200 g of vegetables 
per day and at least 2 servings of fruit per day.
Follow-up. After receiving individually tailored recommendations and life- style 
interventions during follow-up, the amount of smokers was reduced from 51 to 40 of 
176 patients with follow-up (−6.7%; p < .0001; Table 3). The number of patients who 
reduced their alcohol consumption to the recommended standards increased from 114 
to 135 of 176 patients (−11.7%; p <.0001). Healthy physical activity, however, decreased 
from 86 to 79 of 175 patients on a recommended level (−4.1%; not significant). Most 
patients adjusted their eating habits to a healthy standard (from 7 to 129 of 159 patients 
(+81.3%; p < .0001). In addition, a significant reduction in systolic blood pressure 
(138.3 ± 20.7 mmHg to 128.7 ± 17.7 mmHg; p < .01) and LDL-cholesterol level (2.55 
± 0.87 mmol/L to 2.16 ± 0.73 mmol/L; p < .01) was observed after follow-up. However, 
toward the end of the follow-up, less patients were physically active, and consequently, 
waist circumference increased from 97.4 ± 13.3 to 98.5 ± 12.8 cm and BMI from 26.6 




This study demonstrated that CVD occurs in the presence of multiple risk factors, 
including behavioral risk factors, in almost all patients who were referred with a 
manifest CVD at the Radboud University Medical Centre. Structural multidisciplinary 
evaluation and initiation of the best medical treatment in combination with lifestyle 
interventions decreased cardiovascular risk as seen by a reduction in smoking, alcohol 
consumption, unhealthy eating, blood pressure, and LDL-cholesterol level. However, 
physical activity level decreased and BMI increased in this patient population.
The magnitude of present risk factors in this population is comparable with previous 
studies in patients as well as with the general Dutch population. 2 In 2010, approximately 
27% of the Dutch population were tobacco smokers, 16% regularly consumed unhealthy 
amounts of alcohol, 44% performed inadequate amounts of physical activity, 42% 
was over- weight, and a majority did not meet the guidelines for healthy eating habits. 
However, less is known about more relevant accumulation of risk factors in individual 
vascular patients compared with the general population.
Health care strategies often fail to achieve optimal risk reduction and treatment 
goals are frequently not reached.20 However, our results showed risk factor cessation 
or reduction after a strategy of structural screening for complete cardiovascular risk, 
receiving multidisciplinary recommendations for medication and lifestyle changes, and 
structural feedback on these results by a professional. The observed changes in lifestyle 
and cardiovascular risk pro- file were similar to those of a previously reported integral 
approach in vascular patients 21, with a moderately more pronounced effect on systolic 
blood pressure in the current study. Characteristics of both approaches were sufficient 
attention to lifestyle habits and unequivocal advice from health care professionals, in 
accordance to the patient’s acceptance of responsibility for their own care. Furthermore, 
we applied a stepped care approach, which has been recently proved to have the ability to 
greater lifestyle behavioral outcomes compared with care as usual.22 Encouragement and 
an accurate, systematic evaluation or follow-up of behavioral change by professionals 
has been indicated to reduce the risk for CVD and to enhance the quality of life.23










































































































































































































































































































































































































































































Integral nurse-led risk reduction may be more successful than an approach of risk factors 
isolated from presenting CVD. Personalized treatment, such as individualized treatment 
plans, has shown that they can tailor the nurses’ care to the patients sufficiently.24 
Furthermore, nurse- led interventions on lifestyle may be more efficient than interventions 
by physicians.21 Although the role of nursing professionals in smoking cessation is 
less-clearly defined, there is reasonable evidence that smoking cessation advice and/or 
counseling given by nurses to patients can be effective. Suggested success rates range 
from 5% to 29% in the general population.5,25 Previously, it was demonstrated that the 
feasibility and effectiveness of nurse-based motivational interviewing on top of routine 
patient-based lifestyle inventory with feedback was beneficial.19 In this study, 16% of 
all included smokers refrained from smoking after 3 months follow-up. The absolute 
reduction in smoking appeared 6.7% after a longer follow-up period in the current 
study (relative risk reduction was 22.9%).
Besides effectiveness on smoking cessation, there is also evidence that nurse-based risk 
factor management leads to frequent achievement of treatment  goals for different risk 
factors, for example, lifestyle factors other than smoking, such as blood pressure and 
LDL-cholesterol.26 For example, in this study, alcohol consumption was reduced, and 
more patients met the criteria for healthy alcohol consumption. Compared with other 
studies, this result is more pronounced.27 Next to this, a substantial enhancement in 
healthy eating habits was also observed in this study. This could be explained by a lack of 
knowledge about unhealthy habits. Moreover, the eating habits of majority of patients 
were easily improved by making small adjustments. Blood pressure and lipid level were 
also improved after the best medical treatment and lifestyle interventions in accordance 
with general expectations after initiating drug treatment.28 Furthermore, interventions 
addressing diet, exercise, and smoking have additional effects on blood pressure and 
lipid level.29 Matching the stage of behavioral change of patients with the planned 
intervention seems crucial to improve its success.30 
Waist circumference and BMI did not improve after intensive follow-up. This result 
could be explained by the reduction in physical activity observed after follow-up, 
potentially caused by the inability of patients to exercise after manifestation of the CVD. 
For example, after a stroke, more than 80% of patients suffer one or more paralyses and 
more than 70% of patients are affected by chronic fatigue. Furthermore, it is well known 
that patients indicate different levels of performance they believe they can surmount 
and there is an underestimation of the difficulty of self-management of behavioral 
risk.31 Therefore, physical activity needs to be mitigated by appropriate preparticipation 
screening, patient counseling, and a gradual, staged approach to an exercise program to 
gain the best result.32 
An increase in waist circumference and BMI during follow-up was also observed by 
Goessens et al.26, which was attributed to weight gain after smoking cessation and 
increased inactivity after cardiovascular event. Individuals who successfully quit smoking 
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typically gain between 3 and 10 kg within 8 years of quitting, whereas those who 
continue to smoke gain an average of 2 to 3 kg.33,34 Furthermore, intervention based 
on motivational interviewing may be less sufficient to obtain weight reduction, and 
participation in specific behavioral therapy may be necessary to establish a reduction in 
weight. 33,35 Remarkable differences between participating departments were observed, 
with, in general, a more pronounced cardiovascular risk in patients from vascular 
surgery, compared with other vascular patients. Most likely patients with peripheral 
arterial diseases with an increased comorbidity burden often have a lower socioeconomic 
status.36,37 Furthermore, patients with acute coronary syndrome were younger, whereas 
patients with Transient Ischemic Accident (TIA) or stroke were older than the mean age 
of the study population.
A potential limitation of this study was the lack of a control population without CVD 
undergoing the same intervention. In addition, this study was restricted in that changes 
from baseline could only be evaluated during follow-up in those patients who had their 
follow-up at the outpatient clinic. These were patients with, in general, more complex 
morbidity, predominantly in patients of cardiology and vascular surgery in which a longer 
follow-up was indicated. Patients from neurology could be more frequently referred 
back to their general practitioner within 3 months. It is currently unclear whether 
these patients also differed from cardiovascular risk or motivation to change behavior. 
Furthermore, no comparisons within patients could be made from results obtained by 
their general practitioner. However, cardiovascular risk management in primary care 
showed wide variation within and between countries and the effects of a 1-year intensive 
intervention for cardiovascular prevention could no longer be demonstrated after a 
long-term follow-up.10,38 
Finally, the possibility exists that the observed results were less pronounced because a 
majority of  the patients already used risk lowering medication after advice from their 
general practitioner. This study demonstrated that structural screening of risk factors in 
patients who were referred with a manifest CVD shows unfavorable cardiovascular risk 
profile and lifestyle in majority of the patients. A multidisciplinary integrated approach, 
with interventions by dedicated nurses, may be successful in improving cardiovascular 
risk profile, including lifestyle, in outpatients with different clinical presentations of 
vascular disease.
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E-health interventions and improving 
therapy compliance
Chapter 3




Reduced compliance with medication therapy is one of the most important determinants 
in the treatment of patients with chronic disorders and asymptomatic disorders in 
particular. According to the World Health Organization, 30-50% of patients do not 
take their medications or do not use them as prescribed.1 This can lead to hospital 
admissions, disease progression, resistance to treatment, failure to achieve treatment 
goals and death.2-4 Therefore, interventions that can improve patient therapy compliance 
are urgently needed.
In recent years, much research has been conducted into the effect of interventions 
with the aim of improving therapy compliance. These interventions include additional 
consultations with and information from pharmacists, group meetings with other 
patients focusing on information and education, and reward systems such as gift vouchers 
in response to verified therapy compliance. However, these interventions appear to be 
effective only in the short term. Moreover, the interventions are often complex, and that 
is one of the reasons why they are difficult to implement in daily practice.
Interventions that are supported by the internet, known as e-health interventions, may 
have a positive effect on therapy compliance. With internet applications, health-related 
information and support can be offered to large groups of patients in a relatively simple 
way. An e-health intervention is an internet-supported program in which patients look 
for health-related information. The intervention aims to bring about a positive change 
or to increase knowledge, awareness and understanding. This is done by offering health-
related information and using internet-based interactive components.5
The generally accepted definition of e-health does not exclusively concern internet-
supported interventions, but also includes e-health interventions based on technologies 
such as apps, web portals or text message services.6 Previous research has shown that 
these types of interventions can positively influence healthy behavior,7 which can also 
result in a positive effect on therapy compliance. In this article, we provide an overview 
of the role of e-health interventions in improving therapy compliance. We also describe 
the studies on interventions that have been published since 2010.




As a basis for this article we used the systematic review ‘Effects of e-health interventions 
on medication adherence: a systematic review of the literature’, published in 2011.8 The 
review described the effect of e-health interventions on therapy compliance based on 
the available literature up to 2010, was carried out in accordance with the guidelines 
for systematic reviews and carried out tests on internal and external validity. 9 The 
inclusion criteria were: (a) the study described a patient-centered internet intervention; 
(b) the study described an intervention for patients who used medication for a chronic 
condition; (c) one of the outcome measures was medication therapy compliance; (d) it 
was a quantitative study; and (e) the study was published in Dutch or English. Based on 
the search criteria in the present review, we repeated the search, this time searching for 
articles that were published after 2010. The search covered publications from 1 January 
2010 to 1 June 2014. The studies described in the 2011 review were not assessed for the 
present review. We searched for relevant articles in the PubMed, Cinahl, PsycInfo and 
Embase databases. The inclusion and exclusion and retrieval of complete manuscripts 
was performed by one author (AS). In the event of a lack of clarity about the article, a 
second author (HvO) assessed whether the article in question should be included.
Search strategy (2010-2014)
PubMed: (medication therapy management OR medication adherence) AND (internet) 
AND (intervention study OR randomized controlled trial OR clinical controlled trial)
Cinahl: medication compliance AND internet PsycInfo: patient compliance AND 
internet
Embase: (medication therapy management OR medication adherence) AND (internet) 






Search strategy (2010-2014) 
PubMed: (medication therapy management OR medication adherence) AND (internet) AND 
(intervention study OR randomized controlled trial OR clinical controlled trial) 
Cinahl: medication compliance AND internet PsycInfo: patient compliance AND internet 
Embase: (medication therapy management OR medication adherence) AND (internet) AND 
(intervention study OR randomized controlled trial OR clinical controlled trial) 
 
        
           
           
          















FIGURE Flow chart of the search strategy for relevant articles on the effect of e-health interventions on 
medication therapy compliance. * The inclusion criteria are listed in the article under the heading 'Search 
strategy'. 
164 articles selected 
 
151 articles screened by title and 
abstract 
 
13 duplicate articles excluded  
 
 
100 articles excluded that did not 
meet inclusion criteria* 
 
41 articles read entirely (full text) 
before inclusion 
 
16 articles included 
 
25 articles excluded review (n = 7) 
study protocol (n = 3) opinion 
piece (n = 4) no full text available 
(n = 4) aimed at prescribers (n = 1) 
no intervention study (n = 3) 
qualitative study (n = 1) included in 
systematic review from 2011 (n = 
11) therapy compliance not 
measured (n = 1) 
 
Figure 1. Flow chart of the search strategy for relevant articles on the effect of e-health interventions on medication 
therapy compliance. * The inclusion criteria are listed in the article under the heading ‘Search strategy’.
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Table Characteristics of the 16 included studies on medication therapy compliance
intervention; reference condition
method for measuring 
therapy compliance
effect of intervention on 
therapy compliance
educational material via email and 
monitoring asthma management 10 11 asthma pharmacy sales data improvement (p = 0.01)
website with feedback based on social 
cognitive theory 12
asthma non-validated questionnaire no improvement
action plan and alerts based on online 
questionnaires about quality of life, 
therapy compliance, adverse effects, 
disease activity and body weight 13
IBD ‘Morisky medication 
adherence scale’ – 
questionnaire
no improvement
patients were given access to their 




web-based program of 6 weeks with 
modules on sleep, medication or 
stress 15
epilepsy ‘Medication adherence scale’ 
– questionnaire
improvement (p = 0.049)




VAS and ‘AIDS clinical 
trials group adherence’ – 
questionnaire
improvement (p = 0.005)
website with feedback by web-
doctor17
IBD non-validated questionnaire 
and partial pharmacy sales 
data
improvement (p = 0.005)
website with video information and 
feedback; formulating improvement 
goals for therapy compliance, exercise 
and diet with or without social 
support and group meetings18
diabetes 
mellitus
‘Hill-Bone compliance scale’ 
– questionnaire
no improvement
intervention for parents (tools), 
children (game) and case managers 
via e-mail and website with discussion 
group with fellow patients 19
asthma ‘Wisconsin Medicaid’ – 
program with insurance 




website with audio and interactive 
modules on therapy compliance 
with explanations, questionnaires for 
making a personal plan on therapy 
compliance, stress and HIV 20
HIV ‘AIDS clinical trials group 




interactive website with text message 
alert, filled with messages and 
reactions about therapy compliance, 
informative literature and videos; 
financial reward for logging in 
frequently 21
HIV non-validated questionnaire no improvement
access to personal medical eye care 
records with graphical representation 
of glaucoma test results and 
medication22
glaucoma pharmacy sales data no improvement
automatically generated 
questionnaires on symptoms and 
side effects with reminder to take 
medication and feedback from 
clinicians to patients 23




method for measuring 
therapy compliance
effect of intervention on 
therapy compliance
online questionnaires with specific 
feedback for parents about symptoms 
of their child and medication therapy 
compliance24
asthma questionnaire improvement (p = 0.04)
app with reminder function to take 
medication, including photos of the 











website with animation, interactive 
activities with peer videos and 
expert videos; feedback on missed 
medication and blood values 26
HIV non-validated questionnaire improvement (p = 0.008)
IBD = inflammatory bowel disease; VAS = visual-analogue scale.
Results of the literature study
The search resulted in a total of 164 titles and abstracts. After removing duplicate 
publications and applying the inclusion criteria, the full text of 41 articles was retrieved. 
After further assessment, 16 articles remained (see Figure). The characteristics of these 
studies are shown in the Table.
Publications until 2010
The authors of the systematic review from 2011 identified 13 articles. 8 The most 
commonly used intervention was a website in which the level of personalization ranged 
from ‘none’ (online access only) to ‘complex’. In the latter case, a personal health program 
was made available that was based on measurement results, registration of symptoms, 
use of emergency medication and other parameters. In addition, diaries or information 
brochures were offered online to patients. Other programs focused on changing the 
attitudes or beliefs of patients with regard to the treatment and eliminating barriers; 
personal goals could be set and pursued. Of the 13 studies, 5 reported a significant 
positive effect on medication therapy compliance. In 6 studies the reported effects were 
not significant.
Publications from 2010 through 2014
Of the 16 included studies published after 2010, 15 studies used a website and 1 used 
an app. The studied interventions involved patients with the following conditions: 4 
studies with HIV patients, 4 studies with asthma patients (both adults and children), 2 
studies with inflammatory bowel disease patients and 2 studies in patients with various 
disorders, i.e. they were frequent visitors to their GP and used medication regardless 
of the condition. Furthermore, the intervention was investigated in some studies in 
patients with epilepsy, glaucoma, diabetes mellitus and depression. 
The most commonly used methods to measure therapy compliance were patient-
completed questionnaires (n = 14), both validated and not validated, and pharmacy 
E-health interventions and improving therapy compliance
47
3
sales data (n = 4). Ten studies reported a significant improvement in therapy compliance 
after the intervention. This is an increase in the proportion of successful interventions 
relative to the results of the 2011 review: 5/13 (38%) versus 10/16 (63%).
Most studies investigated an intervention that consisted of a combination of information 
about the disease, which was specified based on the knowledge and symptoms that the 
patients reported themselves, and reminders in the form of e-mails or text messages. The 
interventions were often extensive and tried to match the various determinants for the 
individual patients. These determinants include training or education, perception and 
interpretation of the disorder and treatment, and belief in the efficacy of medication. The 
Table provides an overview of the studies with a description of the e-health interventions. 
Seven studies tested interventions in which patients were asked to define personal goals 
based on information that they had entered online or that had been obtained from 
measurements.12,13,17,18,20,24,26 Based on these personal goals, feedback was provided in 
follow-up consultations. Of these 7 studies, 4 reported a significant improvement in 
therapy compliance.17,20,24,26 In 5 studies, patients were reminded when it was time to 
take their medication, in addition to other interventions.  Three of these studies reported 
a significant improvement in therapy compliance.13,23,25
Four studies involved relatively simple interventions.14,16,22,25 In 2 studies, the intervention 
involved making medical records available to the patient.14,22 In an American study, 
patients could design their own text message that was sent as a reminder when it was 
time to take their medication,16 In a Spanish study, an app was used in which details 
about the medication, including a picture of the packaging, could be saved. 25 It was 
also possible to send reminders to take the medication that included a photo of the 
packaging. All 4 of these interventions reported a significant positive effect on therapy 
compliance.
Interpretation of the results
Since the publication of the systematic review from 2011, a total of 16 new studies 
have been published on the effect of e-health interventions on therapy compliance. 
Of these studies, 10 reported an improvement in therapy compliance. Compared to 
the review from 2011, the proportion of successful interventions has increased. The 
interventions studied were usually complex and addressed multiple determinants for 
reduced therapy compliance. Various therapy compliance factors can be categorized as 
patient-related, care-related and environment-related factors. In addition, the causes 
of reduced therapy compliance can be roughly categorized as either intentional or 
unintentional. Do patients forget their medication or do they actively decide not to 
take the medication? All these factors interact in a unique way for each patient, making 
it difficult to predict the effect of a complex intervention on an individual. Of the 10 
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studies that reported improvements in therapy compliance,4 involved a relatively simple 
intervention. This observation supports previous recommendations in which the use of 
complex interventions was not preferred.1-4
One factor that complicates the interpretation of therapy compliance data is the method 
used to measure therapy compliance. This makes it difficult to compare the effects of the 
interventions on therapy compliance with each other. In 14 of the 16 studies, therapy 
compliance was measured with questionnaires. Although questionnaires are simple to 
use in practice, it is known that questionnaires generally do not provide good insight 
into therapy compliance. This data should therefore always be seen in the light of the 
clinical outcome measures.
Even though the various interventions are difficult to compare because they are all 
designed differently, they have two common aspects: they used e-health and they aimed 
to increase the participation of patients. This was done by actively involving patients in 
their treatment by setting goals and providing feedback, or by giving patients more access 
to their medical records and informing them about the treatment. Patient participation 
in healthcare has an increasingly important role and, as shown in this overview, appears 
to improve therapy compliance. However, it is difficult to improve control over the other 
determinants. Despite these limitations, the development of e-health interventions is a 
logical step forward in research into therapy compliance. More and more patients have 
contact with mobile devices, and more and more online applications are available for 
these devices. In addition, the use of mobile devices is commonplace in daily life and 
enables patients to find information about their condition online quickly and easily. The 
interventions studied are therefore relatively easy to use in daily practice.
Conclusion
E-health interventions to promote therapy compliance appear to be becoming 
increasingly effective. Research on simple interventions and their implementation 
should therefore continue. 
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Background: Poor adherence to medication is one of the limitations in the treatment 
of cardiovascular diseases, thereby increasing the risk of premature death, hospital 
admissions, and related costs. There is a need for simple and easy-to-implement 
interventions that are based on patients’ perspectives, beliefs, and perceptions of their 
illness and medication.
Objective: The objective is to test the effectivity of this intervention to improve 
medication adherence in patients with established cardiovascular disease, that is, in 
secondary prevention.
Methods: In this study the effect of a personalized visualization of cardiovascular risk 
levels through a website aiming at supporting self management in combination with 
a group consultation and communication intervention by a nurse on adherence to 
treatment in 600 patients with manifest cardiovascular diseases will be assessed. The 
health belief model was chosen as main theoretical model for the intervention.
Results: Primary outcome is adherence to treatment calculated by refill data. Secondary 
outcomes include the Beliefs about Medication Questionnaire and the Modified 
Morisky Scale. Patients are followed for one year. Results are expected by 2015.
Conclusions: This study assesses adherence to treatment in a high-risk cardiovascular 
population by applying an intervention that addresses patients’ capacity and practical 
barriers as well as patients’ beliefs and perceptions of their illness and medication.





According to the World Health Organization almost 50% of all chronic patients 
do not adhere to their prescribed drug regimen.1 This is also true for cardiovascular 
diseases (CVD) ; only 60% of all cardiovascular patients adhere to their cardiovascular 
medications (e.g. statins, antihypertensives, antithrombotic agents).2 This prevalence 
is similar across all individual CVD medications and occurred in patient who take 
these medications for primary and secondary prevention of CVD.2 These figures are 
startling given that poor adherence results in an increased risk of death in cardiovascular 
patients.3-5
Current methods for improving adherence are mostly complex and have limited 
effectiveness; simple interventions that are easy to implement in daily practice are 
preferred.6 Evidence suggests that interventions should be based on the patients’ 
perspective7, target patients’ capacity and practical barriers, and address their beliefs 
and perceptions regarding illness and medication.8,9 In CVD, life-long adherence is 
important, and interventions should improve patients’ intentions to take medication, as 
well as solve emergent practical barriers.
These principles were used in the development of the current trial. Specifically, the 
intervention is based on the health belief model (HBM)10,11, tailored for the specific 
purpose of this trial. HBM provides a useful framework for designing behavior change 
strategies.12 It is based on the understanding that a person will take health‐related action 
(eg, being adherent to cardiovascular medication) given four main factors. The first two 
factors are perceived susceptibility and perceived severity; understanding of the high 
personal risk and seriousness of a condition (eg, because of the cardiovascular event 
in the past I am at greater risk for another cardiovascular event. The third factor is 
perceived benefits; belief that a negative health condition can be avoided (eg, being 
adherent to the cardiovascular medication can help to prevent another cardiovascular 
event. The last factor are the perceived barriers, cue to action and self‐efficacy; belief in 
the ability to successfully undertake the recommended health action; (eg, I know how to 
take my medication on a daily base).12,13
Trial design and aim of the study
The study will use a single‐center, prospective, randomized controlled clinical trial design. 
This study will examine the effectiveness of a new intervention that incorporates the 
HBM and behaviour change strategies to improve adherent behaviour in cardiovascular 
patients. The intervention consists of a patient-based screening method; a specific nurse-
based intervention (structural informative consulting and motivational counseling) and 
personalized visualization of cardiovascular risk levels via a website. The objective is to 
test the effectivity of this intervention to improve medication adherence in patients with 





Participants will be drawn from a hospital‐wide screening program. This screening 
program is situated at the cardiovascular outpatient clinics in an academic medical 
center in Nijmegen, the Netherlands. All new patients diagnosed in the last 6 months 
with acute coronary syndrome, peripheral arterial disease, an aneurysm of the aorta or 
stroke/ transient ischemic attack (TIA) referred to the departments of Vascular Surgery, 
Neurology or Cardiology are automatically included in this program.
Eligibility criteria
From this population, participants aged 18 years and older will be selected based on 
the following inclusion criteria: presence of CVD (acute coronary syndrome, peripheral 
arterial disease, an aneurysm of the aorta, or stroke/TIA), diagnosed in the last 6 months 
by a medical specialist; willingness to remain in follow‐up for a period of one year, and 
provision of signed, informed consent. Exclusion criteria are; pregnancy (reported by the 
patient); severe co‐morbidity (eg, a mental health diagnosis considered by a physician to 
be a contraindication); problems with the Dutch language (reported by the nurse), or 
logistic problems such as lack of computer access.
Intervention
For the intervention, the group participants will be split in three groups. Participants in 
group I (control group) receive only usual care. Group II participants receive usual care 
plus access to a personalized website. For the group III participants, in addition to usual 
care and access to the personalized website, the intervention program will also include 
a single group consultation of 60 minutes led by a nurse and a pharmacist, followed by 
two individual consultations  of 30 minutes with a nurse.
We want to test if treatment II (only the web portal) can give the same results as treatment 
III (the web portal and the single group consultation followed by two individual 
consultations). The need for low-cost effective interventions in our health care system 
lead to the motivation for this three-arm protocol.
Usual Care (Groups I, II and III)
All new CVD-patients receive the hospital‐wide screening program according to 
the Dutch guidelines14 (based on the European guidelines0.15 The screening assesses 
cardiovascular risk factors in all patients with CVD. It screens for lifestyle risk factors, 
blood lipid levels, blood pressure, waist circumference, body mass index, blood glucose 
levels and a family history of CVD’s. Lifestyle is evaluated through a questionnaire 
which is a compilation of existing validated questionnaires, regarding demographic 
data, smoking, alcohol use, physical activity and eating habits. For each of these lifestyle 
issues, the patient’s motivation to change is evaluated.16 Adherence is measured by the 
Modified Morisky Scale © (MMS)17 and the Beliefs about Medication Questionnaire 
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(BMQ).18 Medication use will be monitored. If necessary and if the patients agree they 
attend consultations with a nurse based on motivational interviewing to help them lose 
weight, stop using alcohol or stop smoking. 
According to European guidelines15 all patients with established CVD (this means all 
participants of this trial) should have antiplatelet therapy (eg, aspirin or clopidrogel) 
and a lipid lowering drug (eg, simvastatin or atorvastatin). The use of antihypertensive 
drugs is dependent on the systolic blood pressure. Except for the specific additions 
for the study, all participating and non-participating patients receive the same regular 
preventive cardiovascular care, including monitoring of medication use. All patients 
receive regular vascular care from their medical specialist.
Website (Groups II and III)
The website contains an individualized web portal called Interactive File Vascular Care’, 
(Interactive Dossier Vaatzorg, or iVAZ). his is developed to support patient-based self-
evaluation and management.19,20 Patients can log on and see their own cholesterol levels, 
blood pressure, and lifestyle (smoking habit, exercise and eating habits) in a risk monitor. 
Patients can ask questions by e-mail to their nurses, and they can enter changes in their 
medication. iVAZ provides risk communication, the feedback of clinical outcome will 
be provided individually and patients are invited to be active in managing their illness 
and medication. 
Group and Individual Consultations (Group III)
For group III, the intervention program will also include a single group consultation of 
60 minutes led by a nurse and a pharmacist followed by two individual consultations of 
30 minutes with a nurse. 
During the group consultations patients receive information about their disease, 
cardiovascular medication (such as statins, antihypertensive, and antithrombotic agents) 
and the importance of treatment adherence. Patients will receive an information booklet 
with all information presented during the plenary session. At the end of this consultation 
patients are asked to keep a diary of their medication intake during a 2-week period and 
to set a personal goal for the upcoming individual consultation with a nurse. The group 
consultation is regarded as an efficient way to increase knowledge and understanding of 
the risks. It also provides a gathering with other patients (peers).
During individual consultations, the intervention is further tailored based on the goal 
previously set, patient’s concerns, and necessities using the results of the screening 
questionnaire (see Data Collection). The following topics will be discussed during 
the individual consultation:  patient’s motivation and confidence (barriers, concerns, 
and positive self-motivational statements about their adherence behavior), options for 
increasing adherence to treatment, and a global summary of the counseling session.
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Both the group and the individual consultations take place at the outpatient clinic. The 
involved nurses have had training in motivational interviewing21 and were especially 
trained for this intervention by a psychologist.
For each of the constructs, we used the recommended behavior change strategies.12,13 
We tailored the intervention further by using the taxonomy of Abraham and Michie22,23 
and the coding manual by de Bruin24 to categorize the behavior change techniques to be 
included in the intervention. For each of the components of the HBM, the determinants, 
techniques and application strategy were developed and are detailed in Figure 1 to 4.
Table 1. Techniques and applications influence perceived susceptibility in the current trial. The main determinant behind 
perceived susceptibility is a lack of knowledge, regarding prescribed medications and the influence on risk reduction.
Technique Practical applications/Strategy
Increase understanding
Provide general information 
Risk communication
Persuasive communication
Group sessions with peers
Group consult:
Providing general information about atherosclerosis
Providing written material with information about cardiovascular 
medication and how it should be taken
Providing general information about cholesterol and blood pressure 
and their influence on cardiovascular risk.
Providing general information about cardiovascular medication and 
how it works.
Discussion within a group of cardiovascular patients about being 
adherent and non-adherent to medication
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Table 2. Techniques and applications influence perceived severity in the current trial. The main determinant behind 
perceived severity is patients’ beliefs, perception and management of their illness (awareness, outcome expectations).
Technique Practical applications/Strategy
Risk communication 
Feedback of clinical outcome 
Revaluation of outcomes, self-evaluation
Goal setting
Personalized website:
Visualization of the personal cardiovascular risk through a risk 
monitor
Individual consult:
Evaluating a medication taking diary
 
Group consultation and individual consult:
Ask patients to describe a goal according to their medication 
adherence and evaluate this on their next appointment with their 
nurse
Table 3. Techniques and applications influence perceived benefits in the current trial. The main determinant behind 
perceived benefits is patients beliefs, perception and management of their illness (awareness)
Technique Practical applications/Strategy
Persuasive communication
Revaluation of outcomes, self-evaluation
Reinforcement on behavioural progress
Individual consult:
Consults are given based on motivational interviewing 
and goal setting
Evaluating target levels 
Personalized website:
Providing a risk monitor that will be green if outcome 
targets are achieved
Table 4. Techniques and applications influence perceived barriers, cue to action and self-efficacy in the current trial. The 







Set graded tasks, goal setting
Let the patient keep a diary of his medication taking two 
weeks for each individual consultation
Individual consult:
Talk with the patients about  the barriers and effect and 
side effects of the medication 
If necessary, the nurse and patient make a plan together 
how to overcome the barriers.
The patient and nurse formulate a goal at the end of each 
consultation reflecting the barriers they evaluated
Outcomes
Primary Outcome
The primary outcome of our study is adherence to the CVD –medication ( classified by 
the Anatomic Therapeutic Chemical classification system), measured with a dedicated 
calculation of refill data of the used plated aggregation inhibitors and lipid modifying 
agents, obtained from patient’s pharmacy.
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Refill records of computerized pharmacy systems will be collected from 3 years prior to 
a patient’s cardiovascular event through up to 3 years after the study follow‐up period. 
Prescription records include the names of all of the dispensed drugs, prescribed daily 
dose, quantity dispensed at each pharmacy fill, and the dates of the prescription fills. 
Adherence will be calculated for the CVD- medications, as the theoretical duration 
divided by the period between the start date and the date of the last prescription filled. 
The theoretical duration will be calculated by dividing the number of units dispensed by 
the prescribed daily dose.25
Patients will be categorized into non-adherent and adherent patients. Patients with 
an adherence level of at least 80% will be classified as adherent, and patients with an 
adherence level less than 80% will be classified as non-adherent. Secondary prevention 
studies showed that patients with an adherence of less than 80% have an increased risk 
of death.26
Refill adherence rates have been used extensively for the assessment of drug acquisition 
and dispensing. Compared with electronic monitoring, refill data provide researchers 
with a relatively simple method for investigating exposure to medication in large 
populations.27-29 Moreover, this method is suitable for investigating long‐term persistence 
to treatment and gaps in medication supply.30 
Secondary Outcomes
All secondary outcome measurements will be obtained just before inclusion (in the 
usual care screenings program) and one year after inclusion. The secondary outcome 
measurements include clinical responses to drug therapy (eg, cholesterol level), self-
report questionnaires, and changes in systolic blood pressure.
Clinical responses to drug therapy will be recorded. A recorded low-density lipoprotein 
cholesterol level above 20% of pre estimated low-density lipoprotein cholesterol 
reduction during follow up will be considered as possible indication of poor adherence. 
If the patient also uses anti hypertension drugs, the blood pressure on baseline will 
be compared to blood pressure after one year and will need to be within target blood 
pressure for cardiovascular risk management (systolic <135 mmHg). These office 
blood pressure measurements are performed according to the recommendations of the 
European Society of Hypertension31 with a validated automated device and is based on 
a mean of four office measurements. 
Second, two validated self-report questionnaires will be used. The MMS © 17 will be 
used to measure adherence. Each of the 8 items measures a specific medication‐taking 
behavior. MMS© scores can range from 0 to 8 and can be classified into three levels of 
adherence: low adherence (score off less than 6), medium adherence (score of 6 to less 
than 8) and high adherence (score of 8).32 The Beliefs about Medication Questionnaire 
(BMQ)18 will be used to provide information about the beliefs, perceived necessity, and 
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concerns patient have regarding their illness and prescribed medication. Respondents 
indicate their degree of agreement with each individual statement about medicines on 
a 5‐point Likert scale. It is then possible to differentiate between patients on the basis of 
their beliefs about the necessity of their medication and their concerns about taking it. 
Patients can be classified into four different categories: accepting (high necessity and low 
concerns), ambivalent (high necessity and high concerns), skeptical (high concerns and 
low necessity), and indifferent (low concerns and low necessity).33,34 
Participant Timeline
Baseline scores will be collected for all groups. Follow-up scores will vary depending 
on group and will be collected at 6 and 12 weeks (all groups), and 16 and 28 weeks 
(intervention groups II and III) (see Figure 1 for flow chart).
Sample Size
This study is mainly powered on the primary outcome, the detection of a significant 
difference between the three degrees of care (usual, additional website, additional 
counseling) on medication adherence as determined by refill records of computerized 
pharmacy systems. Based on previous research in our population and data from the 
literature 26, we estimate that the adherence at the start of the study will be 65% in each 
group with a standard deviation (SD) of 30%. We hypothesize that the intervention 
given in group II and the intervention given in group III, will result in an increase of 
10% in adherence to treatment, resulting in mean adherence rates of 75% and 85% in 
groups II and III, respectively. To detect these differences in medication adherence the 
estimated group size with a power of 80% and an alpha of 0.05 (2‐sided) would be 200 
in each group, resulting in 600 participants in total.
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Figure 1: Flow Chart 
            
 

























Visit one  
N=600 cardiovascular patients 
Baseline screening: BP, LCHC, glucoses, BMI, waist circumference, Lifestyle questionnaire, 
MMS/BMQ 
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Final visit (T=12 months)  
Evaluation screening: 
BP, lipid, glucoses, BMI, waist circumference, Lifestyle questionnaire, MMS/BMQ,  PRD (until three year 
past event) 
 
Figure 1. Flow Chart




All cardiovascular patients who receive the regular cardiovascular preventive care will be 
asked to participate by a nurse when they arrive at the outpatient clinic for their screening 
consult. Patients will receive a letter explaining the study, documenting their ability to 
withdraw at any time without explanation and confirming that their medical care will 
in no way be influenced by their decision regarding participation. At a minimum of 24 
hours later written consent will be sought by a research assistant, prior to the patient 
entering the study. 
We chose to include all cardiovascular patients in our study, rather than only non-
adhering patients as done in many other studies.6,9,35 We have a three-year follow-up 
planned and want to be able to see how adherence develops over time, for initial adherers 
and non-adherers alike. 
Assignment of interventions
Patients who meet the criteria and consent to participate will then be randomized by the 
nurse, using blocked randomization, stratified by department (eg, neurology, vascular 
surgery, and cardiology) in a 1:1:1 ratio into one of the three groups using computer 
randomization.
Blinding
The principal investigator and the researcher will be blind to randomization. However, 
due to the need for active participation, the patient, nurse, and pharmacist delivering 
the individual consultations will not be blind to assignment of individuals in group III.
Data Collection and Management
The primary data collected will be provided by the initial screening. Obtained data 
from the screening are blood lipid levels, blood pressure, waist circumference, body 
mass index, blood glucose levels, and medication use. Lifestyle is evaluated through 
a questionnaire which is a compilation of existing validated questionnaires, regarding 
demographic data, smoking, alcohol use, physical activity and eating habits. For each of 
these lifestyle issues, patient’s motivation to change is evaluated.16 Adherence is measured 
by the MMS © 17 and beliefs about medication by the BMQ.18
To monitor whether the website intervention is used, log‐in information per patient, 
expressed as the number of log‐ins and times and dates of log-in, will be recorded. 
To measure the nurses’ performance skills required in the individual consultations, the 
behavior change counseling index will be used36. This validated checklist aims to measure 
the nurses’ competence in behaviour change counseling and adaptation of motivational 
interviewing in healthcare settings. The group consultations are video recorded and 




Data will be entered by the nurses who perform the screening and the intervention 
consults in iVAZ. iVAZ is a secured website which can only be entered by the participants 
by using their social security codes and by selected nurses  using security codes. In 
addition, all patients’ pharmacists will receive a letter of information about the trial, 
consent of the ethical committee and the informed consents of the participants. They 
will be asked to send the data on refill records of their computerized pharmacy systems 
through a secured e-mail address. All the data will be anonymized according to the 
privacy protocols from the ethical committee and imported by the researcher into SPSS 
(IBM Corp).
Statistical Methods
The data will be analyzed based on the intention‐to‐treat principle and evaluated using 
SPSS, with descriptive statistics (mean, median, SD, and interquartile range) being 
determined for all variables. The data will be presented in quantitative format (eg, 
biometrics, laboratory results, blood pressure, lifestyle scores, adherence score on the 
basis of refill data and the MMS ©) and in descriptions of observed effects (eg, change 
in BMQ, determinants for adherence, evaluation of the use of iVAZ, and appreciation 
of nurse intervention). 
To evaluate the difference between the groups, an analysis of variance test will be 
performed on the outcome measures for the three patient groups. Specifically, we 
will compare the difference between the first and last time point between groups 
for the primary and secondary outcomes measures. For the intervention groups 
II and III, we will also compare the outcomes of the clinical data at 16 and 28 
weeks. To correct for multiple comparison, a Duncan’s multiple range test will 
be performed. Furthermore, we will perform a receiver operating characteristic 
(ROC) curve analysis to compare the outcome of the screening instruments (MMS 
© and BMQ) with the pharmacy refill dates. In the ROC curve plot, -specificity of 
the questionnaire is on the x-axis and sensitivity of the question is on the y-axis.. 
Plausible relations between parameters of cardiovascular risk factors, 
motivation to change, and socio-economic class, and parameters of adherence 
(calculated refill score and, BMQ score and MMS scores) will be tested in a 
univariate manner. Individual parameters will be tested for normality using 
the Kolomogorov-Smirnov test, in order to select adequate univariate tests. 
Multiple logistic regression analysis will be performed to assess the relative importance 
of selected parameters for the likelihood of low adherence, as defined by the refill data 
algorithm. In all analyses, potential confounders will be included if they independently 
changed the beta -coefficient for dedicated calculation of refill data by at least 5%, or 
when consensus about inclusion existed within the team of researchers, supported by 
clinical evidence from literature.
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Missing data is unfortunately very common in eHealth research. Therefore we follow 
the recommendation for eHealth research to use the multiple imputation technique in 
SPSS ( SPSS MI) when analyzing our dataset with missing observations.37
Ethics and Dissemination
The study protocol has been approved by the local ethical committee before inclusion 
of patients into the study. The study has been registered (trial registration ID number 
NCT01449695, approved May 2011). Since the only intervention consists of a web 
tool support or communication with a nurse, serious adverse events and suspected 
unexpected serious adverse reaction related to the trial protocol are unlikely to 
occur. Subjects may leave the study protocol at any time for any reason, without any 
consequences for regular cardiovascular care. The investigator or patients ‘specialists 
may also decide to withdraw a subject from the study for urgent medical reasons. 
There are no conflicts of interest to report (all authors). The authors are did not develop 
the intervention-website.
Discussion
Nonadherence to medication prescriptions in cardiovascular patients reduces the 
positive effects of medical treatment in chronic care. However, improvement of 
medication adherence in these patients is a serious challenge. Patient beliefs, perceptions 
and management of medication, their illness (intentional nonadherence), and skills to 
integrate medication taking in their daily life (unintentional nonadherence) need to be 
addressed to make an intervention successful.
There is no one‐size‐fits‐all solution for nonadherence35,9 nor does previous research 
provide evidence to choose a single intervention 38. By reviewing the literature it becomes 
evident that determinants for non‐adherent behavior are complex and underlying 
theory for a successful intervention is frequently lacking 35,39,40. In a review of 193 health 
behavior change articles only 36% of the authors mentioned a theory and only 22% of 
them applied the theory 41.
We based our method on the HBM adopted the approach of Horne42, and defined 
the main determinants of non adherent behavior in intentional and nonintentional 
determinants. Because we address both types of determinants, we expected to develop 
an intervention that will be more successful than most existing interventions, which 
only take into account one of these sets of determinants.
Specifically, by choosing a group consultation, information is provided in an efficient 
manner and the patient is given an opportunity to discuss the need for adherence 
(intentional nonadherence) as well as getting practical information (unintentional 
adherence) with peers. Further tailoring the intervention in individual contacts provides 
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the opportunity for the nurse to identify the need to change objectives of unintentional 
or intentional nonadherence (or a mix of both). These individual consultations are 
patient‐centered, with emphasis on patient perspective and shared‐decision making43. 
The individual website and visualization of personal cardiovascular risk furthermore 
addresses one of the difficulties in cardiovascular adherence: awareness of the influence 
of taking medication on personal cardiovascular risk.41 Lastly, the combination of Web-
based intervention with face-to-face contact is expected to give better results than either 
alone44.
Based on this integration of factors, we hope that the resulting data of this trial will 
contribute important knowledge about adherence in this population.
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Background: Poor medication adherence is a limitation in the secondary prevention of 
cardiovascular diseases and leads to increased morbidity, mortality and costs.
Purpose: To examine the process and effect of a nurse-led, web-based intervention 
based on behavioral change strategies to improve medication adherence in patients with 
cardiovascular disease.
Patients and methods: In this single-center, prospective, controlled clinical trial, 
cardiovascular patients were assigned to usual care, usual care plus a personalized website 
or usual care plus a personalized website and personal consultations. Primary outcome 
was the level of adherence to cardiovascular medication. Data collection occurred 
between October 2011-January 2015.
Results: In total 419 patients were randomized. Just 77 patients logged on the website 
and half of the invited patients attended the group consultation. Due to the limited 
use of the website we combined the results of usual care and the usual care plus website 
group in one group (usual care ) and compared these with the results of the group 
which received the nurse intervention (intervention group). No significant difference in 
adherence between the usual care group and the intervention group was observed. The 
adherence level in the usual care group was 93%, compared to 89% in the intervention 
group (p=0.08). 29% (usual care) and 31% (intervention group) of the patients showed 
a low adherence according to the Modified Morisky Scale® (p-value=0.94). The mean 
Necessity Concern Differential was 3.8 with no differences between the two studied 
groups (mean 3.8 vs. mean 3.9, p-value =0.86).
Conclusion: Our intervention program did not show any effect. This could indicate 
that structured usual care provided to all cardiovascular patients already results in high 
medication adherence or that shortly after a cardiovascular event adherence is high. It 
could also indicate that our intervention program did not have enough impact because 
there was not enough compliance with the intervention protocol.
Trial registration ID number NCT01449695, approved May 2011.
Keywords: medication adherence, nurses, e-health, Health Belief Model, cardiovascular, 
changing behaviour, process evaluation.




Cardiovascular disease (CVD) is the leading cause of death worldwide. Although 
lifestyle risk factors of patients with high cardiovascular risk are monitored regularly as 
part of the risk reducing programs, there is limited structural attention to medication 
adherence.1 This is startling because it is known that poor medication adherence is a 
major limitation in the secondary prevention of cardiovascular diseases (CVD) that 
may lead to increased morbidity, mortality, and costs.2-4 Approximately 50% of the 
patients using medication for a chronic disorder do not adhere to the prescribed drug 
regimen according to The World Health Organization (WHO).5 In patients with CVD 
adherence rates remain low, ranging between 50-79%.2,6 As a consequence, in Europe 
an estimated 9% of preventable CVD events can be attributed to poor adherence to 
vascular medications alone.7
Current methods for improving adherence are mostly complex and not very effective, 
and simple interventions that are feasible in usual practice settings are preferred.8 
There is however a need for more understanding in patient-related determinants 
of poor adherence to medication. These determinants can either be intentionally or 
unintentionally driven. Unintentional poor adherence occurs when patients are inclined 
to adhere but are not able to because of a lack of capacity or resources. Intentional poor 
adherence occurs when patients decide not to follow the agreed recommendations.9 To be 
effective, interventions should address both unintentional and intentional determinants 
of poor adherence.10 Central to patients’ medication adherence is their judgment of 
their personal need for taking medication. Key beliefs that influence patients’ judgment 
about their medication are perception of personal needs for treatment (necessity beliefs) 
and concerns about several potential negative consequences (concern beliefs).9,11,12 
Though life-long adherence is important in CVD, absence of symptoms in the years 
after an event may result in the perception that the illness is benign. This may lead 
to doubts about the necessity of continuous treatment.13 A patient-centered approach 
with emphasis on patients’ perspectives might encourage CVD patients to take their 
medication.14,15 The principles of the patients’ perspective were used in the development 
of the intervention under study. The intervention was therefore based on the Health 
Belief Model (HBM)16,17 in which the Necessity-Concern Framework was applied9 and 
adapted for the specific purpose of this trial. 
Material and methods
Aim
This study aimed to evaluate the process and outcomes of an intervention program 
consisting of a single group consultation, two individual follow-up consultations with 
a nurse and access to an interactive personalized website, incorporating evidence-based 
determinants of poor adherent behaviour in high risk cardiovascular patients. The Health 
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Belief Model (HBM)18 was chosen as central theoretical model for the interventions. 
The intervention program aims to improve patient’s necessity and concern beliefs about 
medication, which is expected to lead to better adherent behaviour in cardiovascular 
patients.
Design / Methodology
The design of this study ( with an acronym: the MIRROR-trial) has been described 
in detail earlier.19 The MIRROR study is a single-center, prospective, three-arm 
randomized controlled clinical trial. Patients were randomly assigned to usual care 
(group I), usual care plus access to a personalized website (group II), or usual care, 
access to a personalized website plus a group consultation with a pharmacist and a nurse, 
followed by two individual nurse-led consultations at the outpatient clinic (group III).
Sample
All patients referred to the Radboud University Nijmegen Medical Center with a new 
diagnosis of acute coronary syndrome, myocardial infarction, peripheral arterial disease, 
an aneurysm of the aorta or transient ischemic attacks (TIA) or stroke over the last 
6 months were included into the hospital CVD screening program. This screening 
program aims to identify cardiovascular risk factors and consists of screening of lifestyle 
(smoking, diet and exercise), blood lipid levels, blood pressure, waist circumference, 
body mass index (BMI), glucose blood levels and a family history of cardiovascular 
diseases. If indicated, preventive therapies (medication and lifestyle interventions) are 
structurally initiated and followed over time.20 From this program, participants aged 18 
years and older were eligible for the MIRROR-trial if they were willing to stay in a one 
year follow‐up period, and provided signed informed consent for an intervention on 
medication adherence. Exclusion criteria were pregnancy reported by the patient, severe 
co‐morbidity (e.g. lung cancer, end stage heart failure), difficulties with Dutch language 
or no access to a computer.
Randomization
Patients who consented to participate were randomized using block randomization 
stratified by department (i.e. neurology, vascular surgery, and cardiology) in a 1:1:1 ratio 
into one of the three groups. Randomization was blinded for the principal investigator 
and the primary researcher. Either the patient, the nurse or the pharmacist delivering the 
individual consultations could be blinded to the intervention assignment in group III.
Power calculation
The study was powered on adherence to medication expressed as MPR. We estimated 
that adherence levels at the start of the study would be 65% in each group with a 
standard deviation of 30%. We hypothesized that the intervention given in group II 
and the intervention given in group III would result in an increase of 10% and 20% in 
adherence to treatment, resulting in a mean adherence rate of 75% and 85% in group II 
and III, respectively. Consequently, the estimated group size with a power of 80% and 
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an alpha of 0.05 (two‐sided) would be 200 in each group, resulting in 600 participants 
in total.
Timeline
The intervention period lasted 12 months. Within, on average, six weeks after the CVD-
event, baseline characteristics were collected for all patients. Follow-up outcomes were 
collected at twelve months after inclusion for all patients. 
Data collection
Process evaluation
As recommended by the Medical Research Council Guidance 21 we included a process 
evaluation of this intervention program. A process evaluation helps to understand the 
relationship between how well an intervention was delivered, the different elements 
of an intervention and the main outcomes of a trial.22,23 It furthermore improves the 
validity and interpretation of these outcomes and gives information so the intervention 
can be replicated.24 This intervention program was performed at an outpatient clinic 
for cardiovascular risk management in our academic hospital. Nurses, who deliver 
the individual consultations, already counsel cardiovascular patients in changing 
their lifestyle (e.g. stop smoking. losing weight) through motivational interviewing 
techniques. In addressing the problem of non-adherence as a behavioral problem, the 
intervention program could fit really well in the existing clinical setting. There is also a 
broad recognition that nurses have a key role in understanding and addressing patients 
‘beliefs during consultations about their medication. 
Adherence
The primary outcome of our study was adherence to cardiovascular medication. Adherence 
was based on pharmacy refill dates (PRD) of participants’ filled prescriptions obtained 
from computerized pharmacy systems. Data were collected for prescribed cardiovascular 
drugs (plated aggregation inhibitors, lipid modified agents and antihypertensive drugs) 
for the period of 3-years prior to a patient’s cardiovascular event and at least one year 
after cessation of the intervention of this trial. All prescription records included the 
Anatomic Therapeutic Chemical code (ATC), the names of the dispensed drugs, 
prescribed daily dose, quantity dispensed at each pharmacy fill, and the dates of the 
prescription fills. Adherence was reported as the mean possession ratio (MPR) for all 
cardiovascular medication. The MPR was defined as the number of days of treatment 
dispensed divided by the number of days prescription refills25. We calculated adherence 
levels at baseline (T1), at the end of the intervention (T2) and at one year after ending 
the intervention (T3). Patients with an adherence level of at least 80% were considered 






According to the hospital screening program, blood was drawn from all patients to 
determine LDL cholesterol levels. A recorded LDL-cholesterol level of 20% above the 
baseline level during follow up was considered as an indication for of poor adherence. If 
patients used antihypertensive drugs, they were classified adherent if the systolic blood 
pressure was below 135 mmHg after the intervention. Target blood pressure levels 
were set according to the European Society of Hypertension (ESH) recommendations 
(i.e. a systolic blood pressure level of < 135 mmg Hg). These office blood pressure 
measurements were performed according to the recommendations of the ESH  with a 
validated automated device and based on a mean of four office measurements.26
Patient outcomes 
All patients filled out the MMS® and the BMQ at baseline and at the end of the follow-
up period. The MMS®  is a validated questionnaire consisting of eight items aimed 
at measuring adherence.27-29 Each item accounts for 0 or 1 in the case questions are 
answered by No or Yes, respectively. Consequently, total MMS® scores range between 
0 and 8. These scores were divided into three levels of adherence: low adherence (sum 
score < 6), medium adherence (sum score 6 to <8) and high adherence (sum score of 
8). To evaluate patients’ beliefs and perceptions about their medication, the BMQ was 
used.30 Respondents stated their degree of agreement with each individual statement 
about medicines on a five‐point Likert scale. The necessity–concerns differential 
(NCD) was calculated as the difference between necessity and concerns scores and had 
a possible range of -20 to 20. If the difference was positive, the patient perceived that 
the benefits of medication outweighed the concerns. Contrarily, if the differential was 
negative, the patient perceived more costs than benefits.13,31 To separate patients on the 
basis of their beliefs about the necessity of their medication and their concerns about 
taking medication, the total necessity and concern scores (5-25) were split at midpoint 
(thus 5 - 12 was considered as low and 13 t/m 25 was considered as high). Patients 
were then classified into four different categories: accepting (high necessity and low 
concerns), ambivalent (high necessity and high concerns), skeptical (high concerns and 
low necessity) and indifferent (low concerns and low necessity).32-34 From all patients 
the type of CVD (acute coronary syndrome, myocardial infarction, peripheral arterial 
disease, an aneurysm of the aorta or TIA) was recorded. Also, the following baseline and 
clinical characteristics were collected: age, sex, level of education, employment status 
and the country of origin. Whether patients were new or chronic users of cardiovascular 
medication was also registered. To classify patients as a chronic medication user, they 
had to use a plated aggregation inhibitor and/or a lipid modified agents more than two 
months before baseline according to PRD. All other patients were classified as new 
users. The log-on information expressed as the number of log-ins, times and dates on 
the personalized website of each patient were recorded. 




Written informed consent was collected from all patients prior to entering the study. 
The study protocol was approved by the local ethical committee. Approval for this study 
was obtained by the Local Ethical Committee, the human related research committee 
of the Arnhem-Nijmegen region (CMO no 2011/062), which applied criteria described 
in the Medical Scientific Research with People Act (WMO), the Helsinki Declaration, 
the Good Clinical Practice (GCP), EU Guideline Good Clinical Practice, Clinical trials 
guidelines on medicinal products and in CCMO guidelines. 
Data analysis
Data were analyzed based on the intention‐to‐treat principle and evaluated by using SPSS, 
with descriptive statistics (mean, median, standard deviation [SD]) being determined for 
all variables. Differences between the patient groups were tested by performing an ANOVA 
test on the outcome measures. All socio-demographic and disease related factors so they 
could be taking into account as potential confounders.14,35,36 To handle with missing data, 
we followed the recommendations for eHealth research and used multiple imputation 
techniques in SPSS.37 Multiple imputation is considered as the standard procedure for 
dealing with missing data. It has the advantage of incorporating auxiliary information 
about missing data into the analysis, thereby reducing bias and improving accuracy.38 
Analysis of multiple imputated data shows greater power and efficiency than complete 
case analyses. Multiple imputations makes better use of available data and can generate 
different results from simpler techniques.39 The datasets generated and analyzed during 
this study are not publicly available due to the Dutch privacy laws. But they are available 
from the corresponding author on reasonable request.
Validity and reliability
This study used instruments with their validity and reliability tested in previous studies.40,27,30 
Participants were randomized using block randomization. The intervention was delivered 
by well trained nurses who all had a training specific for delivering the intervention. 
Results
Process evaluation
Development of the intervention program
The intervention program consisted of a nurse-based intervention providing structured 
information and motivational counseling, and a personalized visualization of cardiovascular 
risk levels on a website. The intervention was based on evidence-based behaviour change 
theory, the Health Belief Model (HBM)16 and by applying the Necessity-Concern 
Framework.9 This Necessity-Concern Framework is a useful model for understanding 
and addressing both unintentional and intentional nonadherence.9 By using the Beliefs 
about Medicines Questionnaire (BMQ)30, nurses could get insight into the necessity and 
concern beliefs of their patients and were able to tailor their consultation to the needs of 
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each individual patient. The HBM is based on the understanding that a person will take 
health related action (e.g. being adherent to cardiovascular medication) given four main 
factors. The first two factors are perceived susceptibility and perceived severity, reflecting 
the understanding of the high personal risk and seriousness of a condition (e.g. because of 
the cardiovascular event in the past I am at greater risk for another cardiovascular event). 
The third factor is perceived benefits, aimed at the belief a negative health condition can be 
avoided (e.g. being adherent to the cardiovascular medication can help to prevent another 
cardiovascular event). The last factor covers the perceived barriers, cue to action and self‐
efficacy, aimed at the belief to have the ability to successfully undertake the recommended 
health action (e.g. I know how to take my medication on a daily base). The group 
consultation with between ten to twelve patients was chosen for delivering knowledge 
and understanding of the risks. Moreover, it also provided a gathering with other patients 
(peers) in which patients were given the possibility to discuss adherence behaviour and 
learn from each other. In the individual consultations, the intervention was further 
tailored to each individual, so nurses were able to identify objectives for change of (un)
intentional non-adherence (or a mix of both) and were able to address the determinants 
of patients’ beliefs, perceptions and management of their illness and medication next 
to patients’ skills and memory.8 To support the individual and group consultations, an 
interactive and personalized website was developed. On this website, patients could see 
their own cholesterol levels, blood pressure and lifestyle (smoking, physical activity and 
eating habits) in a risk monitor. Patients had the opportunity to ask questions by e-mail 
to their nurse and enter changes in their medication. We choose a three-arm randomized 
controlled trial to determine if the website alone was effective or if group consultations 
and individual consultations had add-on effects. The participating nurses were trained in 
motivational interviewing and had applied this as part of the usual care program for several 
years.41 They received an extra training for this intervention.42,43
The website was expected to be effective on itself by creating awareness (risk monitor), 
providing (written) information and tailoring of the information by the e-mail facility.44,45 
Risk communication and the feedback of clinical outcome can be provided personally 
and patients were encouraged to be active in handling their disease and medication. 
The website was connected to the hospital laboratory system to provide personal clinical 
results. Logging in was due to high privacy levels. Patients had to use a special personal 
code, and had to confirm their password with a code they received from a text message. 
For developing the intervention program, we used the recommended behaviour change 
strategies of the Health Belief Model (HBM). We tailored further by using the taxonomy 
of Abraham and Michie46,47 and the coding manual by de Bruin to categorize the behaviour 
change techniques that required to be enclosed in the intervention.46,48 
For each of the components of HBM, the determinants, techniques, and application 
strategy that were developed are described in Table 1, process evaluation: Method, 
corresponding determinants, techniques, practical applications and the materials of the 
developed intervention.
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Uptake of the intervention Patient enrollment and inclusion
Of a total of 1201 patients with a cardiovascular event who enrolled the screening 
program, 900 were eligible to participate in this study. Of these, 481 declined to 
participate. In total 419 patients were randomized into group I (n=133), group 
II (n=138), and group III (n=148). Data collection occurred between October 
2011-January 2015.  After randomization, 148 patients were invited to attend the group 
and individual consultations of which 79 of these participated in the group consultation. 
One-hundred-and –thirty- four and 79 of these patients visited the first and second 
individual consultation, respectively. In total 286 patients got access to the website and 
were requested to visit the website. Seventy-seven patients actually logged- in on the 
website of which only 37 logged-in more than once. Since only a small proportion of 
the patients in group II en group III logged-in on their personalized website (34 and 
43 patients for group II en III, respectively) it was questionable whether there could be 
an effect of the website when compared to usual care. Therefore, we decided to report 
the results based on two groups, in which group I and II combined were compared to 
group III, i.e. we examined the effects of the group consultation plus the extra individual 
consultations. 
From the 419 randomized patients, refill data of 260 patients were available. We used 




Figure 1. patient enrollment and participation 
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   N=256 exclusion 
                                                                                                                                N=188 no computer 
                             N=78 co morbidity or not 
                                                                                                                                speaking Dutch language 
 N=45 missing ( no reason described) 
  
          








   
  
    












Patients asked to participate N=900 
       Patients consented N=419  
 
                Total population eligible for CVRM-screening between  01.10.2011 en 27.10.2013 
     N=1201 
Group I  N=133    Group II N=138     Group III  N=148 
 Baseline screening: BP, LCHC,  BMI, , Lifestyle questionnaire, MMS/BMQ 
    
 
Evaluation screening:  
BP, lipid, glucoses, BMI, waist circumference, Lifestyle questionnaire, MMS/BMQ 
Group I N=  88  (no show 30, died 2, serious comorbdity  4, moved 1, other event 2, lost for FU 6) 
    Pharmacy provided PRD N=83 
Group II N= 94  (no show 28, died 2, serious comorbidity 6, moved 1, other event 1, lost for FU 6) 
   Pharmacy provided PRD  N=86 
Group III N= 85  (no show 45,died 2, serious comorbidity 6, moved 2, other event 1, lost for FU 7) 
  Pharmacy provided PRD N=91 
 
 
Visit one (16 weeks) 
Determine lipids and BP for 
website visualization + 
individual consultation 
N=134 visited 
Vist two (28 weeks) 
Determine lipids and BP for 
website visualization 
      
N=79 visited 
 
     Group consultation  
        N=79 participated 
    Visit two (28 weeks) 
 Determine lipids and BP for 
website visualization + 
individual consultation 
N=79 visited      
 Logged in website 
          N=43 
Logged in website 
        N=34 
Visit one (16 weeks) 
Determine lipids and BP for 
website visualization 
      
N=129 visited 
Figure 1 Patient enrollment and participation.
Note: LCHC depicts lipoprotein analysis with determination of high density lipoprotein-cholesterol and low density 
lipoprotein-cholesterol calculation.
Abbreviations: BMI, body mass index; PRD,pharmacy refill dates; FU, follow up; MMS, Modified Morisky Scale; BMQ, 
Beliefs about Medicines Questionnaire; CVRM, cardiovascular risk management; BP, blood pressure.
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Results of the intervention
Baseline characteristics
At baseline the mean age of the participants was sixty one years and 67% were male. 
Forty-seven percent of the participants were diagnosed with a stroke or TIA, 36% with 
an acute coronary syndrome and 17 % with peripheral arterial disease. Ninety-eight 
percent received an antithrombotic agent and 94%  received lipid-lowering medication 
after the event.  At baseline, MPR for all cardiovascular medication was 72%. According 
to the MMS® 20% of all patients were low adherent, 46% and 35% were medium and 
high adherent, respectively. Mean NCD according to the BMQ was 3.6. Mean LDL was 
2.5 mmol/L and mean systolic blood pressure was 137 mmHg. See table 2
Table 2: Patient characteristics at baseline
Usual care (UC) 
N=133
UC + website 
N=138













 Unfit for work
 Retired
 Housewife
Country of origin is the Netherlands (b)
60.4  (10.0)
36      (27.1)
28     (21.9)
65     (50.8)
35     (27.3)
45    (33.8)
7      (5.2)
21    (16.0)
50    (37.5)
10    (7.5)
110  (89.4)
60.2 (8.8)





4   (3)
24 (17.4)
42 (30.4)
7   (5.0)
108 (91.5)
60.9 (11.8)
49    (33.1)
18   (14.4)
55   (44 )
52   (41.6)
47  (31.7)
2     (1.3)
28   (19 )
63   (24.3)




 Acute Coronary Syndrome
 Stroke or Transient Ischemic Attack
 Peripheral arterial Disease




 Totaal cholesterol 
 Triglyceriden
 High- Density Cholesterol
 Low-Density Lipoprotein
Body Mass Index, kg/m2 (a)
46    (34.5)
65    (49.0)
22    (16.5)
137.3 (16.8)
78.1   (11.3)
4.6     (1.2)
1.9     (1.0)
1.2     (0.3)
2.6     (1.0)















76.5   (10.7)
4.5      (1)
1.8     (1.1)
1.2     (0.3)
2.5     (0.9)




Usual care (UC) 
N=133
UC + website 
N=138
UC + website + 
consultations 
N=148
Medication (ATC ) used 
 Antithrombotic agents (B01)
 Diuretics (C03)
 Beta Blocking agents (C07)
 Calcium channel blockers (C08)
 Agents acting on the angiotensin system (C09 )
 Lipid modifying agents (C10)
Chronic users(b+c+d)
128   (98.5)
36     (26.5)
72     (55.4)
20     (15.4)
76     (58.5)
120   (92.3)
85     (64.4)
132  (97.1)
36    (26.5)
85    (62.5)
21    (15.4)
83    (61.0)
129  (95.0)
85     (62)
144   (98.0)
37     (25.1)
82     (55.8)
24     (16.3)
85     (57.8)
138   (93.9)
90     (61.2)
Questionnaires





Beliefs about Medication Questionnaire






23   (18.9) 
63   (51.6)




4    (3.3)







2    (1.6)







3    (2.3)
6    (4.7)
Mean Possession Ratio (d+e)
Cardiovascular medication total
 Antithrombotic agents (B01)
 Diuretics (C03)
 Beta Blocking agents (C07)
 Calcium channel blockers (C08)
 Agents acting on the angiotensin system (C09 )






















(a) Data are presented as  means and SD (+/-)
(b) Data are presented as numbers and percentages (N+%)
(c) Chronic use =starting medication > two months before baseline.
(d) Data from imputated data.
(e) Mean number of days dispended divided by the mean number of days between prescription refill.
Adherence
The intervention did not show an effect on adherence to treatment. Patients in the 
usual care group had an adherence level of 93%, compared to 89% in the intervention 
group (p-value=0.08) at T2. At T3 there also was no significant difference detected 
(adherence level was 81% and 76% respectively for groups I and II with a p-value 
of 0.23). Percentage of adherent patients was 86.3 % in the usual care group and 
76.4 % in the intervention group (p-value= 0.17) at T2. This was 65% and 57.4% 
(p-value=0.38) at T3. Though we didn’t see differences in adherence between the usual 
care and intervention group, we observed a difference in adherence in time for both 
groups combined. Therefore we performed a Repeated Measurement ANOVA in time 
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without differentiating in trial groups. At T1, at T2 and at T3 the overall adherence 
was 72%, 92% and 80%, respectively. During the study period medication adherence 
increased with 20% (95% CI 0.065 – 0.335). One year after this period it declined with 
12% (95% CI 0.073-0.17).
Clinical outcomes
At T2, mean LDL level was 2.2 mmol/L (2.5 mmol/L at baseline) and mean systolic 
blood pressure was 155 mmHg (136 mmHg at baseline) for both groups. There were 
no differences in LDL and blood pressure alteration between both groups. Blood 
pressure was above target level in 76% of all patients and 12% showed a recorded LDL-
cholesterol level of 20% above the baseline LDL-level (p-value between groups was 0.52 
and 0.4 respectively).
Patient outcomes
No differences between the MMS® and the BMQ were detected at T2 between both 
groups. 29% (usual care) and 31% (intervention group) of the patients showed a low 
adherence according to the MMS®. There were no differences between the two groups 
studied (p-value=0.94). The mean NCD was 3.8 at T2. Again, no differences between 
the two studied groups were present (mean 3.8 vs. mean 3.9, p-value =0.86). We did 
observe a difference in the four BMQ categories. In the intervention group there was 
a shift from ambivalent (from 60% at T1 to 37% at T2) towards accepting (25% at 
baseline to 33% at T2). In the usual care group this shift was from ambivalent (63% to 
43%) to skeptical (4% to 15%) and indifferent (6% to 15%).
See table 3: Differences in adherence, beliefs about medication and clinical outcomes 
is shown in table 3A. The observed adherence difference in time is shown in table 3B: 
Differences in mean medication adherence in time.
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Table 3A: Differences in medication adherence, beliefs about medication and clinical outcome between usual care and 









Total of cardiovascular medication
 Baseline (T1)
 After intervention (T2)











 Antithrombotic agents (B01)
 Diuretics (C03)
 Beta Blocking agents (C07)
 Calcium channel blockers (C08)
 Agents acting (.) 
 angiotensin..(C09)
 Lipid modifying agents (C10)
 After intervention (T2)
 Antithrombotic agents (B01)
 Diuretics (C03)
 Beta Blocking agents (C07)
 Calcium channel blockers (C08)
 Agents acting (..)
 angiotensin..(C09)
 Lipid modifying agents (C10)
 Follow up of 12 months (T3)
 Antithrombotic agents (B01)
 Diuretics (C03)
 Beta Blocking agents (C07)
 Calcium channel blockers (C08)
 Agents acting (.) 
 angiotensin..(C09) 



















































 After intervention (T2)































Beliefs about Medication Questionnaire
Necessity Concern Differential (f )
 Baseline (T1)











































Systolic Blood Pressure (mmHg)
 Baseline (T1)
 After intervention (T2)
 Adherent (h)  
Low- Density Cholesterol (mmol/L)
 Baseline (T1)



















a) Usual care and usual care + are combined and compared with usual care ++ group.
b) Mean number of days dispended divided by the mean number of days between prescription refill.
c) Percentage of patients (%) considered adherent according to PRD total of the cardiovascular medication ( PRD was 
above or equal to 0.8). 
d) Percentage of patients (%) who had low, medium or high adherent scores.
e) Low and medium adherence are combined and compared with high adherence group.
f ) Differences between concern and necessity scores (means).
g) Percentage of patients (%) who are classified in the four different categories of the BMQ.
h) Percentage  of patients (%) considered adherent according to systolic bloodpressure (<135 mmHg) and  percentage 
(%) of patient using anti hypertension drugs.
i) Percentage of patients (%) considered adherent according to LDL-level (The recorded LDL- level after intervention 
was 20% lower of baseline LDL-cholesterol).
Table 3B: Differences in mean medication adherence in time.
All participants (N=419) Baseline (T1) After intervention(T2) Follow up 12 months (T3)
Mean Possession Ratio
Total of cardiovascular medication 0.72 0.92* 0.80**
* p-value <0.05 relative to T1




This study evaluated a nurse-led web-based intervention based on the Health Belief 
Model 11,16,49 and the Necessity-Concern Framework50 on medication adherence to 
treatment. Although we developed the intervention considering the recommendations of 
major reviews on medication adherence interventions8,51-53 we did not see an effect of the 
developed intervention on our main adherence outcome. There are several explanations 
for the absence of an effect of this intervention. First, all patients in our study received the 
same structural cardiovascular care according to the European Guidelines of prevention of 
cardiovascular diseases.20 A previous evaluation of our cardiovascular screening program 
showed that a structural multidisciplinary evaluation and initiation of the best medical 
treatment in combination with addressing unhealthy lifestyle reduces cardiovascular 
risk as indicated by a reduction in smoking, alcohol consumption, unhealthy eating, 
blood pressure, and LDL-cholesterol level.54 Although medication adherence was not a 
structural approach in our usual care setting, the attention and screening on CVD-risk 
factors may have influenced adherence to medication adherence positively.
Second, in this study we used pharmacy refill data as adherence measure. Refill adherence 
rates have extensively been used for the evaluation of medication adherence. Compared 
to electronic monitoring, refill data provide researchers with a relatively simple method 
for investigating adherence to medication in large populations.55 However, due to 
the increasing availability of automatic refills in the Netherlands, this measure may 
represent high adherence levels while patients do not necessarily take their medication.10 
By combining the refill data with a self reported questionnaire we therefore wanted to 
gain a fuller understanding of the adherence behaviour of the patients. The results of 
the used questionnaire also showed no differences in medication adherence between the 
groups. Last, although the use of eHealth interventions is recommended to improve 
healthy behaviour and for tailoring adherence interventions44,56, the website was rarely 
used by our patients. Consequently, we were not able to study the perceived benefits of 
our eHealth intervention on adherence. Future studies should address this. There are 
several explanations why patients didn’t use the website. Patients had to use a special 
personal code, and had to confirm their password with a code they received from a text 
message. These complicated steps may have influenced the use of the website negatively. 
High dropout rates may be a natural and typical feature of eHealth interventions57, 
as was observed in our trial. There were fewer patients as expected who actually used 
the website and/or participated in the group consultation. This could be an indication 
that the intervention might be too intensive and experienced as a burden for patients. 
It could also mean that the intervention program was not enough exposed to enough 
patients to show a significant difference between the intervention group and usual care 
group. We developed the intervention program by using constructs of the HBM en 
the Necessity-Concern Framework but without involving patients. By personalizing the 
content of the individual consultations we believed we tailored the intervention to the 
personal need of the patients. On the other hand, the process in which the content of 
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the program was delivered was not tailored at all. Maybe only tailoring the content is 
not enough and should the process in which the intervention is delivered also be more 
tailored. For further research, we highly recommend involving patients in designing the 
intervention. 
The study did show a difference in adherence in time for all groups. Adherence rates were 
higher during the study period and declined to levels comparable to baseline one year 
after the end of the study. Several explanations can be addressed for this phenomenon. 
First, participation in a study may have encouraged patients to be more adherent.9 
Second, all patients who participated in this study recently had a cardiovascular event. 
For these patients, the need for adherent behaviour is emerging.35,58 Yet, as the event 
fades and there are no more symptoms, adherence can also decline.2 This was also 
observed in our study. We looked even further to see if there was a difference in new 
users of CVRM medication and chronic users. We did observe a relatively high cohort 
of chronic users in our population but this did not have any effect on the outcome. 
Although we did not establish a difference between groups in the NCD, we observed a 
shift in the categories from ambivalent towards accepting in the intervention group, this 
shift was not observed in the usual care group. In the ambivalent group necessity beliefs 
are high but concern beliefs also. In the acceptance group necessity beliefs are high but 
the concern beliefs are low. In order to know if the change in necessity category for the 
intervention group will have a positive effect on the adherence rate over time, we need 
to measure the adherence rate further in time. 
Although overall adherence was relatively high at 12 months follow-up, only 20 % of 
all patients had a systolic blood pressure within target. The mean blood pressure was 
even higher than it was at baseline. In contradiction, only 12% of all patients showed 
a LDL-cholesterol level of 20% above the baseline LDL-level. We can’t really explain 
this difference. Several major studies have demonstrated nonadherence as a major 
determinant for not reaching target levels, as well for lipid lowering medication as for 
antihypertensive medication.59,60 It can be suggested that not reaching target level of 
systolic blood pressure is not necessarily due to nonadherence of the medication.61-63
Limitations
The study had several shortcomings. There were challenges with recruitment and due to 
an organizational decision to no longer supporting the website, we had to stop inclusion 
early and the original recruitment target was not met. This may have underpowered our 
results. However, the confidence interval of the mean of the main outcome (the MPR), 
showed only a very small interval from -.005 to 0.082. Therefore we may assume that 
a larger population size would not have made a difference in MPR between groups. 
We also had to deal with missing data especially on the pharmacy refill data. The 
Dutch healthcare system doesn’t provide a closed pharmacy system to a point of care 
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(like a hospital). Therefore, we were dependent on the willingness of the pharmacists 
to provide us with refill data. This led to missing data. We also had a relatively high 
percentage of patients who did not complete the intervention and/or did not show up 
at the evaluation screening. By using multiple imputations golden standard for dealing 
with missing data we believe we still provided a valid result of this study.38,39 Last, the 
nurses who performed the individual usual care consultations if needed (e.g. to loose 
weight or to quit smoking) were the same nurses as the nurses who performed the 
consultations in our intervention group. This and the fact that all patients visited the 
same outpatient clinic while on chronic care support may led to contamination among 
the groups. In order to prevent from contamination among the groups, the nurses who 
give the usual care should be different from those in the intervention groups.
Conclusion
Our intervention to improve medication adherence in cardiovascular patients did not 
show an effect on improving poor medication adherence. The intervention program was 
developed using the existing evidence and by applying this evidence. The intervention 
was also developed so it could easily be applied to the already existing structured usual 
care for secondary preventive cardiovascular care. By performing a process evaluation 
we gained information that could help future researchers to include elements of this 
intervention. Elements of our intervention program could still lead to improving 
medication adherence, but we were not able to demonstrate it in this trial. This is maybe 
due to high adherence rates in both groups and/or the limited number of patients that 
complied with the intervention program. Adherence rates after the intervention were 
high in both the usual care and the intervention group. This could indicate that the 
structured provided care we already deliver to all cardiovascular patients has a positive 
effect on medication adherence. Or the effect of having a cardiovascular event was the 
key to better adherence.
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Background: Poor medication adherence is a major factor in the secondary prevention 
of cardiovascular diseases (CVD) and contributes to increased morbidity, mortality, and 
costs. Interventions for improving medication adherence may have limited effects as a 
consequence of self-selection of already highly adherent participants into clinical trials. 
Methods: In this retrospective cohort study, existing levels of medication adherence 
were examined in self-decided participants and non-participants prior to inclusion in a 
randomized controlled study (RCT), evaluating the effect of an intervention to improve 
adherence. In addition, the non-participants were further divided into ‘responders’ and 
‘non responders’. All individuals had manifest cardiovascular disease and completed a 
questionnaire with baseline characteristics, the Beliefs about Medicines Questionnaire 
(BMQ) and the Modified Morisky Scale® (MMS®) as part of a regular screening 
program. A logistic regression was conducted to examine the relationship between study 
participation willingness, adherence level and the beliefs about medication. 
Results: According to the MMS® the adherence level was comparable in all groups. 
In both (non)-participants groups, 36 % was classified as high adherent; 46% 
participants versus 44% non-participants were classified as medium adherent and 19% 
of the participants versus 20% of the non-participants were low adherent (p=0.91. The 
necessity concern differential (NCD) from the BMQ was 3.8 for participants and 3.4 
for non-participants (p=0.32). 
Conclusion: This study shows that adherence to medication and beliefs about 
medication do not differ between participants and non-participants before consenting 
to participate in an RCT. The study design seems not to have led to greater adherence 
in the study group.
Keywords: randomized controlled trials, informed consent, participation, selection bias, 
adherence.




Cardiovascular risk reduction is predominantly based on lipid and blood pressure 
lowering treatment, inhibition of platelet aggregation, smoking cessation and control 
of obesity1. A limitation in lowering cardiovascular risk is poor adherence to prescribed 
medication2 which may consequently can lead to increased morbidity, mortality and 
costs3-6. Nevertheless, a recent review with mostly cohort studies, showed that only 60% 
of people who use cardiovascular medication, were adherent to their cardiovascular 
medication7. In view of that there is a need for interventions to improve medication 
adherence in this population. Although there is a considerable amount of research in 
the field of interventions to improve medication adherence in cardiovascular patients, 
they often show only small effects8. It is suggested that patient recruitment methods 
in randomized controlled trials (RCT) to improve patient adherence to medication 
may influence outcome8, 9. An important observation is that patients participating in 
RCTs generally have higher adherence rates at baseline than could be expected based on 
observational studies10-14. It is conceivable that the informed consent procedure results 
in a selection of patients with higher adherence rates12. Willingness to participate is 
positively influenced by patients’ engagement with their medical condition, high level 
of education and the influence of an important person11, 15. These characteristics are also 
considered as positive determinants for medication adherence16. Although a recent review 
showed that the inclusion of non-adherent patients was the single feature significantly 
associated with effective adherence interventions, most studies seem to include patients 
because they are willing to participate not because they are poor adherent11. It is 
suggested that patients participating in these RCTs already have a pre-existing high 
adherence level at baseline10, 12-14. Selection of participants with high levels of adherence 
at baseline, makes it difficult to show an improving intervention effect (ceiling effect)8. 
More understanding about the medication adherence of participants as well as non-
participants before the start of these RCT’s may contribute to a better understanding 
of why so many studies show no improvement in medication adherence. One possible 
explanatory determinant for (non) adherent  behaviour is medication beliefs. Personal 
beliefs about need for treatment (necessity beliefs) and concerns about several potential 
adverse consequences (concern beliefs) could explain a large part of (non) adherent 
behaviour16-18. If patients perceive that the need for medication outweighs the concerns, 





The aim of this study is to explore possible differences in adherence to existing prescribed 
medication in cardiovascular patients who did or did not consent to participate in an 
RCT which expressly explored the effects of an intervention to improve adherence. We 
hypothesized that patients who are willing to participate in a clinical trial are more likely 
to be medication adherent and have more ‘necessity beliefs’ about their medication 
compared to patients who are not willing to participate.
2.2 Study design and setting 
In this retrospective cohort study we included patients who participated or declined 
participation in the (MIRROR) trial ( a Multifaceted nurse -and web-based Intervention 
for impRoving adheRence to treatment in patients with cardiOvasculaR disease)20. 
In brief, the MIRROR trial was a prospective, randomized controlled trial in which 
patients aged ≥ 18 years and diagnosed with a manifest cardiovascular disease (i.e. acute 
coronary syndrome, peripheral arterial disease or stroke/Transient Ischemic Attack 
(TIA)) after providing written informed consent, were included. The MIRROR trial 
aimed to study the effect of different adherence enhancing strategies on cardiovascular 
medication adherence. Within this context, patients were randomized to usual care, 
an e-health intervention, and an e-health intervention combined with motivational 
technique consultations. 
2.3 Participants
All patients referred to the Radboud University Medical Center with a new diagnosis of 
acute coronary syndrome, myocardial infarction, peripheral arterial disease, an aneurysm 
of the aorta or TIA or stroke over the prior 6 weeks were included into the hospital 
CVD screening program. This screening program aims to identify cardiovascular risk 
factors and consists of screening for lifestyle (smoking, diet and exercise), medication 
adherence by the self reported questionnaires Modified Morisky Scale ® (MMS®) and 
the Beliefs about Medication Questionnaire (BMQ), blood lipid levels, blood pressure, 
waist circumference, body mass index (BMI), glucose blood levels and a family history 
of cardiovascular diseases. If indicated, preventive therapies (medication and lifestyle 
interventions) are initiated and followed over time1. All patients referred to this screening 
program were asked to participate in the MIRROR- trial. ‘Participants’ were patients 
who were willing to participate in the intervention study and ‘non-participants’ were 
patients who declined informed consent for the MIRROR trial. Because adherence to 
medication may also differ between responders and non- responders to surveys, with 
responders having higher adherence levels21 we divided the group of non-participants 
further. Retrospectively of the MIRROR trial, a letter was sent to all non-participants 
for a different study not subject to this paper. For this study, a signed informed consent 
was requested from the non-participants. Non-responders were patients who did not 
sign this letter. Responders were patients who signed the informed consent letter. We 
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aimed to explore if the non-responding subgroup of the non-participants differed from 
the responders with respect to their level of medication adherence on the basis of prior 
MMS® from the screening program. 
2.4 Ethical Approval
The Ethical Committee waived the need for a formal informed consent for this study. 
The study was conducted according to the good clinical practice protocol and we used 
usual care data considering the research question of this study. Data was anonymized 
according to the research protocols of the Ethical Committee.
2.5 Outcomes
Participation or declining to participate to the RCT was the independent variable in 
this study. Adherence to medication and the beliefs about medication the dependent 
variables. Adherence to cardiovascular medication was calculated by the MMS® 22-24. 
It consists of eight items aimed at measuring adherence. Each item accounts for 0 or 
1 in the case questions are answered by no or yes  respectively. Consequently, total 
MMS® scores range between 0 and 8. These scores were divided into three levels of 
adherence: low adherence (sum score < 6), medium adherence (sum score 6 to <8) and 
high adherence (sum score of 8)25 . To evaluate patients’ beliefs and perceptions about 
their medication, BMQ  26 was used. This validated questionnaire provides information 
about the beliefs, perceived necessity and concerns the patient has regarding their illness 
and prescribed medication. There are five statements regarding “necessity beliefs” and 
five regarding “concern beliefs”. Patients indicated their degree of agreement with each 
individual statement about the use of their medicines on a five‐point Likert scale. Thus, 
total scores for the necessity and concerns scales could range from 5 to 25. The necessity– 
concerns differential (NCD) was then calculated as the difference between necessity and 
concerns scores and had a possible range of -20 to 20.19, 27. To differentiate between 
patients on the basis of their beliefs about the necessity of their medication and their 
concerns about taking medication, the total necessity and concern scores5-25 were split 
at midpoint (thus 5 - 12 was considered as low and 13 t/m 25 was considered as high). 
Patients were then classified into four different categories: accepting (high necessity and 
low concerns), ambivalent (high necessity and high concerns), skeptical (high concerns 
and low necessity) and indifferent (low concerns and low necessity) 28-30.
From all patients the type of CVD (acute coronary syndrome, myocardial infarction, 
peripheral arterial disease, an aneurysm of the aorta or TIA) was recorded. Also, the 
following baseline and clinical characteristics were collected: age, sex, level of education, 




2.6 Data collection and timeline
Data were derived from the screening program. Data were registered in a secure website 
which could only be accessed by nurses involved in the screening program. Within, on 
average, six weeks after the CVD-event, baseline characteristics and the questionnaires 
were collected for all patients as part of the screening program. 
2.7 Statistical analyses
Data were analyzed and evaluated using SPSS version 22. Descriptive statistics (mean, 
median, standard deviation) were used for all variables. A Mann-Whitney Test was 
used to compare groups (participants and non-participants) with the non parametric 
outcome, the MMS®. Confounders were explored by performing a logistic linear test of 
all the characteristics in the case the groups significantly differed (including the NCD). 
The same Mann-Whitney test was performed to compare the NCD between the groups. 
A logistic regression was used to explore differences between (non) participants and 
the four belief groups. The same statistical analyses were performed for the responders 
and non-responders. A Kruskal-Wallis test was performed to explore the relationship 
between the NCD and the MMS® for all groups.
3. Results
In total, 900 patients with a new cardiovascular event between October 2011 and 
October 2013 were eligible for participation into the MIRROR trial. Of these, 419 
agreed and 481 refused participation. Of all the non-participants who received a letter 
for another study, 220 did not respond. Consequently, 261 non-participants were 
classified as responders ( Figure 1).
3.1 Patient Characteristics 
The total cohort (participants and non-participants) had a mean age of 62 years and was 
predominantly male (67%). Participants significantly differed from non-participants 
with respect to age (61 years versus 63 years, p=0.001), male sex (71% versus 58%, 
p=0.001), systolic blood pressure (136 mmHg versus 142 mmHg, p=0.001). Participants 
were more frequently diagnosed with an acute coronary syndrome (36% versus 16%, 
p<0.001]), were using more beta blocking agents or agents acting on the renin-angiotensin 
system (58 % versus 46 % p= 0.001 and 59% versus 44 % p=0.001, respectively), and 
were using more lipid lowering medication (94% versus 82%, p<0.001). Among the 
non-participants, responders were older (64 versus 60 years, p=0.002) and used more 
agents acting on the renin-angiotensin system (48% versus 37 %, p=0.02) than non-
responders (Tables 1 and 2).
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Age [mean, ±SD) 60.5 [±10] 63 [11] 0.001
Gender (N [%])
 Male 296 [7] 279 [58] < 0.001
 Female 123 [29 202 [42]
Education level (N[%]) < 0.001
 Primary 66 [18] 141 [31]
 Secondary 185 [49] 180 [39]
 University 124 [33] 140 [30]
Labour (N[%]) 0.08
 Paid labour 137 [37] 123 [27]
 Unemployed 98 [26.3] 138 [30]
 Retired 138 [37] 199 [43.3]
Country of origin is the Netherland (N[%]) 0.66
 Yes 327 [90] 398 [86]
 No 37 [10] 64 [14]
Reason referral (N[%]) < 0.001
 acute coronary syndrome 150 [36] 79 [16]
 peripheral arterial disease 71 [17] 101 [21]
 troke/TIA 198 [47] 301 [63]
Blood pressure (mmHg; mean ± SD) < 0.001
 Systolic 136 [±18] 142 [±20] 0.23
 Diastolic 77 [±11] 78 [±11]
Body Mass Index (mean ± SD) 27 [±4] 26 [±4] 0.30
Waist (mean ± SD)
 Male 99.5 [±9] 98.4 [±12] 0.10
 Female 92 [±14] 90 [±13] 0.07
Lipids (mmol/ltr, mean SD)
 Totaal cholesterol 4.5 [±1.1] 4.6 [±1] 0.7
 Triglyceriden 1.8 [±1] 1.7 [±1] 0.01
 HDL 1.2 [±0.3] 1.2 [±0.3] 0.002
 LDL 2.5 [±0.9] 2.6 [±0.9] 0.66
Medication (N [%])
 Antithrombotic agents [ATC B01] 404 [98] 461 [98] 0.78
 Diuretics [ATC C03] 109 [26] 135 [29] 0.44
 Beta Blocking agents [ATC C07] 239 [58] 218 [46] 0.001
 Calcium channel blockers [ATCC08] 65 [16] 72 [15] 0.86
 Agents acting on [..] system [ATC C09] 244 [59] 206 [44] 0.001
 Lipid modifying agents [ATC C10] 387 [94] 384 [82] < 0.001




We did not observe differences in adherence measured by the MMS® between both groups 
(p= 0.99). According to the MMS® 19% of the participants was classified as low adherers 
compared to 20% in the non-participants group. Forty-six percent of the participants 
and 44% of the non-participants were classified as medium adherers, whereas 36% and 
37% were classified as high adherers, respectively. There were no differences in adherence 
according to the MMS® between responders and non-responders (p=0.47). In both the 
responders and non-responders group, 36% scored high on adherence. Sixteen percent 
of the responders were low adherent compared to 24% in the non-responder group. 
Forty-eight percent of the responder group scored a medium adherence and 41% of the 
non-responders. Compared to study participation all characteristics that significantly 
differed between both groups were separately analyzed by a logistic regression analyses. 
None of the variables significantly influenced the association between study participation 
and adherence according to the MMS®.  (Tables 3 and 4)






Age (mean ± SD) 64 [10] 60 [12] 0.002
Gender (N [%])
 Male 120 [58] 129 [59] 0.93
 Female 86 [42] 91 [41]
Education level (N[%])
 Primary 52 [26] 67 [32] 0.43
 Secondary 80 [41] 81 [39]
 University 66 [33] 62 [29]
Labour (N [%])
 Paid labour 49 [25] 68 [33] 0.08
 Unemployed 55 [28] 64 [31]
 Retired 94 [47] 77 [36]
Country of origin is the Netherlands(N[%])
 Yes 174 [88] 181 [86] 0.62
 No 24 [12] 29 [14]
Reason referral (N[%]) 0.89
 acute coronary syndrome 34 [16] 37 [17]
 peripheral arterial disease 47 [23] 46 [21]
 stroke/TIA 125 [61] 137 [62]
Blood pressure (mmHg; mean ± SD)
 Systolic 140 [±19] 142 [±20] 0.30
 Diastolic 78 [±11] 79 [±10] 0.23








Waist (mean ± SD)
 Male 97 [±11] 99 [±12] 0.16
 Female 91 [±13] 89 [±13] 0.36
Lipids (mmol/ltr; mean ± SD)
 Totaal cholesterol 4.6 [±1] 4.6 [±0.9] 0.73
 Triglyceriden 1.7 [±1] 1.7 [±0.9] 0.01
 HDL 1.3 [±0.3] 1.2 [±0.3] 0.06
 LDL 2.5 [±0.9] 2.6 [±0.9] 0.78
Medication(N [%])
 Antithrombotic agents [ATC B01] 196 [97] 213 [98] 0.27
 Diuretics [ATC C03] 62 [31] 56 [26] 0.28
 Beta Blocking agents [ATC C07] 93 [46] 96 [44] 0.74
 Calcium channel blockers [ATCC08] 30 [15] 34 [16] 0.80
 Agents acting on [..] system [ATC C09] 98 [48] 80 [37] 0.02
 Lipid modifying agents [ATC C10] 166 [82] 173 [80] 0.59
3.3 Beliefs about medication
Based on the BMQ the necessity concerns differential (NCD) was 3.8 among participants 
compared to 3.4 among non-participants (p= 0.13). Of all the participating and non-
participating patients 26% were in the accepting group, 67% in the ambivalent group, 
3% in the skeptical and 4% in the indifferent group. No differences were observed 
between the two groups (p=0.23). The mean score of the NCD in the responders 
and non-responders groups was 3.6 and 3.1 respectively (p=0.21). Among the non-
responders 24% were in the accepting group, 61% in the ambivalent group, 6% in the 
skeptical group and 9% in the indifferent group. For the responders this was 27%, 72%, 
2% and 0% respectively. Differences between both groups were statistically significant 
(p<0.01).  Logistic regression analysis on NCD did not significantly influence the 
association between study participation and adherence according to the MMS®. 
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Table 3 Differences participants and non-participants in adherence and beliefs about medication
Totaal Non-participants Participants P-value
Adherence according to the MMS N [%] 0.99
 Low adherence 119 [19] 49 [20] 70 [19]
 Medium adherence 279 [45] 109 [44] 170 [46]
 High adherence 222 [36] 90 [36] 132 [35]
NCD mean [SD] 3.65[±4.8] 3.4 [±5] 3.8 [±4.9] 0.13
Belief Groups [N%] 0.23
 Accepting 160 [26] 61 [24] 100 [27]
 Ambivalent 418 [67] 165 [67] 255 [68]
 Sceptical 19 [3] 10 [4] 9 [2]
 Indifferent 23 [4] 13 [10] 10 [3]
Table 4 Differences responders and non-responders in adherence and beliefs about medication
Totaal Non-responders Responders P-value
Adherence according to the MMS N [%] 0.47
 Low adherence 43 [20] 24 [24] 19 [16]
 Medium adherence 99 [45] 41 [40] 58 [48]
 High adherence 79 [36] 36 [36] 43 [36]
NCD mean [SD] 3.6 [±4.9] 3.1 [±5] 4 [±4.9] 0.17
Belief Groups [N%] 0.001
 Accepting 56 [25] 24 [24] 32 [27]
 Ambivalent 148 [67] 62 [61] 86 [72]
 Sceptical 8 [4] 6 [6] 2 [2]




To our knowledge this is the first study exploring the differences in medication adherence 
in patients who did or did not consent to participate in an RCT evaluating the effect of an 
intervention to improve medication adherence. Our study showed that patients willing 
to participate in an RCT evaluating the effect of an intervention to improve medication 
adherence, have a comparable adherence level to patients who declined participation. 
Even by further exploring the non-participant group in responders and non-responders, 
we did not observe differences in adherence between the groups. Consequently, the results 
of this study suggest that a population representative in adherence level participated in 
an RCT evaluating the effect of an intervention to improve medication adherence.
Previous studies suggested that patients not participating in RCTs to improve medication 
adherence have a different pre-existing adherence level from patients who participate10-14. 
This was supported by the observed differences in adherence levels between these RCTs 
and observational studies10-14.  Typically, adherence levels among patients in RCTs were 
higher than in observational studies. Although not different among participants and 
non-participants, adherence in this study was also high. An explanation for the high 
adherence rate in both groups could be that we started inclusion for the RCT within six 
weeks after the cardiovascular event. For cardiovascular patients who just had an event, 
the need for adherent behaviour is emerging31, 32. Yet, as the event fades and symptoms 
subside, adherence levels can also decline33. Research with a long follow up is needed 
to establish if there will be a difference in adherence between participants and non-
participants over time. 
In all groups, we observed significant differences in patient characteristics. Compared to 
non-participants, participants were younger and more were highly educated. This was 
also observed among responders and non-responders. These are known as prognostic 
characteristics for patients who are willing to participate in a clinical trial15 and for 
a high adherence level34, 35. Although the relationship between socio-demographic 
variables and adherence is mainly weak and inconsistent34, 36, 37 it was expected that these 
characteristics could have been an explanation for the assumed higher adherence rates 
in the participant groups. However, we could not support this hypothesis. Also, next to 
the high adherence rate, a high mean NCD score was present in all groups. This only 
confirmed the adherent behaviour in both groups19.  It is also congruent with earlier 
studies showing that medication beliefs can be a more powerful predictor of medication 
adherence than clinical and socio-demographic factors19, 38. However, we did not observe 
a relationship between NCD and trial participation. We did observe a significant 
difference in the beliefs about medication groups in the (non) responder groups. More 
patients of the non-responder group were also in the indifferent and skeptical group. 
Non-responders of surveys are known for more negative evaluations of healthcare39. 
This could be associated with higher concern beliefs in medication as these are partly 
influenced by the prescriber-patient relationship in healthcare40. The number of patients 
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who differed in these groups was very small and the NCD did not differ. More research 
is needed to draw any conclusions on this point.
This study had some limitations. We had to deal with missing data especially in 
the self reported questionnaires BMQ and MMS®. There were fewer missing in the 
participants group compared to the non-participants group. The questionnaires were 
just implemented in the screening program. As the questionnaires were also part of the 
MIRROR trial, more attention could have been paid to participants for documenting 
these questionnaires. So there were more patients in the non-participant group who 
did not fill out the MMS®. These patients could very well be non-adherent21. There 
are different methods available to measure adherence. Each method has advantages 
and disadvantages. The MMS® 22, 24, 41 is a validated questionnaire that can be easily 
applied to large populations. As MMS® is a subjective measure, adherence levels may be 
higher than what is expected in real life. Refill data from the out-patient pharmacy on 
the other hand has been used extensively to provide insight into drug acquisition and 
dispensing42. However, to use the pharmacy refill data we need an informed consent 
from patients. This study however used data from patients collected only in standard 
care because we wanted to include patients who declined participation in a RCT. Other 
methods, such as MEMS or pill count, seem to influence patient’s behavior through 
direct confrontation . Moreover, application of MEMS is relatively expensive, especially 
when applied in standard care42. The BMQ was used because, to our knowledge, is the 
only validated questionnaire that evaluates patients’ beliefs, necessity and concerns the 
patient has according to his illness and prescribed medication. This in contrast to other 
validated adherence questionnaires that measure specific medication-taking behavior of 
patients26, 43. The high NCD score confirmed the prediction of adherent behaviour in 
both groups19, 38.
4.1 Conclusion
This study showed no differences in medication adherence between participants and 
non-participants prior to the inclusion of the MIRROR trial. A representative group 
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Background: Poor medication adherence limits the secondary prevention of 
cardiovascular diseases (CVDs) and leads to increased morbidity, mortality, and costs. 
Identifying groups of patients at risk of poor adherence behavior could enable an 
intervention to be developed and target patients appropriately. 
Objective: The first aim of this study was to identify homogeneous subgroups of 
cardiovascular outpatients based on their cardiovascular risk factors. Subsequently, 
differences in medication adherence between these groups were examined. 
Methods: In this retrospective, observational study, patients with an established CVD 
were included. Well-known cardiovascular risk factors such as smoking, diet, exercise, 
blood lipid levels, blood pressure, and body mass index were collected. To identify patient 
subgroups, a 2-step cluster analytic procedure was performed. Differences between the 
groups on medication adherence were determined on the outcome of the Modified 
Morisky Scale. Data collection took place between October 2011 and January 2013. 
Results: Cardiovascular risk factors of 530 patients were included in the cluster analysis. 
Three groups were identified. Compared with other clusters (clusters 1 and 2), cluster 
3 contained significantly fewer patients who could be classified as highly adherent and 
more patients classified as medium adherent (23% and 57%, respectively; P = .024). 
This group was characterized by a younger age (53% were <55 years old) and using a 
relatively low number of different medications (41% used <4 different medications). 
Besides, in this subgroup the most smokers (37%), unhealthy alcohol users (27%), 
and patients with unhealthy eating habits (14%) were present. Conclusion: This study 
showed that cardiovascular patients who are relatively young and have an unhealthy 
lifestyle are at risk for nonadherent behavior.
Key words: cardiovascular nursing, cluster analysis, lifestyle, medication adherence, 
secondary prevention




Cardiovascular disease (CVD) remains a major cause of death worldwide. In 2015, 
17.9 million people died of the disease.1 Twenty-five percent of these CVD events occur 
in individuals with a previously established CVD.2 The risk for CVDs can be reduced 
by improving the behavioral risk factors associated with CVD, such as smoking, an 
unhealthy diet, obesity, physical inactivity, and harmful use of alcohol.3 In addition to 
these behavioral interventions, pharmaceutical
treatment with aspirin, statins, and blood pressure (BP)–lowering medication significantly 
reduces morbidity and mortality in patients with established CVD.4,5 Unfortunately, a 
substantial proportion of people do not adhere adequately to cardiovascular medications. 
A recent review showed that only 60% of people who use cardiovascular medication 
were adherent to their cardiovascular medication.6 About 10% of all CVD events may 
even be attributed to poor adherence to medications alone.7 Barriers contributing to 
suboptimal medication adherence can be distinguished in objective factors, such as 
sociodemographic and clinical variables, and more subjective factors, such as patients’ 
personal beliefs about medication.8 Such determinants for nonadherent behavior are 
mostly difficult to change and influence each other.9
Even though there are numerous interventions to improve medication adherence in 
cardiovascular patients, they often show only small effects.10 Besides, these interventions 
are often complex, which make adaptation, implementation, scalability, and 
sustainability difficult in cardiovascular risk management (CVRM).2 To adequately 
target interventions to patients who are at risk of nonadherent behavior, we need to have 
a better understanding of who should be targeted through what interventions.
According to the European guidelines in CVRM, in all patients who have had a 
cardiovascular event, risk factors of CVD (high BP, high cholesterol levels, and unhealthy 
lifestyle behavior) should be identified and preventive therapies (medication and lifestyle 
interventions) should be taken.11 It is known that multiple barriers can influence 
adherence.12 Therefore, these risk factors, together with baseline characteristics (such as 
age and occupation),may also be used to identify patients with CVD who are at risk of 
nonadherent behavior. Other studies applying cluster analysis to medication adherence 
indicate that these homogeneous groups can be identified.13-15 By combining and 
clustering the risk factors of CVD, patient groups who are at risk of nonadherent behavior 
might be better determined. Consequently, an intervention to improve medication 
adherence can be better targeted. The present study applies the well-known CVD risk 
factors of individual patients to a subgroup of patients with suboptimal adherence levels. 
The discriminative power of these subgroups might be enhanced by incorporating data 
about patients’ beliefs about medication. Building on results of previous research,16 the 
first aim of this study is to identify homogeneous subgroups of cardiovascular patients 
based on their potential cardiovascular risk factors and beliefs about their medication. 
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The second aim of this study is to examine whether these subgroups of patients differ 
in the level of medication adherence. Identifying these high-risk groups could enable an 
intervention to be developed and patients to be targeted more appropriately.13
METHODS
Setting and Sample
All patients referred to the Radboud University Medical Center with a new diagnosis 
of 1 of the following conditions are included in the hospital CVD screening program: 
acute coronary syndrome, myocardial infarction, peripheral arterial disease, an aneurysm 
of the aorta, or transient ischemic attacks or ischemic stroke. This regular screening 
program aims to identify cardiovascular risk factors and consists of a screening of 
lifestyle (smoking, diet, and exercise), blood lipid levels, BP, and body mass index(BMI).
If indicated, preventive therapies (medication and lifestyle interventions) are structurally 
initiated and followed over time.11 For the sample size, all the patients who participated 
in this hospital screening program between 2012 and 2013 (530) were included in 
the analysis. Seven percent of the patients did not fill out the Modified Morisky Scale 
(MMS) document and therefore were excluded.
Data Collection and Timeline
Data were derived from the screening program and captured in a secured website that 
could be accessed only by the nurses involved in the screening program by entering a 
security code. 
Within, on average 6 weeks after the CVD event, baseline characteristics and the 
questionnaires were collected for all patients as part of the screening program. The data 
used to identify patients at risk for nonadherent behavior were organized using the World 
Health Organization (WHO) Multidimensional Adherence Model. This conceptual 
framework allows the construction of poor adherence profiles in patients with chronic 
diseases.17 The WHO organizes adherence barriers into 5 dimensions; healthcare/health 
system–, therapy-, condition-, social/economic-, and patient-relatedbarriers.18 Data 
from the regular screening program and from an additional questionnaire used in a 
previous study were classified according this framework.
Healthcare System–Related Factors
Major components of the healthcare system dimension are patients’ perceptions about 
the healthcare system, satisfaction with pharmacy services, and availability of financial 
compensation for the medication.12 In our population, all patients were drawn from the 
same hospital wide screening program and were already discharged from the hospital. 
The hospital care and drugs for all these patients are reimbursed according to the 
national healthcare insurance terms. As a result, healthcare-system characteristics do not 
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vary among eligible patients and were therefore not considered as a separate dimension 
in the present study.
Therapy-Related Factors
Examples of barriers identified in this dimension are occurrence of side effects, complexity 
of drug regimens, and interference of medication taking with daily routines.12 Collected 
data from the regular screening program for this dimension were the number of doses of 
all medication and the type of cardiovascular drugs (platelet aggregation inhibitors, lipid-
modifying agents, and antihypertensive drugs) prescribed. All data included the names 
of the medication arranged by the Anatomic Therapeutic Chemical code. The Anatomic 
Therapeutic Chemical classification system is a measuring unit for international drug 
utilization monitoring and research.19 For the cluster analysis, the number of prescribed 
medications was categorized by the researchers into small (<4 different drugs), medium 
(4–8 different drugs), and large (using ≥9 different drugs).
Condition-Related Factors
Absence of symptoms in the years after an event may result in the perception that the 
illness is benign. This may lead to doubts about the necessity of continuous treatment. 
20 All different CVDs were recorded in our sample. Although a high BMI and especially 
hypertension and hyperlipedemia are clinical outcomes, they can also be considered as 
an indicator for (non)adherent behavior.21 In conformity with the hospital screening 
program, blood was drawn from all patients to determine low-density lipoprotein (LDL) 
cholesterol levels. Blood pressure was measured according to the recommendations of 
the European Society of Hypertension22 with a validated automated device and based on 
a mean of 4 office measurements. The BMI was calculated for each patient. All variables 
were dichotomized for the cluster analysis (within target levels or not). Target BP levels 
were set according to the European Society of Hypertension recommendations (i.e., a 
systolic BP level of <140 mm Hg). Target LDL cholesterol level should be 1.8 mmol/L 
(70 mg/dL). Overweight (yes or no) was defined by a BMI ranging greater than 25 kg/
m2.
Social/Economic Factors
Barriers identified from this dimension can be a lack of social support, financial burden 
of medications, and health literacy.12,23 It is also generally assumed that older (≥65 years) 
patients with CVD usually have worse medication adherence compared with younger 
(<55 years) patients.23,24 The following social economic characteristics were collected as 
part of the usual screening program: age, level of education, and employment status. 
Age was divided into 3 groups: young (<55 years), middle-aged (55–75 years), and aged 
(>75 years).
Patient-Related Factors
An unhealthy lifestyle (smoking, unhealthy diet, and a lack of physical exercise) is 
associated with an increased risk of cardiovascular events.22 It is questionable whether 
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poor medication adherence directly causes worse health outcomes or whether there 
are concomitant factors. It has been speculated that medication adherence is a marker 
for other health choices, the so-called “healthy adherer effect.” 25 Indeed, adherence to 
lifestyle modification was significantly associated with medication adherence in patients 
with post–acute myocardial infarction, suggesting that patients with low medication 
adherence may have an unhealthy lifestyle. 26 If this hypothesis is correct, an (un)
healthy lifestyle could be a marker for (non)adherent behavior. 27 The hospital CVRM 
program includes a lifestyle risk assessment for smoking, alcohol use, physical activity, 
and eating habits. 28  Lifestyle is evaluated through self-report using a computerized 
lifestyle questionnaire and covers smoking, alcohol use, physical activity, and eating 
habits, based on validated questionnaires.  They comprise the following sections ; 
Questions regarding smoking status using questions from the Fragerström questionnaire 
with11questionsaboutcurrent smoking status, smoking history, smoking patterns, and 
smoking addiction.29 If a patient smoked at the time the questionnaire was completed, 
he/she was identified as having a risky smoking lifestyle.
Ten questions from the Alcohol Use Disorders Identification Tests were used to measure 
the quantity and frequency of alcohol consumption and problems associated with 
it. 30-32  Three questions ask about the frequency and amount of use,3 questions ask 
about alcohol dependency, and 4 questions ask about drinking-related problems. Risky 
alcohol consumption was defined by the Dutch College of General Practitioners as men 
drinking more than 3 (standard Dutch glass) units a day and women drinking more 
than 2 units a day 33 and concerned a score of 6 or more on the Alcohol Use Disorders 
Identification Tests.
Three questionnaires, with in total 28 questions, measured eating habits. These 
questionnaires have been validated in a Dutch eating-habits study about fat, fibre, fruit, 
and vegetable intake.34,35 36,37 Fourteen questions measured total and saturated fat intake 
as a percentage of total caloric intake. Eight questions measured fibre intake in grams/
kilocalories, and 6 questions measured fruit and vegetable intake in grams per day. 
Having an unhealthy diet was based on 4 criteria: more than 35% of the total caloric 
intake as fat, less than 3 g of fibre per day, more than 200 g of vegetables per day, and 
less than 2 servings of fruit per day. These criteria fit the Dutch standards of healthy diet.
Finally, 7 questions assessed habitual physical activity. These questions were taken from 
the short version of the International Physical Activity Questionnaire.38,39 The questions 
asked about the frequency and intensity of physical activity each week. Patients who had 
fewer than 30 minutes of moderate exercise per day were placed into the “risky lifestyle” 
category.
Central to patients’ medication adherence is their judgment of their personal needs 
for taking medication. 9,40,41 One possible explanatory determinant for (non)adherence 
behavior comprises the beliefs about medication. Personal beliefs about needs for 
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treatment (necessity beliefs) and concerns about several potential adverse consequences 
(concern beliefs) could explain a large part of (non)adherent behavior.9,40,41 If patients 
perceive that the need for medication outweighs the concerns, they are more likely to 
be adherent to their medication.42  To evaluate these patients’ beliefs and perceptions 
about their medication, the Beliefs About Medicine Questionnaire (BMQ) 43 was used. 
This questionnaire was completed as part of the parent study.16 Respondents stated 
their degree of agreement with each individual statement about medicines on a 5-point 
Likert scale. To separate patients based on their beliefs about the necessity of their 
medication and their concerns about taking medication, the total necessity and concern 
scores (5–25) were split at midpoint (thus, 5–12 was considered as low and 13–25 was 
considered as high). Patients were then classified into 4 different categories according to 
the guideline : accepting(high necessity and low concerns), ambivalent (high necessity 
and high concerns), skeptical (high concerns and low necessity),and indifferent (low 
concerns and low necessity).44-46 Adherence was measured using the MMS © 47-49 a 
validated questionnaire consisting of 8 items aimed at measuring adherence. Each item 
accounts for 0 or 1 when questions are answered by no or yes, respectively. Consequently, 
total MMS scores range between 0 and 8. These scores were divided into 3 levels of 
adherence: low adherence (sum score <6), medium adherence (sum score 6 or 7), and 
high adherence (sum score of 8).
Statistical Analysis
Cluster analysis was used to identify groups of patients at risk for nonadherence.
To identify patient subgroups with different adherence behavior, a 2-step cluster analytic 
procedure was performed. 13 First, a hierarchical cluster analysis (the Ward method) was 
performed to determine the number of clusters. The dendrogram obtained with the 
Ward procedure was inspected to identify the best cluster solution. Then, a K-means 
cluster analysis was undertaken to specify the cluster number derived from the Ward 
method. To establish the difference between the groups on medication adherence, the 
groups (clusters) were compared by a χ2 test (all variables were categorical) on the 
outcome of the MMS. SPSS version 25 was used to perform the analyses.
RESULTS
Study Sample
A total of 530 patients participated in this hospital screening program between 2012 and 
2013. Thirty-eight (7%) patients did not fill out the MMS, so 492 patients were included 
in the analysis. For the demographics of the total sample, see Table 1. On average, most 
patients used a medium amount of medication (n = 325 [66%]) and almost all used a 
plated aggregation inhibitor (n = 485 [99%]). Lipid-modifying medication was also used 
by a large number of patients (n = 453 [92%]). The least frequently used medication was 
cardiac therapy (n = 65 [13%]). Blood pressure and LDL were within target level for 
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294 (60%) and 281 (57%) of the patients, respectively. Most patients were middle aged 
(n = 296 [60%]) and retired (n = 192 [39%]) and had completed secondary education 
(n = 223 [45%]). Based on the BMQ, we could differentiate between 4 belief groups. In 
total, 134 patients (27%) were in the accepting group and 324 (66%) in the ambivalent 
group. Concerning their lifestyle, 117 patients (24%) were smokers, 77 patients (15%) 
had unhealthy alcohol consumption, 175 patients (36%) had an unhealthy physical 
activity, and 54 patients (11%) had unhealthy eating habits. The sample characteristics 
regarding the variables as addressed in the Methods section are presented in Table 2.
Table 1: Demographics Total Sample
n (%) or Mean ± SD
Gender Male 324 (66)
Age, y 61 ± 11
Young (<55) 150 (31)
Middle-age (56–75) 296 (60)
Aged (>75) 46 (9)
Education level Primary 109 (22)
Secondary 223 (45)
University 160 (33)






Cluster analysis using the Ward method led us to the selection of a 3-cluster solution. 
This was followed by a K-means cluster analyses where  the number of clusters was 
defined in advance. Table 3 shows the validity of the cluster solutions. Some of the 
used medication, LDL, level of education, and the belief groups showed no significant 
difference between the clusters. According to the variables on which the clusters 
significantly differed, the cluster profiles are described as follows.
Cluster 1
This cluster comprised 212 patients (43% of the total population).Compared  with 
other clusters, patients were of higher age (n = 36[17%] were>75 years), used more 
medication (n = 38 [18%] used >9 different medications), and reached target BP the 
least (n = 95 [55%] did not reach target BP). On the other hand, patients were more 
likely to have a healthy lifestyle, as reflected by healthy eating habits (n = 64 [31%]) and 
healthy alcohol use (n = 153 [72%]).
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Table 2: Medication Details, Clinical Outcomes, Lifestyle Characteristics, and the Belief Groups;
Total Sample (N = 402) n (%) or Mean ± SD
Number of used medication Small (<4) 99 (20)
Medium (4–8) 325 (66)
Large (>9) 68 (14)
Used medication Platelet aggregation 485 (99)
Lipid modifying 453 (92)
Antihypertensive Cardiac therapy 65 (13)
Diuretics 120 (24)
β-Blockers 269 (55)
Calcium channel blockers 70 (14)
RAAS inhibitors 268 (55)
Blood pressure, mm Hg 138.3 ± 19.4
Blood pressure at target level 294 (60)
LDL, mmol/L 2.5 ± 0.9
LDL at target level 281 (57)
BMI, mean ± SD 26.9 ± 4.3
BMI at target level 181 (37)
Currently smoking 117 (24)
Alcohol use Healthy 318 (65)
Could be improved 97 (20)
Unhealthy 77 (15)
Physical activity Healthy 265 (54)
Could be improved 52 (11)
Unhealthy 175 (36)
Eating habits Healthy 118 (24)
Could be improved 320 (65)
Unhealthy 54 (11)




Abbreviations: BMI, body mass index; LDL, low-density lipoprotein; RAAS, Renin-angiotensin-aldosterone system 
inhibitors.
Cluster 2
This cluster comprised 174 patients (35% of the total population). Compared with the 
other clusters, the highest number of patients reached target BP (n = 133 [76%]) and 
were mostly overweight (n = 134 [77%]). In this cluster, patients used the lowest number 
of medications (n = 4 [2%] used<4 medications). Most used a medium number of drugs, 
of which β-blockers (n = 164 [94%]), Renin-angiotensin-aldosterone system inhibitors 
(n = 147 [85%]), cardiac therapy (n = 45 [26%]), and lipid modifying medication (n 
= 168 [97%]) were highest when compared with those in the other groups. According 
to their lifestyles, most patients were unhealthy with respect to physical activity (n = 86 
[49%]) and healthy eating habits (n = 32 [18%]). On the other hand, non-smokers were 
highly present in this group(n=151[87%]).
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Table 3: Cross tabulation of the 3-cluster solutions using Ward and K-Means Methods Cohen K= 0.42)
K-Means Total
Ward Cluster 1 Cluster 2 Cluster 3
Cluster 1 200 11 1 212
Cluster 2 108 1 65 174
Cluster 3 0 0 106 106
Cluster 3
This cluster comprised 106 patients (22% of the total population). Compared with 
other clusters, patients were relatively young (n = 56 [53%] were younger than 55 years) 
and were employed (n = 100 [94%]). This group contained the highest number of 
patients who used a small amount of medication (n = 44 [41%]) and represented a low 
use of β-blockers (n = 23 [22%]), RAAS inhibitors (n = 35 [33%]), and cardiac therapy 
(n = 1 [1%]). On the other hand, compared with other clusters, most of these patients 
used more than 3 units of alcohol a day (n = 29 [27%]), smoked (n = 39 [37%]), and 
had unhealthy eating habits (n = 15 [14%]).
Table 4 presents the demographics, medication details, clinical outcomes, lifestyle 
characteristics, and the belief groups for all clusters.
Medication Adherence
Eighteen percent (n = 90) of all patients had a suboptimal level of adherence. Forty-six 
percent (n = 225) were medium adherent and 36% (n = 177) were highly adherent. 
Among the 3 clusters, patients in cluster 3 were significantly less highly adherent (n = 38 
[23%]). In addition, 57% (n = 60) of the patients in cluster 3 were classified as medium 
adherent. Differences among the 3 clusters were significantly different (P = .024).
Table 4: Demographics, Medication Details, Clinical Outcomes, Lifestyle Characteristics, and the Belief Groups for All 
Clusters
Cluster 1 (n = 212) Cluster 2 (n = 174) Cluster 3 (n = 106) P
Number of used medication <.001
 Small (<4) 51 (24) 4 (2) 44 (41)
 Medium (4–8) 123 (58) 145 (84) 57 (54)
 Large (>9) 38 (18) 25 (14) 5 (5)
Used medication Platelet aggregation 209 (99) 171 (98) 105 (99) .87
 Lipid modifying 189 (89) 168 (97) 96 (91) .02
 Antihypertensive Cardiac therapy 19 (9) 45 (26) 1 (1) <.001
 Diuretics 58 (27) 33 (19) 29 (27) .12
 β-Blockers 82 (39) 164 (94) 23 (22) <.001
 Calcium channel blockers 34 (16) 28 (16) 8 (8) .08
 RAAS inhibitors 86 (40) 147 (85) 35 (33) <.001
Blood pressure at target level 95 (45) 133 (76) 66 (62) <.001
LDL at target level 111 (52) 112 (64) 58 (55) .051
Identification of Cardiovascular Patient Groups at Risk for Poor Medication Adherence
127
7
Cluster 1 (n = 212) Cluster 2 (n = 174) Cluster 3 (n = 106) P
BMI at target level 95 (45) 40 (23) 46 (43) <.001
Age <.001
 Young (<55) 33 (16) 61 (35) 56 (53)
 Middle-age (56–75) 143 (67) 103 (59) 50 (47)
 Aged (>75) 36 (17) 10 (6) 0 (0)
Level of education .09
 Primary 55 (26) 40 (23) 14 (13)
 Secondary 96 (45) 77 (44) 50 (47)
 University 61 (29) 57 (33) 42 (40)
Employment status <.001
 Employed 0 (0) 62 (36) 100 (94)
 Unemployed 3 (1) 6 (3) 6 (6)
 Incapacitate 51 (24) 31 (18) 0 (0)
 Retired 122 (58) 70 (40) 0 (0)
 Housewife/-men 36 (17) 5 (3) 0 (0)
Belief group .18
 Accepting 62 (29) 40 (23) 32 (30)
 Ambivalent 136 (64) 125 (72) 63 (59)
 Skeptical 4 (2) 6 (3) 5 (5)
 Indifferent 10 (5) 3 (2) 6 (6)
Currently smoking 55 (26) 23 (13) 39 (37) <.001
Alcohol use <.001
 Healthy 153 (72) 109 (63) 56 (53)
 Could be improved 38 (18) 38 (22) 21 (20)
 Unhealthy 21 (10) 27 (15) 29 (27)
Physical activity <.001
 Healthy 116 (63) 71 (41) 78 (74)
 Could be improved 26 (12) 17 (10) 9 (9)
 Unhealthy 70 (33) 86 (49) 19 (18)
Eating habits .05
 Healthy 64 (31) 32 (18) 22 (21)
 Could be improved 130 (61) 121 (70) 69 (65)
 Unhealthy 18 (8) 21 (12) 15 (14)
Belief group .18
 Accepting 62 (29) 40 (23) 32 (30)
 Ambivalent 136 (64) 125 (72) 63 (59)
 Skeptical 4 (2) 6 (3) 5 (5)
 Indifferent 10 (5) 3 (2) 6 (6)
Data are presented as n (%) of patients.
Abbreviations: BMI, body mass index; LDL, low-density lipoprotein; RAAS, Renin-angiotensin-aldosterone system 
inhibitors.
Table 5 presents the differences in level of adherence based on the MMS, by cluster.
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Table 5: Differences in Level of Adherence Based on the Modified Morisky Scale by Cluster
Cluster 1 Cluster 2 Cluster 3 P
Low adherence 43 (20) 26 (32) 21 (20) .024
Medium adherence 88 (42) 77 (44) 60 (57) a
High adherence 81 (38) 71 (63) 38 (23) b
DISCUSSION
In this study, we identified homogeneous subgroups of cardiovascular patients based on 
their cardiovascular risk factors and beliefs about medication. We determined 3 different 
clusters, in which we were able to identify patients’ profiles associated with adherence 
levels. The WHO model in which the 5 dimensions of adherence are classified18  was 
used to organize the classical cardiovascular risk factors that might influence adherence 
behavior. Three different groups of patients with CVD could be distinguished in level of 
medication adherence. Consistent with the conclusions found in other research, isolated 
established predictors of adherence are often  insufficient  to identify individual patients 
who are likely to be nonadherent.27
Compared with clusters 1 and 2, patients in cluster 3 had a significantly poorer 
medication adherence. This patient group was characterized by those of a relatively 
young age, using a limited number of medication, and an unhealthy lifestyle. As older 
age has previously been identified as a major determinant for nonadherence.23,24
We looked for explanations for these findings. We found that a younger age at the 
time of a stroke or acute coronary syndrome could possibly be associated with reduced 
medication adherence.50 Although this was an inconclusive finding, it suggests that 
younger patients may be more likely to be nonadherent to preventive medications 
because of lower perceived risk of another CVD, misconceptions about the duration 
of treatment, or concerns about potential harm fromstatins.51 By analysing the single 
variable age in relation to adherence in this population, there was no significant difference 
in adherence among the 3 age groups observed. Only when clustering the variables 
was there a significant difference between the groups on adherence. This also suggests 
that nonadherence manifests itself in interaction with underlying vulnerabilities.27 
Considering an unhealthy lifestyle as a marker for nonadherent behavior27 seems to 
be confirmed in this study. Although clinical outcomes are well-known indicators for 
nonadherence,52,53 our cluster analyses did not show such association. Patients who did 
not reach target BP and LDL levels were not more likely to be nonadherent. There 
may be several explanations for this finding. In our population, LDL and BP were 
measured just at cardiovascular follow-up. Consequently, residual confounding may 
have limited our analyses. Another explanation could be the relatively young age of 
this group. With aging, the prevalence of metabolic syndrome (including hypertension 
and dyslipidaemia) increases.54 Thus, younger patients may already have a (sub)optimal 
level of LDL and BP before the cardiovascular event. Also, a suboptimal adherence 
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level might still achieve clinical benefits with respect to BP and cholesterol levels.55 
Another remarkable finding was that, although a complex drug treatment plan is often 
associated with lower medication adherence,56 only a small number of medications were 
used in the cluster that showed the poorest adherence. This could be explained by the 
clinical outcomes that already were at target. Indication for prescribing medication was 
simply less present. We expected there would be a difference between the clusters in the 
outcome of the BMQ. The clusters, however, showed no significant differences in the 
outcome categories of the BMQ. In our previous studies, the continuous outcome of the 
BMQ, that is, the necessity-concern differential (NCD), was used.57,58 In these studies, 
the NCD corresponded with the outcome of the MMS; next to the high adherence rate, 
a high mean NCD score was present. In the present study, we applied the categorical 
outcomes of the BMQ, the 4 different belief groups, because categorical outcomes are 
the preferred measure for a cluster analysis. The difference between the continuous and 
categorical outcome may explain the absence of an association between the BMQ and 
the MMS.
This study had some limitations. First, we had to deal with non responders of the self-
reported questionnaires BMQ and MMS. It is suggested that non responders have poorer 
adherence levels and beliefs about medication.59 This may limit the extra polarity of the 
results obtained. Second, there are different methods available to measure adherence. 
Each method has advantages and disadvantages.60 The MMS is a validated questionnaire 
that can be applied easily to large populations. However, as MMS is a subjective measure, 
adherence levels may be higher than what is expected in real life.60 Other methods, such 
as the Medication Event Monitoring System or pill count, seem to influence patient’s 
behavior through direct confrontation. Moreover, application of Medication Event 
Monitoring System is relatively expensive, especially when applied in standard care.61 
Second, although comorbidities can play an important role in medication adherence, 
we did not have access to valid data for this study.8
Hence, determinants for nonadherent behavior are mostly complex and influence each 
other.9 Identifying nonadherent behavior in cardiovascular patients by clustering these 
determinants based on their structural cardiovascular screening outcomes can lead to 
a more effective CVRM. The group of patients that showed the poorest medication 
adherence was characterized by a relatively young age, using a limited number of 
medications. This might explain why interventions to improve medication adherence 
in cardiovascular patients were not very successful if they were targeting the elderly, 
polypharmaceutical patients. By developing a new intervention to improve medication 
adherence in cardiovascular patients, there should be a different approach, targeting 
a different patient group. Further research in interventions to improve medication 





Cardiovascular patients who are relatively young and have an unhealthy lifestyle should 
be identified as patients who are at risk for nonadherent behavior. When identified 
these patients should be offered more guidance  on medication adherence. Specifically, 
adherence improving interventions targeting this population may be successful and 
should be subject for future research.
What’s New and Important
• Identifying nonadherent behavior in cardiovascular patients by clustering 
determinants based on the structural cardiovascular screening outcomes can lead 
to a more effective approach to improve medication adherence.
• The group of patients that showed the poorest medication adherence was 
characterized by a relatively young age, using a limited number of medications. 
This is in contrast to the more traditionally known determinants of poor 
adherence (elderly age and polypharmaceutical use of medications).
• Further studies could lead to a different approach to improve medication 
adherence in patients with CVD, targeting a different patient group.
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Aim & summary of the chapters
In this chapter we provide information about the aim of the thesis and a summary of 
the chapters.
1.1 Aim of thesis
Cardiovascular diseases (CVD’s) remain a major cause of death worldwide. In 2019 
there were an estimated 523 million prevalent cases of CVD and 18 million people 
died from CVD (one-third of all deaths in 2019) globally, with projections showing an 
increase to 23.3 million in 2030.1,2 Twenty-five percent of these CVD events are relapses 
in individuals with a previously established CVD. Many studies have proven that the 
risk for a new event can be reduced by improving the behavioural risk factors associated 
with CVD such as smoking, an unhealthy diet, obesity, physical inactivity and harmful 
use of alcohol.3 In addition to these behavioural interventions, pharmaceutical treatment 
with aspirins, statins and blood pressure lowering medication significantly reduces 
morbidity and mortality also in patients with established CVD.4,5 This knowledge has 
been incorporated into the World Health Organization guidelines for the prevention of 
CVD.3 Unfortunately, a substantial proportion of people does not adhere adequately to 
prescribed cardiovascular medications. It was shown that only 60% of the people who 
use cardiovascular medication, was adherent to their cardiovascular medication as it was 
prescribed.6 Poor medication adherence may be responsible for ten percent of the relapse 
CVD events.7 Therefore, improving medication adherence may have significant impact 
on reducing the number of CVD relapses.
The overall aim of this thesis was to develop and evaluate an intervention to enhance 
medication adherence in cardiovascular patients. The intervention should improve 
patients’ adherence behaviour, change patients’ treatment perceptions and beliefs, and 
it should increase the number of patients reaching their target cholesterol and blood 
pressure level. In developing the intervention, the subsequent recommendations for 
adherence intervention were followed: simple interventions that are easy to implement 
in daily practice8, based on patients’ perspectives9, target patients’ capacities and practical 
barriers as well as patients’ beliefs and perceptions of their illness and medication. 
10,11 In the following paragraphs the context and the targeted population (chapter 2), 
the effectiveness of an eHealth intervention (chapter 3) and the development of the 
intervention (chapter 4) are described. The subsequent paragraph deals with the effect 
of the intervention on improving adherent behaviour (chapter 5). The studies on the 
pre-existing adherence levels of participants and non-participants in a randomized 
controlled study (chapter 6) and the identification of cardiovascular patient groups who 
are at risk for non-adherent behaviour (chapter 7) conclude this chapter.
1.2 Context and population (chapter 2)
The existing cardiovascular risk management program for new patients diagnosed with 
acute coronary syndrome, peripheral arterial disease, an aneurysm of the aorta, or stroke/
Chapter 8
140
transient ischemic attack (TIA) was the starting point for our intervention. The routines 
of structured cardiovascular risk management (CVRM) program and performing nurse 
led lifestyle-focused consultations to reduce other cardiovascular risks such as smoking, 
already exist in the outpatient clinic of the Radboud university medical center.12,13 Nurses 
are running this program very successfully. Therefore, it was likely that nurses were also 
very well capable in running an intervention program for medication adherence. They 
are close to the patient and often his family, so there can be a therapeutic partnership 
that is respectful of the beliefs and choices of the patient in determining when and 
how treatment is followed.14 There is also a broad recognition that nurses have a key 
role in understanding and addressing patients‘ beliefs during consultations about their 
medication. 15,16
1.3. eHealth interventions (chapter 3)
Interventions to improve adherent behaviour which are easy to implement in daily 
practice led us to the opportunities of adherence enhancing eHealth interventions. 
With internet applications health-related information support can be offered to large 
groups of patients in a relatively simple way. The definition of eHealth concerns 
internet-supported interventions and eHealth interventions based on technologies such 
as apps, web portals or text message services.17 A review of the literature on this topic 
was executed (chapter 3).17,18 The various interventions appeared to have two common 
aspects: they used eHealth and aimed to increase the participation of patients. This was 
done by actively involving patients in their treatment by setting goals and providing 
feedback, or by giving patients access to their medical records and informing them about 
the treatment. Patient participation in healthcare is playing an increasingly important 
role and can positively influence healthy behaviour, which can result in a positive effect 
on adherence.19 It aims to bring about a positive change or to increase knowledge, 
awareness and understanding. This is done by offering health-related information and 
using internet-based interactive components.20 Based on this knowledge we designed 
an interactive website to provide individual risk communication, feedback of clinical 
outcomes and also an invitation for the patient to become active in managing his/her 
illness and medication. 
1.4 Development of the intervention (chapter 4).
Medication adherence enhancing interventions should improve patients’ intentions to 
take medication and take away emergent practical barriers as well. Such interventions 
should be based on patients’ perspectives9, target patients’ capacities and practical 
barriers, and address their beliefs and perceptions regarding illness and medication 
10,11 All these principles have led us to adopt the Health Belief Model (HBM) as the 
theoretical framework which we used to design the intervention.21, 22 The HBM provides 
a useful framework for designing behaviour change strategies. 
The intervention included 1) the existing care from the cardiovascular risk management 
program (CVRM) 12 ; 2) access to a personalized website. This website provided risk 
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communication, feedback on whether or not target levels of cholesterol and blood 
pressure have been reached, and patients were invited to be active in managing their 
illness and medication; 3) a single group consultation led by a nurse and a pharmacist 
followed by two individual consultations with a nurse. During the group consultations 
patients received information about their disease, cardiovascular medication (such as 
statins, antihypertensive, and antithrombotic agents) and the importance of medication 
adherence. The group consultation was regarded as an efficient way to increase 
knowledge and understanding of the risks. It also provided a social gathering with 
other patients (companions). During the individual consultations, the intervention was 
further tailored on patient’s concerns using the results of the screening questionnaires. 
The involved nurses were especially trained in the importance of medication adherence 
and in motivational interviewing 22. In order to tailor the individual consultations to 
individual patients’ beliefs and perceptions about their medication, the Beliefs about 
Medication Questionnaire (BMQ)23,24 and the Modified Morisky Scale (MMS®)25 
were part of the intervention. These questionnaires provide a structured evaluation of 
possible adherence problems and enable nurses to emphasize patient centeredness in 
their consultation.
1.5 Results of the intervention (chapter 5)
To study the effectiveness of the intervention, a single-center, prospective, controlled 
clinical trial was performed. The outcomes for the RCT were set for three levels; how 
much did the intervention change patients’ adherence behaviour, how much did it 
change patients’ perceptions and beliefs and did the intervention successfully improve 
the clinical outcome by achieving target levels in cholesterol and blood pressure? The 
primary outcome was adherence to CVD medication measured with a dedicated 
calculation of refill data (pharmacy refill dates). The secondary outcomes were the 
outcomes of the BMQ, the MMS and clinical outcomes. As recommended by the 
Medical Research Council Guidance 26 a process evaluation of this intervention program 
was also included.27,28
The process evaluation showed that in total 419 patients were randomized to the 
different groups. After randomization, 148 patients were invited to attend the group 
and individual consultations of which 79 of these participated in the group consultation. 
One-hundred-and–thirty-four and 79 of these patients visited the first and second 
individual consultation, respectively. In total 286 patients got access to the website 
and were requested to visit the website. Seventy-seven patients of both groups actually 
logged-in on the website of which only 37 logged-in more than once.
The intervention did not show an effect on adherence to medication. The percentage of 
adherent patients was 86% in the usual care group and 76% in the intervention group at 
the end of the intervention. One year after the intervention, there also was no significant 
difference detected (percentage of adherent patients was 65% in the usual care group 
and 57% in the intervention group). According to the MMS, 71% (usual care) and 68% 
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(intervention group) was medium or high adherent at the end of the intervention. There 
were no significant differences between the two groups
No differences between the groups in the results of the BMQ were observed either. At 
the end of the intervention, mean LDL level was reduced from 2.5 mmol/L at baseline 
to 2.2 mmol/l and mean systolic blood pressure was increased from 136 mmHg to 155 
mmHg at baseline. There were no differences in LDL and blood pressure alterations 
between both groups. 
1.6 Adherence in (non) participants in a randomized controlled trial 
(chapter 6)
Because of the unexpected high adherence rates in the group of patients that only 
received usual care, we wanted to explore if this could be related to patient characteristics. 
It has been suggested that patients participating in these RCT’s already have a pre-
existing high adherence level at baseline 29-32. Selection of participants with high levels 
of adherence at baseline makes it difficult to show an improving intervention effect 
(ceiling effect)33. The aim of this analysis was to explore possible differences in adherence 
to existing prescribed medication in cardiovascular patients who did or did not consent 
to participate in an RCT which explored the effects of an intervention to improve 
adherence. We hypothesized that patients who are willing to participate in a clinical trial 
are more likely to be medication adherent and score higher on the necessity concerns 
differential (NCD) of the BMQ compared to patients who are not willing to participate. 
In this retrospective cohort study, we included patients who participated or declined 
participation in the (MIRROR) trial (chapter 5).
Participation or declining to participate to the RCT was the independent variable in this 
study. Adherence to medication and the beliefs about medication were the dependent 
variables. Adherence to cardiovascular medication was calculated by the MMS. To 
evaluate patients’ beliefs and perceptions about their medication, the BMQ was used. In 
total, 900 patients with a new cardiovascular event were eligible for participation in the 
MIRROR trial. Of these, 419 agreed and 481 refused participation. The total cohort 
(participants and non-participants) had a mean age of 62 years and was predominantly 
male (67%). Participants significantly differed from non-participants with respect to 
age (61 versus 63 years), male sex (71% versus 58%) and systolic blood pressure (136 
versus 142 mmHg). We did not observe differences in adherence measured by the MMS 
between both groups. According to the MMS 19% of the participants were classified 
as low adherers compared to 20% in the non-participants group. Forty-six percent of 
the participants and 44% of the non-participants were classified as medium adherers, 
whereas 36% and 37% were classified as high adherers, respectively. Based on the BMQ, 
the necessity concerns differential (NCD) was 3.8 among participants compared to 3.4 
among non-participants.
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For the MIRROR trial all patients who had a CVD event were included. However, 
considering the results of our previous studies we came to new insights. We were not 
able to show a significant difference in medication adherence behaviour before or after 
the intervention because there was already a high level of adherent behaviour at start. We 
could not attribute this to participation in a randomized control trial. So we needed to 
have a better understanding of who is at risk for non-adherent behaviour in this specific 
population. This led to the next study.
1.7 Identification of cardiovascular patient groups at risk for poor 
medication adherence (chapter 7)
According to the European guidelines in cardiovascular risk management, in all patients 
who have had a cardiovascular event, risk factors of CVD (high BP, high cholesterol 
levels, and unhealthy lifestyle behaviours) should be identified and preventive therapies 
(medication and lifestyle interventions) should be taken.34 These risk factors, together 
with baseline characteristics (such as age and occupation), may also be used to identify 
CVD patients who are at risk of non-adherent behaviour. By combining and clustering 
the risk factors of CVD, patient groups who are at risk of non-adherent behaviour might 
be better determined. Consequently, an intervention to improve medication adherence 
may be better targeted. The study described in this chapter, applied the well-known 
CVD risk factors of individual patients to a subgroup of patients with suboptimal 
adherence levels. In this retrospective, observational study, patients with an established 
CVD were included. The discriminative power of these subgroups might be enhanced by 
incorporating data about patients’ beliefs about medication. The first step of this study 
was to identify homogeneous subgroups of cardiovascular outpatients based on their 
cardiovascular risk factors. Subsequently, differences in medication adherence between 
these groups were examined. To identify patient subgroups, a 2-step cluster analytic 
procedure was performed. Differences between the groups on medication adherence 
were determined on the outcome of the Modified Morisky Scale. During one year, 530 
patients participated in this hospital screening program. Cluster analysis using the Ward 
method led to the selection of a 3-cluster solution. Eighteen percent of all patients had a 
suboptimal level of adherence. Forty-six percent were medium adherent and 36% were 
highly adherent. Differences in adherence between the three clusters were significantly 
different. 
Compared to clusters 1 and 2, patients in cluster 3 had a significantly poorer medication 
adherence. This patient group was characterized by a relatively young age, the use of a 




The blended intervention we developed and implemented on the basis of currently 
existing knowledge did not result in higher medication adherence rates. In this chapter 
we discuss the results and place them in perspective of the findings in similar studies by 
others.
2.1 Process evaluation
There were fewer patients than expected who actually used the website and/or participated 
in the (group) consultations. Although the use of eHealth interventions is recommended 
to improve healthy behaviour and for tailoring adherence interventions17,35, the majority 
of the participants in the study visited the website only once. Only a small proportion 
visited the website regularly. Consequently, we were not able to study the perceived 
benefits of our eHealth intervention on adherence. There are several explanations why 
patients did not use the website much. High dropout rates are a well-known feature of 
eHealth interventions36, as was confirmed in our trial. Our patients had to use a special 
personal code with an SMS-text authentication. These steps may have complicated the 
use of the website. The website gave access to patients’ LDL and blood pressure results. 
However, these results could also be obtained by making a telephone appointment. 
Or, as one patient put it: “If there would be something wrong with my outcomes you 
would have called me anyway.” We assumed patients would prefer to see their outcomes 
in their own time and not depend on the availability of a nurse in the outpatient clinic. 
This assumption may not be correct. Also, the uptake of the group- and individual 
consultations was less than expected. All patients signed an informed consent form 
before participation in our study in which the information about the possibility of the 
high frequency of extra visits was explained. We made extra phone calls if they did not 
show up to ask them if they still wanted to participate. Most of them answered with yes 
but still did not show up the next time. Again, perhaps the effort they had to put in did 
not outweigh the potential benefits. We learned that despite a thorough literature search, 
the use of evidence and the use of a theoretical framework, we ignored a crucial element; 
we did not ask patients themselves for their wishes in terms of e-support. When we 
started the development of this intervention, patient participation was not as common 
as it is now. The process evaluation gave us much insight in the patient perspective. This 
evaluation showed that the patients did not use the intervention enough to be effective 
as planned. By tailoring the intervention for the individual consults we made the content 
of the intervention as individualized as possible. But maybe only tailoring the content is 
not enough. The format and the way in which the intervention is delivered may also be 
tailored to patient’s information and support preferences.  
We developed the intervention considering the recommendations of major reviews 
on medication adherence interventions8,37-39. However, we did not see an effect of the 
developed intervention on our main adherence outcome. There are some explanations 
for the absence of an effect of this intervention.




First, patients may not have been exposed enough to the intervention (see paragraph 3.1). 
Second, in this study we used pharmacy refill data (PRD) as adherence measure. Refill 
adherence rates have extensively been used for the evaluation of medication adherence. 
Compared to electronic monitoring, refill data provide researchers with a relatively simple 
method for investigating adherence to medication in large populations.40 However, due 
to the increasing availability of automatic refills in the Netherlands, this measure may 
represent high adherence levels while patients do not necessarily take their medication.41 
Since there is no ideal medication adherence measure, it is appropriate to use more than 
one measure. This recommended multi-measure approach was applied in this study and 
both showed medium to high adherence rates. The results of the MMS also showed no 
differences in medication adherence between the groups. One can consider to perform 
adherence research with more direct measurements as measurement of the medication 
in body fluids, such as blood or urine or the presence of a biological marker given 
with the drug or a direct observation of patient’s medication-taking behavior.42 Even 
though these measures are considered to be the very accurate and can be used as physical 
evidence to prove that the patient has taken the medication, there are also concerns 
regarding their use. They simply generate a yes or no result without revealing any pattern 
of nonadherence. Also drug metabolism should be taken into account while considering 
using these methods. Furthermore, direct measures are very expensive and difficult 
to perform. It will also make the patient aware of the observation of his medication 
adherence which can be seen as an intervention in itself.42 However, much more research 
in adequate and objectively measuring medication adherence is needed because even 
after decades of research, it is difficult for healthcare professionals and researchers to 
choose the most suitable adherence measures. Third, all patients in our study received 
the same structural cardiovascular risk assessment, lifestyle intervention and best medical 
treatment and supportive care according to the European Guidelines of prevention of 
cardiovascular diseases.34 All patients in our study received the same usual cardiovascular 
care from the nurses. Although medication adherence was not a structural approach 
in our usual care setting, the attention and screening on CVD-risk factors may have 
influenced adherence to medication positively. A previous evaluation of our nurse-
led cardiovascular vascular risk program showed that a structural multidisciplinary 
evaluation and initiation of the best medical treatment in combination with addressing 
unhealthy lifestyle reduces cardiovascular risk as indicated by a reduction in smoking, 
alcohol consumption, unhealthy eating, blood pressure, and LDL-cholesterol level.12 
A reduction in mortality and morbidity by these nurse-led programs is shown more 
often.43 Moreover, nurses are achieving results, equal or even better than GPs, for the 
management of cardiovascular risk factors.44 Nurses do have a key role in understanding 
and addressing patients’ beliefs during consultations about their medication. Nurses 
are close to the patient and often his family, so there can be a therapeutic partnership 
that is respectful of the beliefs and choices of the patient in determining when and 
how treatment is followed.14 The CVRM at our hospital is performed by specifically 
trained nurses. They are trained in knowledge about cardiovascular diseases and their 
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risk factors. They are also trained in motivational interviewing to support patients to a 
healthy life style. And they are successful in it.12 Nonetheless, the present study did not 
evaluate the actual performance of the nurses in this matter, and quality and individual 
differences in nurses’ communication are likely to exist.
2.3 High adherence in all groups
Because of the high adherence rates in all groups, it was difficult to demonstrate a 
difference between the groups. A power calculation was executed to establish the number 
of patients needed to demonstrate a difference in adherence. But contrary to the level of 
poor adherence we found in our literature search, the overall adherence rate in our total 
population was much higher (50-60% in the literature to 80% in our population). So, 
patients who participate in an adherence study may be patients who already are more 
adherent. This will be discussed further in paragraph 3.5. 
2.4 Pharmacy Refill Dates (PRD)
Trying to get the data needed to calculate the PRD turned out to be a major challenge. 
There was no central database we could use. There was no information about refill 
dates of our patients available for the prescribing clinicians. We had to ask every single 
pharmacist (more than a hundred) if they would be willing to provide us with the refill 
dates of the patients participating in this study. Some pharmacy databases were easy 
to use for the calculation of the PRD. Other databases needed to be cleaned up first 
because all kinds of supplements were documented like non-prescription medication 
and medical aids. Eventually we were able to calculate the PRD for over 80% of the 
patients. It made us aware that in the circle around the patient nobody knows exactly 
if and how often a patient’s medication is supplemented. A prescribing clinician or a 
pharmacist can only rely on the information a patient reports and has no other tools 
at his disposal. Personalized feedback using data obtained from electronic devices who 
monitor the patient’s adherence also tends to have a positive effect on medication 
adherence.45
2.5 Patient’s perceptions and beliefs
In order to enhance adherent behaviour, the perceptions and beliefs of the patient 
need to be taken into account.46 Using the answers of the BMQ enabled the nurses 
to individualize their consultations. A shift in the categories showed from ambivalent 
towards accepting in the intervention group was shown. This was not observed in the 
usual care group. was observed in this study. In the ambivalent group, necessity beliefs 
were high but concern beliefs too. In the acceptance group necessity beliefs were high 
but the concern beliefs were low. In order to know if the change in the necessity category 
for the intervention group would have a more positive effect on the adherence rate over 
time, we need to measure the adherence rate more than one year after the intervention, 
because one year after the intervention, adherence rates were still high in both groups.
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2.6 Effect on cholesterol and blood pressure levels
Although overall adherence was relatively high at 12 months follow-up, only 20% of 
all patients had a systolic blood pressure within target. The mean blood pressure (BP) 
was even higher than it was at baseline. We did not expect this result at all. Several 
major studies did, however, demonstrate that nonadherence is a major determinant for 
not reaching target levels, for lipid lowering medication as well as for antihypertensive 
medication.47,48 There are several ways to elaborate on this finding. The PRD and 
the MMS, even if in combination, may not have been sensitive enough to detect 
nonadherence in our population. We discussed this in paragraph 3.1. Another 
explanation could be that failure to achieve the target systolic blood pressure level is not 
due to nonadherence.30,31 It sometimes seems to be difficult to establish the relationship 
between adherence and BP.49 Also, all BP-measurements were done at the outpatient 
clinic. A 24- hour ambulatory home BP monitoring would have been more accurate.50 
2.7 Adherence in (non) participants of a randomized controlled trial
Because of the unexpected and surprisingly high adherence rates at baseline of our study 
population we wanted to explore the suggestion that patient recruitment methods in 
randomized controlled trials could have resulted in inviting a population with high 
adherence to medication.29,51 Our study of the differences in medication adherence 
among patients who did or did not consent to participate in an RCT showed that 
patients who were willing to participate in the RCT to evaluate the effect of an 
intervention to improve medication adherence had a comparable adherence levels to 
patients who declined to participate. However, the participants were younger and were 
more educated. Because these characteristics are known as prognostic characteristics for 
patients who are willing to participate in a clinical trial 52 and for a high adherence level 
as well,53,54 it was expected that these characteristics could explain the assumed higher 
adherence rates in the participant groups. We could not confirm this hypothesis. 
Also, next to the high adherence rate, a high mean NCD score was present in all groups. 
This is congruent with earlier studies showing that medication beliefs can be a more 
powerful predictor of medication adherence than clinical and socio-demographic 
factors.23,46 However, we did not observe a relationship between NCD and trial 
participation. This suggests that a population representative in adherence levels was 
included in our RCT evaluating the effect of an intervention to improve medication 
adherence. An alternative explanation for the high adherence rates in both groups could 
be that we started inclusion shortly after the initial cardiovascular event, a period in 
which the importance of being adherent is emerging in most patients. Yet, as the impact 
of the event fades and symptoms subside, adherence levels may decline.55,56 Studies with 
a long follow up are needed to establish a difference in adherence between participants 
and non-participants over time. 
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2.8 Identification of patient groups at risk for nonadherent behaviour
In this study, cardiovascular patients who were relatively young, used a limited number 
of medicines and had an unhealthy lifestyle were identified as patients who are at risk 
for non-adherent behaviour. It has been speculated that medication adherence is a 
marker for other health choices, the so-called “healthy adherer effect”.57 Patients with 
low medication adherence may have an unhealthy lifestyle.32 It is suggested that factors 
associated with an unhealthy lifestyle such as poor health knowledge and low self-efficacy 
to change behaviour, also lead to poor adherence. 58 59 But one can also easily turn this 
around. ‘By living as a very healthy person, I don’t need my medication anymore’. This 
would mean that if someone is living really healthy, one would be worse medication 
adherence (trade-off). Both groups are described in the literature.57,60 
Although older age and complexity of drug regimens have previously been identified 
as a major determinant for non-adherence,61,62 we unexpectedly found that a younger 
age at the time of a TIA/stroke or acute coronary syndrome was associated with a 
reduced medication adherence.63 Although this was an inconclusive finding, it suggests 
that younger patients may be more likely to be nonadherent to preventive medications 
due to lower perceived risk of another CVD, misconceptions about the duration of 
the treatment, or concerns about potential harm from statins.64 The other remarkable 
finding was that although a complex drug treatment plan is often associated with lower 
medication adherence 65 in the cluster with the poorest adherence only a small number 
of medicines were used. This could be explained by the clinical outcomes which already 
were at target at baseline. The indication for prescribing medication was simply less 
present. Although cluster three (i.e., patients who are relatively young) showed the poorest 
adherence, our cluster analysis did not show an association between nonadherence and 
clinical outcomes at target level. An explanation could be the relatively young age of 
this group. With aging, the prevalence of metabolic syndrome (including hypertension 
and dyslipidemia) increases.66 Younger patients may already have a (sub)optimal level 
of LDL and BP before the cardiovascular event. By analyzing the single variable age 
in relation to adherence in this population, no significant difference in adherence was 
observed between the three age groups. Only when clustering the variables a significant 
difference between the groups on adherence could be reported.41 
We expected there would also be a difference between the clusters in the outcome of the 
BMQ. The clusters, however, showed no significant differences in the outcome categories 
of the BMQ. In this study, we only used the categorical outcomes of the BMQ (the four 
different belief groups) because categorical outcomes are the preferred measure for a 
cluster analysis. The difference between the continuous and categorical outcome may 
explain the absence of an association between the BMQ and the MMS. Identifying non-
adherent behaviour in cardiovascular patients by clustering determinants based on the 
structural cardiovascular screening outcomes can lead to a more effective approach to 
improve medication adherence. The study showed that isolated established predictors of 
adherence are often insufficient to identify individual patients who are likely to be non-
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adherent.41 Identifying patients who are at risk for nonadherent behaviour should not 
be simply identified with single measures for assessing medication adherence. Different 
risk factors should be taken into account to identify a patient at risk.
3. Conclusion 
Complex problems and partly unexpected interactions between patient characteristics, 
beliefs and behaviour underly poor adherence in cardiovascular patients. Because these 
patients should take their medication for the rest of their lives, the impact of poor 
adherence is huge. Measuring medication adherence is challenging and labour intensive. 
Although the prevalence of non-adherence over a longer period after the initial CVD 
event seems far less than previously thought, there is still a need for interventions to 
tackle this problem. In developing such an intervention, we were convinced that we 
took the right design steps, taking existing knowledge into account. By evaluating this 
study, new insights emerged:
Pharmacy Refill Dates
Improve the way in which data from refill prescriptions are available for the prescribers 
and pharmacists. In order to improve communication about medication adherence 
between prescribers, pharmacists and patients, PRD should be easy to access for 
clinicians. There is a world to win concerning the use of information about medication, 
even in daily practice.
Development of interventions
To improve behavioural change interventions and tailor them to patient’s needs, 
involve patients in the development of these interventions. However, recent studies 
which involved patients in developing interventions did not show a better uptake of 
the interventions. They considered that patient’s needs can differ from each other so 
even if you include patients in intervention development, patients who will be offered 
this intervention can have another, specific need.67,68 A recent review of adherence to 
eHealth technology confirms there still is much to learn about how to adhere patients to 
eHealth.69,70,71 More research should be done on what is effective in getting patients to 
use behaviour change programs in general and eHealth in particular .68,72,71
Cardiovascular risk management (CVRM) by nurses
The key role nurses have in cardiovascular risk programs and improving outcomes 
should be recognized and stimulated. Recognition of the role of nurses in general in 
improving health is increasing. However, nurses have a shared concern about staffing 
problems and inadequate education, training and support. This can result in poor quality 
care.73 Moreover, nurses report that they are frequently not permitted to practice their 
competence to the full and are unable to share their learning, have too few opportunities 
to develop leadership and fulfill leadership roles.74 The world needs 9 million more 
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nurses and midwives to achieve universal health coverage by 2030.75 That is why the 
World Health Organization (WHO) has designated 2020 as the universal year of the 
nurse and the midwife. By investing in and developing nursing worldwide, a triple aim 
should be achieved; greater gender equality, stronger economies and better health.73
Risk profile of patients 
The group of patients that showed the poorest medication adherence was relatively young 
and used a limited number of medicines. This is in contrast to the more traditionally 
known determinants of poor adherence (elderly age and polypharmaceutical use of 
medications). Further studies could lead to a different approach to improve medication 
adherence in CVD patients, targeting a different patient group. 
4. Recommendations 
4.1 Recommendations for further research
In developing an intervention to influence patients’ behaviour, especially e-Health 
programs, we need more insight in patients’ needs and in how to meet these needs. 
In defining the use of a technology and selecting valid adherence measures , the goal 
or the assumed working mechanisms should be leading. Adherence measures can then 
be standardized, which will improve the comparison of adherence rates to different 
technologies with the same goal and will provide insight into how adherence to different 
elements contribute to the outcomes.
In order to confirm that the time to initiate an intervention is important, and perhaps 
should occur much later after a CV event, adherence rates must be measured further in 
time, up to two years after an event. If the adherent rates are lower, a retrospective study 
should be done with the same determinants we used in our study to identify even better 
who are at risk for non adherent behaviour.
The cluster analysis which can help identify CVD patients who are at risk for non 
adherence should be done in a much larger cohort to confirm the findings of this study.
To confirm that our regular nurse led CVRM program is also helpful in improving non 
adherence, we should compare the medication adherence of patients who followed such 
a program with patients who did not.
4.2 Recommendations for clinical practice
Improve the feedback for prescribing clinicians on the refill data on medications of their 
patients. This could be very helpful in the communication between clinician and patient 
about adherent behaviour.
Summary & General Discussion
151
8
Continue with the CVRM program led by nurses. This program is well implemented 
in the Netherlands and could also be very helpful in reducing medication adherence.
Be critical in the kind of patient you think is at risk for nonadherence on the basis 
of their higher age or large number of prescribed medicines. Although these patients 
are often described as at-risk patients, in CVD the relatively young patient with an 
unhealthy lifestyle could be more at risk. Nurses who lead the CVRM programs can 
help their patients and use their skills to help these group of patients especially about 
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Hart- en vaatziekten (HVZ) blijven wereldwijd een belangrijke doodsoorzaak. In 2019 
waren er wereldwijd naar schatting 523 miljoen mensen met een hart- of vaatziekte 
en stierven er 18 miljoen mensen aan een hart- of vaatziekte (een derde van alle 
sterfgevallen in 2019)  Er wordt verwacht dat er in 2030 23,3 miljoen mensen aan een 
HVZ  lijden. 1,2 Vijfentwintig procent van deze HVZ zijn recidieven bij personen met 
een eerder vastgesteld HVZ. Het risico op een nieuwe HVZ kan worden verminderd 
door gedragsinterventies om de risicofactoren die in verband worden gebracht 
met HVZ, zoals roken, een ongezond dieet, obesitas, lichamelijke inactiviteit en 
schadelijk alcoholgebruik, te verbeteren.3 Naast bovenstaande interventies vermindert 
farmaceutische behandeling met antitrombotica, statines en bloeddrukverlagende 
medicatie de morbiditeit en mortaliteit ook aanzienlijk bij patiënten met een HVZ. 
4,5 Deze kennis is opgenomen in de richtlijnen van de Wereldgezondheidsorganisatie 
voor de preventie van HVZ. 3 Helaas houdt een aanzienlijk deel van de mensen zich 
niet voldoende aan de voorgeschreven cardiovasculaire medicatie. Gebleken is dat 
slechts 60% van de mensen die cardiovasculaire medicatie gebruiken, zich houdt aan 
de medicatie voorschriften. 6 Een slechte medicatie therapietrouw kan verantwoordelijk 
zijn voor tien procent van de recidief HVZ-gebeurtenissen. 7 Het verbeteren van de 
medicatie therapietrouw kan een belangrijke invloed hebben op het verminderen van 
het aantal terugvallen van HVZ.
Doel proefschrift
Het algemene doel van dit proefschrift was het ontwikkelen en evalueren van een 
interventie om medicatie therapietrouw bij hart- en vaatpatiënten te verbeteren. De 
interventie heeft als doel het gedrag dat leidt tot medicatie therapietrouw te verbeteren, 
de behandelpercepties en -overtuigingen te veranderen en het aantal patiënten dat hun 
streefwaarden voor cholesterol en bloeddruk bereikt, te verhogen. Bij het ontwikkelen 
van de interventie zijn de volgende aanbevelingen voor interventies ten behoeve van 
verbetering van de medicatie therapietrouw gevolgd: Het moeten eenvoudige interventies 
zijn die gemakkelijk in de dagelijkse praktijk te implementeren zijn 8, gebaseerd op de 
perspectieven van de patient 9, gericht op de capaciteiten en op de praktische barrières 




Samenvatting van de hoofdstukken
Context (hoofdstuk 2)
Het bestaande cardiovasculaire risicomanagement (CVRM) programma voor nieuwe 
patiënten met de diagnose acuut coronair syndroom, perifeer arterieel vaatlijden, 
een aneurysma van de aorta, of een beroerte/transient ischemisch attack (TIA) was 
het uitgangspunt voor onze interventie. Het gestructureerde CVRM programma 
en de uitvoering van door verpleegkundigen geleide leefstijlgerichte consulten om 
cardiovasculaire risico’s, zoals roken, te verminderen, bestaat al in het Radboudumc. 
12,13 Verpleegkundigen voeren dit programma met succes uit. Het was aannemelijk dat 
deze verpleegkundigen ook heel goed in staat waren om een interventieprogramma 
voor verbetering van de medicatie therapietrouw te leiden. Zij staan dicht bij de patiënt 
en vaak ook diens familie, zodat er een therapeutisch partnerschap kan ontstaan met 
respect voor de overtuigingen en keuzes van de patiënt bij het bepalen wanneer en hoe 
de behandeling wordt gevolgd. 14 Ook wordt algemeen erkend dat verpleegkundigen 
een sleutelrol hebben in het begrijpen en aanspreken van de overtuigingen van patiënten 
tijdens consulten over hun medicatie. 15,16
eHealth interventies (hoofdstuk 3)
De aanbeveling voor interventies die eenvoudig in de dagelijkse praktijk te 
implementeren zijn, leidden ons naar de mogelijkheden van eHealth interventies. Via 
internet kan aan grote groepen patiënten op een relatief eenvoudige manier informatie 
worden aangeboden. De Nederlandse definitie van eHealth is als volgt: het gebruik 
van informatie- en communicatietechnologie ter ondersteuning of verbetering van 
de gezondheid en de gezondheidszorg betreft internet ondersteunde interventies en 
eHealth interventies gebaseerd op technologieën zoals apps, web portals of sms-diensten. 
Een review van de literatuur over dit onderwerp werd uitgevoerd. 17,18 De succesvolle 
interventies bleken twee gemeenschappelijke aspecten te hebben: ze maakten gebruik 
van eHealth en hadden tot doel de participatie van patiënten te vergroten. Dit werd 
gedaan door patiënten actief te betrekken bij hun behandeling door doelen te stellen en 
feedback te geven, of door patiënten toegang te geven tot hun medisch dossier en hen te 
informeren over de behandeling. Patiëntenparticipatie in de gezondheidszorg speelt een 
steeds belangrijkere rol en kan een positieve invloed hebben op gezond gedrag, wat kan 
resulteren in een positief effect op medicatie therapietrouw. 19 Het is de bedoeling een 
positieve verandering teweeg te brengen of kennis, bewustzijn en begrip te vergroten. 
Dit gebeurt door het aanbieden van gezondheids gerelateerde informatie en door het 
gebruik van interactieve componenten. 20  
Op basis van deze kennis is er een interactieve website  ontworpen voor individuele 
risicocommunicatie, terugkoppeling van klinische resultaten met een uitnodiging aan 




Ontwikkeling van de interventie (hoofdstuk 4).
Therapietrouw bevorderende interventies dienen de intentie van patiënten om medicatie 
in te nemen te verbeteren en tevens praktische barrières weg te nemen. Dergelijke 
interventies dienen gebaseerd te zijn op het perspectief van de patiënt 9, gericht te zijn 
op de capaciteiten en praktische belemmeringen van de patiënt, en op  de overtuigingen 
en percepties ten aanzien van ziekte en medicatie 10,11 Al deze uitgangspunten hebben 
ons ertoe gebracht het Health Belief Model (HBM) te gebruiken als het theoretische 
kader om de interventie te ontwerpen. 21, 22  Het HBM biedt een nuttig kader voor het 
ontwerpen van gedragsveranderingsstrategieën. De interventie omvatte 1) de bestaande 
zorg van het cardiovasculair risico management programma (CVRM) 12; 2) toegang tot 
een gepersonaliseerde website. Deze website bood risicocommunicatie, feedback over 
het al dan niet bereiken van streefwaarden voor cholesterol en bloeddruk, en patiënten 
werden uitgenodigd actief te zijn in het managen van hun ziekte en medicatie; 3) één 
groepsconsult onder leiding van een verpleegkundige en een apotheker, gevolgd door 
twee individuele consulten met een verpleegkundige. Tijdens de groepsconsulten kregen 
de patiënten informatie over hun ziekte, cardiovasculaire medicatie (zoals statines, 
antihypertensiva en antitrombotica) en het belang van medicatie therapietrouw. Het 
groepsconsult werd beschouwd als een efficiënte manier om de kennis en het begrip van 
de risico’s te vergroten. Het voorzag ook in een sociaal samenzijn met andere patiënten 
(“peers”). Tijdens de individuele consulten werd de interventie verder afgestemd op 
de behoeften van de patiënt. De betrokken verpleegkundigen zijn speciaal getraind 
in het belang van medicatie therapietrouw en in motivational interviewing. 22 Om 
de individuele consulten af te kunnen stemmen op de overtuigingen en percepties 
van individuele patiënten over hun medicatie, maakten de Beliefs about Medication 
Questionnaire (BMQ) 23,24 en de Modified Morisky Scale (MMS®) 25 deel uit van de 
interventie. Deze vragenlijsten bieden een gestructureerde evaluatie van mogelijke 
problemen met medicatie therapietrouw en stellen verpleegkundigen in staat om in hun 
consultatie de nadruk te leggen op patiëntgerichtheid.
Resultaten van de interventie (hoofdstuk 5)
Om de effectiviteit van de interventie te onderzoeken, werd een single-center, 
prospectieve, gecontroleerde klinische trial uitgevoerd. De uitkomsten van de RCT 
werden op drie niveaus vastgesteld; in hoeverre veranderde de interventie het medicatie 
therapietrouw gedrag van patiënten, in hoeverre veranderde de interventie de percepties 
en overtuigingen van patiënten en verbeterde de interventie met succes de klinische 
uitkomst door het bereiken van streefwaarden voor cholesterol en bloeddruk? De 
primaire uitkomst was de medicatie therapietrouw van HVZ-medicatie gemeten met 
een specifieke berekening van apotheek refill data. De secundaire uitkomsten waren 
de uitkomsten van de BMQ, de MMS®  en de klinische uitkomsten. Zoals aanbevolen 




In totaal zijn 419 patiënten gerandomiseerd naar de verschillende groepen. Na 
randomisatie zijn 148 patiënten uitgenodigd voor de groeps- en individuele consulten, 
waarvan er 79 deelnamen aan het groepsconsult. Honderdvierendertig en 79 van 
deze patiënten bezochten respectievelijk het eerste en tweede individuele consult. In 
totaal kregen 286 patiënten toegang tot de website en werd hen gevraagd de website te 
bezoeken. Zevenenzeventig patiënten van beide groepen logden daadwerkelijk in op de 
website, waarvan slechts 37 patiënten meer dan één keer inlogden. 
De interventie bleek geen effect te hebben op de medicatie therapietrouw. Het 
percentage medicatie therapietrouwe patiënten was 86% in de controlegroep en 76% 
in de interventiegroep, aan het einde van de interventie. Een jaar na de interventie is 
er ook geen significant verschil vastgesteld (het percentage therapietrouwe patiënten 
was 65% in de controle groep en 57% in de interventiegroep). Volgens de MMS®  was 
71% (controle groep) en 68% (interventiegroep) gemiddeld of zeer adherent aan het 
einde van de interventie. Er waren ook geen significante verschillen tussen de twee 
groepen in de resultaten van de BMQ. Aan het einde van de interventie was bij alle 
patienten de gemiddelde LDL-spiegel verlaagd van 2,5 mmol/L naar 2,2 mmol/l en 
was de gemiddelde systolische bloeddruk verhoogd van 136 mmHg naar 155 mmHg. 
Er waren geen verschillen in LDL- en bloeddruk veranderingen tussen beide groepen. 
Medicatie therapietrouw bij (niet) deelnemers aan een gerandomiseerde 
gecontroleerde trial (hoofdstuk 6)
Vanwege de onverwacht hoge medicatie therapietrouw in de totale groep patiënten, 
wilden we onderzoeken of dit gerelateerd kon worden aan patiëntkenmerken. Er 
is gesuggereerd dat patiënten die deelnemen aan deze RCT’s bij de start al een hoge 
medicatie therapietrouw hebben. 29-32 Selectie van deelnemers met een hoge medicatie 
therapietrouw op baseline maakt het moeilijk om een verbeterd interventie-effect aan te 
tonen (plafondeffect). 33 Het doel van deze analyse was het onderzoeken van mogelijke 
verschillen in medicatie therapietrouw aan bestaande voorgeschreven medicatie bij 
hart- en vaatpatiënten die wel of niet instemden met deelname aan een RCT waarin de 
effecten van een interventie ter verbetering van de therapietrouw werden onderzocht. 
Wij stelden de hypothese dat patiënten die bereid zijn deel te nemen aan een klinische 
trial vaker medicatie therapietrouw zijn en hoger scoren op de necessity concerns 
differential (NCD) van de BMQ in vergelijking met patiënten die niet bereid zijn deel 
te nemen. In deze retrospectieve cohort studie hebben we patiënten geïncludeerd die wel 
of niet hebben deelgenomen aan de (MIRROR) trial (hoofdstuk 5).
Deelname of afwijzing van deelname aan de RCT was de onafhankelijke variabele in 
deze studie. Medicatie therapietrouw en de overtuigingen over medicatie waren de 
afhankelijke variabelen. De medicatie therapietrouw aan cardiovasculaire medicatie 
werd berekend aan de hand van de MMS® . Om de overtuigingen en percepties van 
patiënten over hun medicatie te evalueren, werd de BMQ gebruikt. In totaal kwamen 




aan de MIRROR trial. Hiervan gingen er 419 akkoord en weigerden er 481 deelname. 
Het totale cohort (de 900 deelnemers en niet-deelnemers) had een gemiddelde leeftijd 
van 62 jaar en was overwegend mannelijk (67%). Deelnemers verschilden significant 
van niet-deelnemers met betrekking tot leeftijd (61 versus 63 jaar), mannelijk geslacht 
(71% versus 58%) en systolische bloeddruk (136 versus 142 mmHg). We hebben geen 
verschillen waargenomen in de medicatie therapietrouw gemeten door de MMS®  tussen 
beide groepen. Volgens de MMS®  werd 19% van de deelnemers geclassificeerd als laag 
medicatie therapietrouw  vergeleken met 20% in de niet-deelnemersgroep. Zesenveertig 
procent van de deelnemers en 44% van de niet-deelnemers werden geclassificeerd 
als gemiddeld medicatie therapietrouw terwijl respectievelijk 36% en 37% werden 
geclassificeerd als hoog therapietrouw. Op basis van de BMQ was de “necessity concerns 
differential” (NCD) 3,8 bij de deelnemers vergeleken met 3,4 bij de niet-deelnemers.
Gezien de resultaten van onze eerdere studies kwamen wij tot nieuwe inzichten. We 
konden geen significant verschil aantonen in medicatie therapietrouw voor of na 
de interventie mede omdat er al een hoog niveau van medicatie therapietrouw was 
bij aanvang. We konden dit hoge niveau niet toeschrijven aan deelname aan een 
gerandomiseerde controlestudie. We moesten dus een beter inzicht krijgen in wie in deze 
specifieke populatie dan wel het risico loopt op niet medicatie therapietrouw  gedrag. 
Dit leidde tot de volgende studie.
Identificatie van cardiovasculaire patiëntengroepen met een risico op 
slechte medicatie therapietrouw  (hoofdstuk 7)
Volgens de Europese richtlijnen voor cardiovasculair risicomanagement moeten bij alle 
patiënten die een HVZ hebben gehad, risicofactoren van HVZ (hoge bloeddruk, hoog 
cholesterolgehalte en een ongezond leefstijlgedrag) worden geïdentificeerd en preventieve 
therapieën (medicatie en leefstijlinterventies) worden gevolgd. 34 Deze risicofactoren 
kunnen, samen met basiskenmerken (zoals leeftijd en beroep), ook worden gebruikt om 
HVZ-patiënten te identificeren die het risico lopen op niet-adherent gedrag. Door de 
risicofactoren van HVZ te combineren en te clusteren, kunnen patiëntengroepen die 
risico lopen op een lage medicatie therapietrouw wellicht beter worden geïdentificeerd. 
Vervolgens kan een interventie om de medicatie therapietrouw te verbeteren gerichter 
ingezet worden. In de studie die in dit hoofdstuk wordt beschreven, zijn de bekende 
HVZ-risicofactoren van individuele patiënten toegepast op een subgroep van patiënten 
met een lage medicatie therapietrouw. In deze retrospectieve, observationele studie 
werden patiënten met een vastgesteld HVZ geïncludeerd. Het discriminerend vermogen 
van deze subgroepen werd vergroot door gegevens op te nemen over de overtuigingen 
van patiënten over medicatie (BMQ). De eerste stap van deze studie was het identificeren 
van homogene subgroepen van cardiovasculaire poliklinische patiënten op basis van 
hun cardiovasculaire risicofactoren. Vervolgens werden verschillen in medicatietrouw 
tussen deze groepen onderzocht. Om subgroepen van patiënten te identificeren werd 
een 2-staps clusteranalyseprocedure uitgevoerd. Verschillen tussen de groepen in 
medicatie therapietrouw werden bepaald aan de hand van de uitkomst van de MMS® . 
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Gedurende een jaar namen 530 patiënten deel aan het CVRM screeningsprogramma 
van het ziekenhuis. Clusteranalyse volgens de Ward methode leidde tot de selectie van 
een 3-cluster oplossing. Achttien procent van alle patiënten had een lage medicatie 
therapietrouw niveau. Zesenveertig procent was gemiddeld medicatie therapietrouw en 
36% was zeer therapietrouw. De verschillen in medicatie therapietrouw tussen de drie 
clusters waren significant verschillend. 
Vergeleken met de clusters 1 en 2 hadden de patiënten in cluster 3 een significant slechtere 
medicatie therapietrouw. Deze patiëntengroep werd gekenmerkt door een relatief jonge 
leeftijd, het gebruik van een beperkt aantal geneesmiddelen en een ongezonde leefstijl. 
Conclusie
Complexe problemen en deels onverwachte interacties tussen patiëntkenmerken, 
overtuigingen en gedrag liggen ten grondslag aan de matige medicatie therapietrouw 
bij hart- en vaatpatiënten. Omdat deze patiënten hun medicatie voor de rest van hun 
leven moeten innemen, is de impact van een suboptimale therapietrouw groot. Het 
meten van medicatie therapietrouw is een uitdaging en bleek arbeidsintensief. Hoewel 
de prevalentie van een lage medicatie therapietrouw over een langere periode na de 
eerste HVZ-gebeurtenis lager lijkt dan eerder gedacht, is er nog steeds behoefte aan 
interventies om dit probleem aan te pakken. Bij het ontwikkelen van de interventie 
voor deze studie, waren we ervan overtuigd dat we de juiste ontwerpstappen hadden 
genomen, rekening houdend met bestaande kennis. 
Onze studie heeft geleid tot de volgende nieuwe inzichten:
Er is een verbetering nodig van de wijze waarop gegevens van herhaal recepten 
beschikbaar zijn voor de voorschrijvers en apothekers. Om de communicatie over 
medicatie therapietrouw tussen voorschrijvers, apothekers en patiënten te verbeteren, 
moet deze informatie gemakkelijk toegankelijk zijn voor zorgverleners. Er is nog een 
wereld te winnen wat betreft het gebruik van informatie over medicatie, zelfs in de 
dagelijkse praktijk.
Zoals de proces evaluatie liet zien, hebben maar weinig patienten gebruik gemaakt van 
de (website) interventie. Om interventies voor gedragsverandering te verbeteren en 
op de behoeften van de patiënt af te stemmen, moeten patiënten bij de ontwikkeling 
van deze interventies worden betrokken. Recente studies waarin patiënten bij de 
ontwikkeling van interventies werden betrokken, wezen echter niet op een betere 
acceptatie van de interventies. Een verklaring hiervoor is dat de behoeften van patiënten 
van elkaar kunnen verschillen, dus zelfs als je patiënten betrekt bij de ontwikkeling 
van interventies, kunnen patiënten die deze interventie aangeboden krijgen een andere, 




van eHealth-technologie door patienten, bevestigt dat er nog veel te leren valt over hoe 
patiënten aan eHealth zullen gebruiken. 37-39 Er moet meer onderzoek worden gedaan 
naar welke interventies effectief zijn om patiënten aan te zetten tot het gebruiken van 
gedrag veranderingsprogramma’s in het algemeen en eHealth in het bijzonder . 36,39,40
De groep patiënten die de slechtste medicatie therapietrouw vertoonde, was relatief 
jong en gebruikte een beperkt aantal geneesmiddelen. Dit staat in contrast met de 
meer traditioneel bekende determinanten van slechte therapietrouw (oudere leeftijd en 
polyfarmaceutisch gebruik van geneesmiddelen). Verdere studies zouden kunnen leiden 
tot een andere aanpak om de medicatietrouw bij HVZ-patiënten te verbeteren, gericht 
op een andere patiëntengroep. 
De sleutelrol die verpleegkundigen spelen bij cardiovasculaire risicoprogramma’s 
en het verbeteren van de uitkomsten moet worden erkend en gestimuleerd. De 
erkenning van de rol van verpleegkundigen in het algemeen bij het verbeteren van 
de algemene gezondheid neemt toe. Verpleegkundigen uiten echter hun zorg over 
een tekort aan personeel en inadequate opleiding, training en ondersteuning. 41 Ook 
melden verpleegkundigen dat zij vaak niet in staat worden gesteld hun bekwaamheid 
ten volle uit te oefenen en dat zij daardoor niet in staat zijn hun kennis te delen, te 
weinig mogelijkheden hebben om leiderschap te ontwikkelen en leiderschapsrollen te 
vervullen. 42 De wereld heeft 9 miljoen meer verpleegkundigen en verloskundigen nodig 
om in 2030 universele dekking van de gezondheidszorg te bereiken.43 Daarom heeft de 
Wereldgezondheidsorganisatie (WHO) 2020 uitgeroepen tot het universele jaar van de 
verpleegkundige en de verloskundige. Door wereldwijd te investeren in verpleging en 
deze te ontwikkelen, moet een drievoudig doel worden bereikt: meer gendergelijkheid, 
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De titel van dit proefschrift had ook kunnen zijn “nooit gedacht…”. Toen ik begon met 
mijn verpleegkundige carrière was het geen normale stap voor een verpleegkundige om 
te promoveren. Gestimuleerd door mijn professionele ontwikkeling van de afgelopen 
jaren denk ik daar inmiddels anders over. Verpleegkundigen zijn continue in contact 
met de patiënt op een kwetsbaar moment in hun leven. De betekenis die wij daaraan 
kunnen geven maakt een wezenlijk verschil. Dat moeten we erkennen, laten zien en 
daar moeten we toe in staat gesteld worden. In de afgelopen jaren heb ik veel betrokken 
en excellente collega’s leren kennen die het verschil maken. Toch blijven we vaak op de 
achtergrond. We kunnen onze expertise veel meer delen en laten zien. En dat kan alleen 
als we onze expertise op peil houden en kenbaar maken aan collega’s, management en 
bestuurders. Dan dragen we bij aan de persoonsgerichte, veilige en onderscheidende 
patiëntenzorg die wij uiteindelijk allemaal ambiëren.
Het onderwerp van dit proefschrift sprak me heel erg aan. Medicatie therapietrouw 
is een samenspel van behandeling en een goede integratie van die behandeling in het 
persoonlijk leven van de patient. Alleen de noodzakelijke medicatie voorschrijven is niet 
voldoende om ook het daadwerkelijke behandeleffect te bereiken. De drie eenheid tussen 
patient, arts en verpleegkundige die hiervoor nodig, is vraagt om goede afstemming en 
teamwork. Laat ik daar nu veel energie van krijgen.
Speciaal woord van dank gaat uit naar mijn promotieteam: prof. dr. Kees van Laarhoven, 
prof. dr. Sandra van Dulmen, dr. Bas Bredie en dr. Hein van Onzenoort.
Kees, dank voor het vertrouwen en het creëren van de randvoorwaarden die nodig 
waren om te kunnen promoveren. Zoals eerder gezegd; het is niet gewoon dat een 
verpleegkundige deze kans krijgt. Dat jij je daarvoor hebt ingezet waardeer ik zeer. 
Bijzonder is ook je interesse als chirurg in het onderwerp gedragsbeïnvloeding om de 
patient te ondersteunen te komen tot een gezonde leefstijl. Daardoor past het onderwerp 
van dit proefschrift heel goed bij je. Ik hoop dat we op dit gebied nog vaker met elkaar 
kunnen samenwerken.
Sandra, niets ten nadele van de heren maar wat vond ik het fijn dat er ook een vrouw 
toegevoegd werd aan het team. Dat gaf toch een andere dynamiek. Je hebt ontzettend 
veel expertise op dit onderwerp, ik heb veel van je geleerd. Daarnaast was je ook heel 
benaderbaar en snel met je (altijd opbouwende) feedback. Het vertrouwen wat je steeds 
weer in mij uitsprak heeft me in staat gesteld elke keer opnieuw de schouders eronder 
te zetten. Ik ben erg blij en dankbaar dat je deel uit hebt willen maken van mijn proces 
om tot dit proefschrift te komen.
Hein, wat heb ik veel van je geleerd. Elke vrijdagmiddag opnieuw kwam je langs om te 
polsen hoe het ging. En elke keer had je het geduld om samen te kijken naar de vragen 
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die ik had. Ik heb wat geworsteld met statistiek en SPSS. Het was bijzonder dat dit jou 
makkelijk afgaat maar dat je tegelijk het vermogen had om mij elke keer opnieuw te 
helpen, onvermoeibaar en zonder mij het gevoel te geven dat ik vreemde vragen stelde. 
Ik heb genoten van de groepsconsulten die wij samen hebben gegeven. Het was mooi om 
samen met patienten in gesprek te gaan over medicatie en belang daarvan. Ook toen je 
tijdelijk het Radboudumc verliet ben je me blijven bellen en stimuleren dit proefschrift 
af te ronden. Ik waardeer je erg als expert op dit onderwerp maar nog meer als mens die 
het vermogen heeft anderen mee te nemen in zijn eigen bijzondere kwaliteiten.
Bas, toen ik te horen kreeg van de manuscript commissie dat mijn proefschrift was 
goedgekeurd appte ik je “nooit gedacht”. Jij appte daarop heel rustig terug “ik wel”. 
Dat geeft in een notendop weer hoe wij twee dit traject zijn gestart. Jij was de eerste die 
uitsprak dat ik op dit onderwerp kon promoveren. Je had er eerder vertrouwen in dan ik. 
Ook jij hebt mij onvermoeibaar steeds opnieuw gestimuleerd om verder te gaan. Je hebt 
altijd de keuze bij mij gelaten maar wist elke keer wel de juiste woorden te vinden zodat 
ik zelf verder wilde. Jij bent een van die mensen die je in je leven op je pad moet krijgen 
zodat je boven jezelf kunt uitstijgen. Ik ben je daar zo dankbaar voor.
Ik dank de leden van de manuscriptcommissie, prof. Dr. Hester Vermeulen, prof. Dr. 
Bram Kroon en prof. Dr. Sander Geurts voor het beoordelen en goedkeuren van dit 
proefschrift.
Dan wil ik mijn grote dank uitspreken aan alle deelnemers van mijn onderzoek. Er 
zijn vele vragenlijsten ingevuld en extra ritjes gemaakt naar het ziekenhuis voor een 
groepsconsult of een extra consult. De meest gehoorde reden om mee te doen aan dit 
onderzoek was dat  men hoopte dat ze iets kon bijdragen voor anderen. Vaak was er ook 
een oprechte interesse in de vorderingen van het onderzoek en mijn proefschrift. Dat 
heb ik erg gewaardeerd. De verpleegkundigen van de verschillende specialismen hebben 
ook een grote bijdrage geleverd. Van het includeren van patienten tot het uitvoeren 
van de extra individuele consulten en bloedafnames. Ontzettend veel dank Marielle 
Hartzema-Meijer, Linda van Druten, Angela Arts-van Duren, Ingeborg Booij Liewes-
Thelosen, Karin Kanselaar, Saskia Exters en Sharon Romviel. En een heel speciale 
dank aan Jeannette Roeleveld, mijn maatje bij de vaatchirurgie. Het zal vast niet altijd 
makkelijk zijn geweest dat ik met zoveel zaken tegelijk bezig was maar je bent niet anders 
dan stimulerend geweest, dank daarvoor!
Bij de start van het onderzoek was ik werkzaam als verpleegkundig specialist bij de 
vaatchirurgie binnen de heelkunde. Er waren een aantal mensen die mogelijk hebben 
gemaakt dat ik dit kon doen. Dank daarvoor; Nan Pluymackers, Robert Opsteeg, Daan 
van der Vliet en Luc Knap. Ik kan niet voldoende benadrukken dat het bijzonder is 
dat er op deze wijze in de verpleegkunde is geïnvesteerd. Op de polikliniek is er ook 




van de vaatchirurgie, de altijd enthousiaste polikliniek assistenten en de verpleegkundig 
specialisten. Dank daarvoor, dat gaf elke keer weer opnieuw de goede energie!
Door de ontwikkeling van de website voor dit onderzoek begon ook mijn interesse 
in eHealth. Ik ben ervan overtuigd geraakt dat de (technologische) innovaties ons 
verpleegkundig vak nog persoonlijker kunnen maken en kunnen zorgen voor een 
hernieuwde energie in deze krappe arbeidsmarkt. Ik heb het geluk gehad deze visie 
verder te ontwikkelen binnen de energieke innovatie afdeling REshape. In het bijzonder 
de samenwerking met mensen als Concha Celeste en Lucien Engelen en de REshape 
reizen naar Exponential Medicine hebben me veel inspiratie gegeven. Op het podium 
staan samen met Lucien op verpleegkundige congressen om ons gedachtengoed verder 
te brengen binnen het verpleegkundig domein, was geweldig.
De periode als voorzitter van de VAR heeft me gedwongen om mijn visie op het 
verpleegkundig domein verder te onderzoeken en te verwoorden. Ik ben daar erg goed 
in ondersteund door de verschillende bestuursleden van de VAR en in het bijzonder 
Chel Coenen. Hij heeft me ook gestimuleerd dit proefschrift af te ronden door elke keer 
weer een proefschrift op mijn bureau neer te leggen met de woorden “tja…die is al wel 
klaar…”. Maar meer nog deelde hij zijn enorme kennis over het verpleegkundig vak en 
in het bijzonder de ontwikkeling hiervan binnen het Radboudumc, met me. Het is best 
uniek dat iemand zijn kennis deelt en anderen coacht en motiveert, zodat die ander het 
podium kan pakken. Daar is Chel een ster in. Ik ben dan ook erg blij en trots dat hij 
vandaag als mijn paranimf naast me staat.
Dankbaar ben ik ook voor alle prachtige, mooie, inspirerende verpleegkundigen die 
ik sinds de start van mijn opleiding heb mogen leren kennen. Rolmodellen zoals ik 
nu ook hoop iemand anders rolmodel te kunnen zijn. Verpleegkundigen die vol passie 
en overtuiging in de directe patiëntenzorg staan, verpleegkundigen die zich hebben 
ontwikkeld als verpleegkundig specialist, verpleegkundig docent, verpleegkundig 
onderzoeker, verpleegkundig manager en nog zoveel rollen en functies meer. Het is en 
blijft een prachtig vak. Ik hoop er recht aan te doen.
De afgelopen jaren heb ik mijn horizon ook buiten het verpleegkundig domein verbreed. 
Binnen de transmurale zorg heb ik veel geleerd van Sietske Grol en het was mooi dat 
ook zij net haar promotie heeft afgerond. Met Yvonne Schoon en Ilse de Walvaart 
hoop ik dat we in de toekomst een prachtig centrum gaan neer zetten wat recht gaat 
doen aan onze visie op zorg. Ik kijk met respect naar de medewerkers van CSKV en 
ik ben ervan overtuigd dat we gezamenlijk en met ieders eigen inbreng en kwaliteiten 
het Radboudumc nog een beetje mooier kunnen maken. In het bijzonder heb ik veel 
geleerd van de duale samenwerking met Joost Hopman. Je kunt pas goed met elkaar 
samen werken als je je bewust bent van je eigen professionele identiteit en waar je elkaar 
kunt versterken. We hebben een unieke samenwerking gevonden die me erg dierbaar is.
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In mijn persoonlijke leven heb ik het geluk omringd te worden door prachtige en 
krachtige vrouwen. Zo inspirerend en energie gevend. Dank voor jullie vriendschap, 
ieder uniek; Debby Drost, Saskia Mink, Nanette Haze, Floor Felet, Suzanne Klep, 
Liesbeth Rota, Heleen Vermeulen, Eefke Zekhuis , Mariken Lohman. En mijn wijze 
vrouwen clubje;  Nicoline Hoogerbrugge, Maroeska Rovers en Hanna Eilbracht.
Mijn broer is vandaag mijn andere paranimf. Zoals altijd als steun aan mijn zijde. Hij 
altijd beduidend de slimste, ik nu de enige gepromoveerde 😊. En wat een steun heeft 
hij mij gegeven. Toen onze vader bij de start van dit proces overleed was hij de eerste die 
zag dat ik wilde opgegeven. Dat vond hij onbespreekbaar en hij is sindsdien een enorme 
stimulerende factor gebleven. 
Lieve en Jan, mijn prachtige kinderen. Dank voor wie jullie zijn en dat ik jullie moeder 
mag zijn. Wordt wat je wilt worden, groei en weet dat ik enorm trots op jullie ben. 
Ik hou van jullie. Maurice, al meer dan twintig jaar mijn partner. Dat is niet altijd 
eenvoudig geweest. Maar je hebt me de ruimte gegeven om te leren en te groeien. Je 
moet een krachtige man zijn om dat te kunnen. Enorm veel dank daarvoor. We zijn nu 
bezig met ons nieuwste project, ons mooie huis waar we samen oud in kunnen worden. 
Ik hou van je.
In dankbare herinnering aan mijn ouders:
Wim Sieben * 1948  +2012






Angelien Sieben is geboren op 3 augustus 1973 
in Boxmeer als dochter van Mien Sieben-van 
Lier en Wim Sieben. Ze groeide samen met 
haar oudere broer op in Vierlingsbeek en 
behaalde in 1990 haar havo diploma op het 
Elzendaalcollege in Boxmeer. Ze heeft altijd 
geweten dat ze verpleegkundige wilde worden 
en is gelijk na haar diplomering gestart met 
de inservice opleiding tot A-verpleegkundige 
in het Radboudumc. Na het behalen van dat 
diploma is zij gestart met de HBO-Vv op de 
hogeschool Inholland in Diemen. Tijdens 
deze opleiding heeft zij als verpleegkundige 
gewerkt bij diverse ziekenhuizen en VVT- 
instellingen in en rond Amsterdam. Na het 
behalen van het HBOV diploma is ze nog 
even blijven hangen in het westen en heeft ze 
gewerkt in de psychiatrie van het Kennemer 
gasthuis en de afdeling hematologie van het 
LUMC.
Uiteindelijk is ze weer terug gegaan naar haar thuishaven; Nijmegen en het Radboudumc. 
Daar heeft ze gewerkt als (senior)verpleegkundige op de afdeling algemene interne 
geneeskunde. Angelien heeft toen ook de opleiding tot docent verpleegkunde gevolgd 
en heeft een tijd les gegeven als docent verpleegkunde op het ROC Nijmegen. Na de 
afronding van de Master Advanced Nurse Practitioner (M ANP) is ze ook nog een aantal 
jaar verbonden geweest aan de HAN als intervisie docent van deze opleiding. De M ANP 
heeft ze gevolgd binnen de vaatchirurgie van de afdeling heelkunde. Samen met collega 
verpleegkundigen van de vaatchirurgie, cardiologie, neurologie en interne geneeskunde 
heeft ze daar vorm gegeven aan de inrichting en uitvoering van het cardiovasculaire 
risicoprogramma van het Radboudumc. Daar is ook de basis gelegd voor dit proefschrift.
In 2013 is Angelien voorzitter geworden van de verpleegkundige en paramedische 
adviesraad van het Radboudumc. In 2015 is Angelien daarnaast gestart als Reshape 
Fellow om de verbinding tussen verpleegkunde en technologische innovaties, te 
verstevigen. Dit heeft ze gecombineerd met het werk als verpleegkundig specialist 
binnen de vaatchirurgie en haar promotietraject. Twee jaar geleden heeft ze uiteindelijk 
de keuze gemaakt om niet meer als verpleegkundige in de directe patiëntenzorg te 
werken. Sindsdien richt ze zich op de transmurale zorg om deze verder te versterken, 
onder andere door het project ziekenhuis verplaatste zorg. Ook werkt ze sinds september 
2019 als verpleegkundig directeur van de concernstaf kwaliteit en veiligheid, een duaal 
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functie met de medisch directeur. Er wacht nu weer een nieuwe uitdaging, namelijk als 
verpleegkundig directeur van het centrum voor geïntegreerde zorg.
Sinds de kennismaking met haar inmiddels echtgenoot, werkt Angelien ook graag 
ernaast in de horeca en probeert dit af en toe nog te blijven doen. Angelien is sinds 2003 






Name PhD candidate: A Sieben PhD period: 11-03-2011-22-10-2021
Promotor(s): prof. dr. C.J.H.M. van Laarhoven 
prof. dr. A.M. van Dulmen
Graduate school: Radboud Institute for 
Health Sciences
Co-promotor(s): dr. S.J.H. Bredie 
dr. H.A.W. van Onzenoort
Courses Year completed ECTS
RIHS PhD introduction course 2011 0.75
Scientific Writing for PhD candidates 2012 3
Presentation Skills 2011 1.5
Biometrics course ( statistiek) PAOG Radboudumc, Nijmegen. 2012 5
Teaching Year completed ECTS
Gastdocent wondverpleegkundige opleiding . Radboud Health Academy, Nijmegen. 2018 2
Opdrachtgever en begeleider bachelor studenten HBO-V kwaliteitsproject 2019 3
Workshop beoordeling wetenschappelijk artikel. NVHVV CNE Vasculair, Utrecht. 2011 1
Opdrachtgever en supervisor innovatieproject bachelor geneeskunde studenten 2019 2
Gast docent Master Advanced Nursing Practice. HAN, Nijmegen. 2018 7
Conferences, seminars and lectures Year completed ECTS
CarVasz, oral presentation. NVHVV, Utrecht. 2011 0.5
ESPACOMP Meeting 2011, poster presentation. European Society for Patient 
Adherence and Compliance, Utrecht.
2011 1
European Wound Management Association Congress. EWMA, Copenhagen, 
Denmark.
2013 1
Jaarcongres CaludicatioNet, oral presentation. Claudiocationet, Utrecht) 2016 0.5
European Society for Vascular Surgery Congress, oral presentation. ESVS, Athens, 
Greece. 
2011 1
Rho Chi Lecture “Zorgtechnologie, focus op werkproces en kwaliteit voor de 
patiënt”.  Sigma Theta Tau International, Honor Society of Nursing, Utrecht.
2018 0.5
ICN NP/APN Conference, oral presentation.  International Council of Nurses, 
Rotterdam.
2018 0.5
HIMS & Health 2.0 European , oral presentation.  The Healthcare Information and 
Management Systems Society , Sitges, Spain.
2018 2
Exponential Medicine. Singularity University, San Diego, USA. 2018 2
ESVS annual meeting. European Society for Vascular Surgery, Porto, Portugal. 2015 2





Data collection and management
The data of the was obtained in accordance with the findable Accessible, Interoperable 
and Reusable ( FAIR) principles.
Data was entered by the nurses who performed the screening and the intervention 
consults in the developed website (iVAZ). iVAZ is a secured website which can only be 
entered by the participants by using their social security codes and by selected nurses 
using security codes. In addition, all patient pharmacists received a letter of information 
about the trial, consent of the ethical committee, and the informed consents of the 
participants. They were asked to send the data on refill records of their computerized 
pharmacy systems through a secured email address.
All the data were anonymized according to the privacy protocols from the ethical 
committee and imported by the researcher into SPSS (IBM Corp). These data will be 
stored for at least 15 years and will then be removed.
Informed consent
All cardiovascular patients who receive the regular cardiovascular preventive care 
were asked to participate by a nurse when they arrived at the outpatient clinic for 
their screening consult. Patients received a letter explaining the study, documenting 
their ability to withdraw at any time without explanation, and confirming that their 
medical care will in no way be influenced by their decision regarding participation. At a 
minimum of 24 hours later, written informed consent was sought by a research assistant 
prior to the patient entering the study. These informed consent paper forms are storage 
in a closed archive from the department of surgery.
Ethical Approval
The MIRROR trial ( chapter 5)
The study protocol was approved by the local ethical committee. Approval for this study 
was obtained by the Local Ethical Committee, the human related research committee 
of the Arnhem-Nijmegen region (CMO no 2011/062), which applied criteria described 
in the Medical Scientific Research with People Act (WMO), the Helsinki Declaration, 
the Good Clinical Practice (GCP), EU Guideline Good Clinical Practice, Clinical trials 
guidelines on medicinal products and in CCMO guidelines. 
Chapters 6 and 7 
The Ethical Committee waived the need for a formal informed consent for this study. 
The study was conducted according to the good clinical practice protocol and we used 
usual care data considering the research question of this study. Data was anonymised 
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Beliefs about medicines questionnaire (BMQ)
Original
Your views about medicines prescribed for you
We would like to ask you about your personal views about medicines prescribed for you.
These are statements other people have made about their medicines. Please indicate the extent 
to which you agree or disagree with them by ticking the appropriate box.
There are no right or wrong answers. We are interested in your personal views.
Rated: strongly agree, agree, uncertain, disagree, strongly disagree.
1. My health, at present, depends on my medicines.
2. Having to take medicines worries me.
3. My life would be impossible without my medicines.
4. Without my medicines I would be very ill.
5. I sometimes worry about long-term effect of my medicines.
6. My medicines are a mystery to me.
7. My health in the future will depend on my medicines.
8. My medicines disrupt my life.
9. I sometimes worry about becoming too dependent on my medicines.
10. My medicines protect me from becoming worse.
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Your views about medicines in general
We would like to ask you about your personal views about medicines in general. 
These are statements other people have made about medicines in general.
Please indicate the extent to which you agree or disagree with them by ticking the appropriate box.
There are no right or wrong answers. We are interested in your personal views.
Rated: strongly agree, agree, uncertain, disagree, strongly disagree.
1. Doctors use too many medicines
2. People who take medicines should stop their treatment for a while every now and 
again.
3. Most medicines are addictive
4. Natural remedies are safer than medicines.
5. Medicines do more harm than good.
6. All medicines are poison.
7. Doctors place too much trust on medicines.





Uw mening over de medicijnen die u zijn voorgeschreven
We willen u graag vragen naar uw persoonlijke mening over aan u voorgeschreven 
medicijnen. 
Hieronder staan uitspraken die andere mensen hebben gedaan over hun medicijnen. 
Geef aan in welke mate u het eens of oneens bent met de uitspraken door het passende 
vakje aan te kruisen. 
Er zijn geen goede of foute antwoorden; het gaat om uw mening.
Mogelijke antwoorden: helemaal mee eens, mee eens, neutraal, mee oneens, helemaal 
mee oneens. Kruis het bolletje aan wat op u van toepassing is.
1. Mijn gezondheid is momenteel afhankelijk van mijn medicijnen.




 Helemaal mee oneens
2. Het baart mij zorgen dat ik medicijnen moet gebruiken.




 Helemaal mee oneens
3. Ik kan absoluut niet zonder mijn medicijnen.




 Helemaal mee oneens
4. Zonder mijn medicijnen zou ik me erg ziek voelen.




 Helemaal mee oneens
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5. Ik maak me soms zorgen over de effecten van mijn medicijnen op de lange 
termijn.




 Helemaal mee oneens
6. Ik weet niets over mijn medicijnen.




 Helemaal mee oneens
7. Mijn toekomstige gezondheid hangt af van mijn medicijnen.




 Helemaal mee oneens
8. Mijn medicijnen ontregelen mijn leven.




 Helemaal mee oneens
9. Ik ben soms bang dat ik te afhankelijk word van mijn medicijnen.




 Helemaal mee oneens
10. Mijn medicijnen zorgen ervoor dat mijn gezondheid niet achteruit gaat. 








Uw mening over medicijnen in het algemeen
We willen u graag vragen naar uw persoonlijke mening over medicijnen in het algemeen. 
Hieronder staan uitspraken die andere mensen hebben gedaan over medicijnen in het 
algemeen.
Geef aan in welke mate u het eens of oneens bent met de uitspraken door het passende 
vakje aan te kruisen. 
Er zijn geen goede of foute antwoorden; het gaat om uw mening.
Mogelijke antwoorden: helemaal mee eens, mee eens, neutraal, mee oneens, helemaal 
mee oneens.
1. Artsen schrijven teveel medicijnen voor.




 Helemaal mee oneens
2. Mensen die medicijnen gebruiken, zouden af en toe hun medicatie een tijdje 
moeten stoppen.




 Helemaal mee oneens
3. De meeste medicijnen zijn verslavend.




 Helemaal mee oneens
4. Natuurlijke geneeswijzen zijn veiliger dan medicijnen.




 Helemaal mee oneens
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5. Medicijnen schaden meer dan dat ze baten.




 Helemaal mee oneens
6. Alle medicijnen zijn vergif.




 Helemaal mee oneens
7. Artsen stellen te veel vertrouwen in medicijnen.




 Helemaal mee oneens
8. Als artsen meer tijd voor patiënten zouden hebben, zouden ze minder medicijnen 
voorschrijven.








Modified Morisky Scale (MMAS-8)
Original :
The first seven questions you can answer by a “yes” or a “no”. The 8th question you can 
answer by : never, rarely, once in a while, sometimes, usually, all the time
1. Do you sometimes forget to take your medication?
2. Over the past two weeks, where there any days when you did not take your 
medicines? 
3. Have you ever cut back or stopped taking your medicines without telling the 
doctor because you felt worse when you took it?
4. When you travel or leave home, do you sometimes forget to take along your 
medicines?
5. Did you take your medicines yesterday?
6. When you feel like your blood pressure is under control, do you sometimes stop 
taking your medicines?
7. Taking medicines every day is a real inconvenience for some people. Do you ever 
feel hassled about sticking to your blood pressure treatment-plan?





Vragenlijst naar het gebruik van uw medicijnen
De eerste zeven vragen kunt u met “ja” of “nee” beantwoorden. De achtste vraag kunt u 
beantwoorden met: nooit, zelden, soms, regelmatig, vaak, altijd.
1. Vergeet u wel eens uw medicijnen in te nemen?
 Ja
 Nee




3. Hebt u ooit uw medicatie verminderd of gestopt zonder het de arts te melden, 
omdat u zich slechter voelde na het innemen van de medicijnen? 
 Ja
 Nee




5. Hebt u gisteren uw medicijnen ingenomen?
 Ja
 Nee
6. Stopt u wel eens met het innemen van uw medicijnen wanneer u het gevoel heeft 
dat uw ziekte onder controle is?
 Ja
 Nee
7. Voor sommige mensen veroorzaakt het dagelijks innemen van medicijnen veel 
ongemak. Voelt u zich wel eens gestrest omdat u zich aan het behandelingsplan 



















Universitair Medisch Centrum St. Radboud
INSTRUCTIE 
Veel klachten en ziekten hangen samen met leefstijl. Met leefstijl bedoelen we de 
dagelijkse gewoonten: wat we eten en drinken, of we roken en hoeveel we bewegen.
Aan de hand van deze vragenlijst willen we uw leefstijl in kaart brengen. Het doel daarvan 
is om methoden te ontwikkelen om mensen beter te kunnen adviseren over hun leefstijl.
De vragenlijst bestaat uit circa 90 eenvoudige vragen en uitspraken. Het invullen kost u 
ongeveer 25 minuten.
De meeste vragen kunt u beantwoorden door het hokje voor het antwoord van uw keuze 
in te kleuren. U kunt steeds maar één antwoord geven. 
Bij een aantal vragen kunt u de antwoorden invullen op de stippellijntjes. 
Deze vragen gaan over het roken van tabak.
1. Rookt u? 
 Ja (u kunt doorgaan met vraag 3)
 Nee
2. Heeft u wel eens gerookt?
 Ja, maar ik ben het afgelopen jaar gestopt (u kunt doorgaan met de vragen 
over beweging op bladzijde 8)
 Ja, maar ik ben langer dan een jaar geleden gestopt (u kunt doorgaan met de 
vragen over beweging op bladzijde 8)
 Nee (u kunt doorgaan met de vragen over beweging op bladzijde 8)
3. Hoe lang rookt u al? (als u tussen door één jaar of langer gestopt bent, deze tijd 
niet meetellen)
………jaar           







5. Rookt u elke dag?
 Ja
 Nee (ga verder met vraag 12)
6. Hoe snel na het ontwaken (’s ochtends) rookt u voor het eerst?
 Binnen 5 minuten na ontwaken
 6-30 minuten na ontwaken
 31-60 minuten na ontwaken
 meer dan 60 minuten na ontwaken
7. Vindt u het moeilijk niet te roken op plaatsen waar het verboden is zoals 
bijvoorbeeld in de kerk, bibliotheek, bioscoop of andere openbare gelegenheden?
 Ja
 Nee
8. Op welk tijdstip van de dag kunt u het roken het moeilijkst missen?
 In de ochtend (eerste sigaret, shagje, sigaar of pijp van de dag)
 Op alle andere tijdstippen
9. Hoeveel sigaretten (of lees hier: shagjes, sigaren, pijpen) rookt u per dag?
 10 per dag of minder
 11-20 per dag
 21-30 per dag
 31 per dag of meer




11. Rookt u wanneer u zo ziek bent dat u het grootste gedeelte van de dag in bed ligt?
 Ja
 Nee
12. Vindt u het een probleem dat u rookt?
 Ja
 Nee






14. Denkt u dat het u lukt om te stoppen met roken, als u dat zou willen?
 Ja
 Nee
15. Bent u van plan de komende maand te stoppen met roken?
 Ja
 Nee
16. Is het u in het afgelopen jaar wel eens gelukt om langer dan één dag bewust niet 
te roken?
 Ja
 Nee (ga verder met vraag 18)
17. Hoe vaak is het u in het afgelopen jaar gelukt om langer dan één dag bewust niet 
te roken?
…………. keer
18. Rookt u wel eens marihuana of hasjies?
 nooit
 minder dan maandelijks
 maandelijks
 wekelijks
 dagelijks of bijna dagelijks
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Deze vragen gaan over beweging.
De volgende vragen gaan over uw lichamelijke activiteit gedurende de afgelopen 7 
dagen. Beantwoordt u alstublieft alle vragen, ook al beschouwt u uzelf als niet lichamelijk 
actief. Denkt u aan activiteiten die u doet op het werk, in en rond het huis, om van de 
ene naar de andere plaats te komen en activiteiten in uw vrije tijd voor recreatie, training 
of sport.
Denkt u aan alle zware lichamelijke activiteiten die u deed in de afgelopen 7 dagen. 
Zware lichamelijke activiteiten zijn activiteiten die veel lichamelijke inspanning kosten 
en voor een veel snellere ademhaling zorgen. Denk alleen aan de activiteiten die u ten 
minste 10 minuten per keer heeft verricht.
1. Als u denkt aan de afgelopen 7 dagen, op hoeveel van deze dagen heeft u zware 
lichamelijke activiteiten verricht zoals zware lasten tillen, spitten, aerobics of 
wielrennen? 
………….dagen per week
 geen zware lichamelijke activiteiten  (ga naar vraag 3)
2.  Op de dagen dat u zwaar lichamelijk actief was, hoeveel tijd heeft u daar dan 
gewoonlijk (ongeveer) aan besteed?
………….uren per dag
………….minuten per dag
 weet ik niet, ook niet bij benadering
Denkt u aan activiteiten die matige lichamelijke inspanning kosten en die u in de 
afgelopen 7 dagen heeft verricht. Matig intensieve lichamelijke activiteit laat u iets 
sneller ademen dan normaal. Denkt u weer alleen aan activiteiten die u ten minste 10 
minuten per keer heeft verricht.
3. Als u denkt aan de afgelopen 7 dagen, op hoeveel van deze dagen heeft u matig 
intensieve lichamelijke activiteit verricht, zoals het dragen van lichte lasten, fietsen 
in een normaal tempo of dubbeltennis? 
Laat wandelen hier buiten beschouwing.
 ………….dagen per week




4. Op de dagen dat u matig intensief lichamelijk actief was, hoeveel tijd heeft u daar 
dan gewoonlijk (ongeveer) aan besteed?
………….uren per dag
………….minuten per dag
 weet ik niet, ook niet bij benadering
5. Als u denkt aan de afgelopen 7 dagen, op hoeveel dagen heeft u tenminste 
10 minuten per keer gewandeld? Denk hierbij aan wandelen op het werk en 
thuis, wandelen om van de ene naar de andere plaats te komen, en al het andere 
wandelen dat u deed tijdens recreatie, sport of vrijetijdsbesteding.
………….dagen per week
 geen wandelen (ga naar vraag 7)
6. Op de dagen dat u ten minste 10 minuten per keer wandelde, hoeveel tijd heeft 
u daar dan gewoonlijk (ongeveer) aan besteed?
………….uren per dag
………….minuten per dag
 weet ik niet, ook niet bij benadering
7. Hoeveel tijd bracht u gewoonlijk zittend door gedurende een doordeweekse dag 
in de afgelopen 7 dagen? Bij deze tijd mag zitten achter een bureau, tijd die 




 weet ik niet, ook niet bij benadering
8. Vindt u dat u te weinig beweegt?
 Ja
 Nee





10. Denkt u dat het u lukt om meer beweging te nemen, als u dat zou willen?
 Ja
 Nee
11. Bent u van plan de komende maand meer beweging te gaan nemen?
 Ja
 Nee
12. Is het u in het afgelopen jaar wel eens gelukt om meer beweging te nemen? 
 Ja
 Nee
Deze uitspraken gaan over eten.
1. Ik gebruik halfvolle of magere melkproducten (zoals halfvolle melk en koffiemelk, 








3. Als ik mijn brood met vleeswaren beleg, dan kies ik uit de volgende soorten: 





 Ik eet nooit vleeswaren op brood. 
4. Als ik mijn brood smeer, dan doe ik daar (dieet) halvarine op of een zogenaamd 








5. Als ik jus of saus gebruik bij mijn maaltijd, dan neem ik een met water aangelengde 




 Ik gebruik nooit jus of saus. 
6. Het bakken of braden van vlees, vis of aardappelen doe ik in roomboter of 




7. Voor het roerbakken (in bijvoorbeeld een wok) van kleingesneden groenten, 




8. Ik vervang vlees wel eens door vis. Bij elkaar eet ik één keer vis per week of vaker 
































15. Mijn ontbijt of lunch bestaat voor het grootste deel uit brood of andere 
graanproducten zoals roggebrood, krentenbrood, muesli, tarwevlokken (in pap 
of ontbijtdranken), havermout, ontbijtkoek of crackers.
 Ja
 Nee
16. Ik kies vooral volkorenproducten (volkoren/bruinbrood, donker roggebrood) als 
ik brood of graanproducten eet.
 Ja
 Nee
17. Ik eet minstens zes dagen in de week aardappelen, rijst of pasta.
 Ja
 Nee
18. Bij de warme maaltijd eet ik minstens drie kleine aardappelen of drie opscheplepels 
(= 150 gram) gekookte rijst of pasta.
 Ja
 Nee
19. Als ik pasta of rijst eet, neem ik meestal de volkorenpasta en zilvervliesrijst 
 Ja
 Nee




20. Ter vervanging of ter aanvulling op de aardappelen, rijst of pasta eet ik ook wel 
eens peulvruchten, zoals kapucijners, witte en bruine bonen, linzen of spliterwten.
 Ja
 Nee
21. Groenten eet ik 
 elke dag
 vijf of zes dagen per week
 hooguit vier dagen per week of minder vaak
22. Tussendoor of bij mijn broodmaaltijd eet ik groenten, zoals rauwkost
 ja, bijna altijd
 soms
 nee, (bijna) nooit
23. Als ik op een dag groenten eet, dan is dat bij elkaar (rauwkost en groenten op 
brood of tussendoor tellen ook mee en een schaaltje rauwkost is ongeveer 50 
gram groenten)
 ongeveer 2 opscheplepels (= 100 gram of minder)
 ongeveer 3 opscheplepels (= 150 gram)
 ongeveer 4 opscheplepels of meer (= 200 gram of meer)
24. Fruit eet ik 
 elke dag
 vijf of zes dagen per week
 hooguit vier dagen per week of minder vaak
25. Als ik fruit eet, dan is dat (één keer fruit is bijvoorbeeld een middelgrote appel 
of twee mandarijntjes, maar ook een dessertschaaltje aardbeien of bessen. Ook 
een glas ongezoet vruchtensap of een dessertschaaltje appelmoes telt  als één keer 
fruit)
 twee of meer keer fruit per dag
 één keer fruit per dag
 ik eet (bijna) nooit fruit
26. Ik drink ongezoete vruchtensappen- vers of uit een pak of fles- en dan meestal
 citrussappen zoals sinaasappelsap en grapefruitsap
 overige sappen zoals appelsap en druivensap
 ik drink (vrijwel) nooit vruchtensappen





28. Denkt u er wel eens over uw eetgewoonten te veranderen?
 Ja
 Nee
29. Denkt u dat het u lukt uw eetgewoonten te veranderen, als u dat zou willen?
 Ja
 Nee
30. Bent u van plan de komende maand uw eetgewoonten te veranderen?
 Ja
 Nee
31. Is het u in het afgelopen jaar wel eens gelukt om uw eetgewoonten te veranderen? 
 Ja
 Nee
Deze vragen gaan over het gebruik van alcohol.
Nu volgen enkele vragen over uw alcoholgebruik gedurende het afgelopen jaar. Met 
alcoholgebruik wordt bedoeld: het drinken van bier, wijn, likeur en andere gedestilleerde 
dranken.
1. Hoe vaak drinkt u alcoholhoudende drank?
 nooit (u bent klaar met de vragen over alcoholgebruik en hoeft alleen de 
laatste vraag nog te beantwoorden) 
 maandelijks of minder
 2 à 4 keer per maand
 2 of 3 keer per week
 4 of meer keer per week
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3. Hoe vaak drinkt u 6 of meer glazen per gelegenheid?
 nooit
 minder dan maandelijks
 maandelijks
 wekelijks
 dagelijks of bijna dagelijks
4. Hoe vaak heeft u in het afgelopen jaar opgemerkt dat u niet in staat was het 
drinken te stoppen nadat u was begonnen met drinken?  
 nooit
 minder dan maandelijks
 maandelijks
 wekelijks
 dagelijks of bijna dagelijks
5. Hoe vaak heeft u vanwege uw drankgebruik in het afgelopen jaar nagelaten om te 
doen wat normaal van u verwacht werd?
 nooit
 minder dan maandelijks
 maandelijks
 wekelijks
 dagelijks of bijna dagelijks
6. Hoe vaak heeft u gedurende het afgelopen jaar de behoefte gehad om ’s ochtends 
uw eerste alcoholhoudende drank te gebruiken om weer op gang te kunnen 
komen na een sessie met overmatig drankgebruik?
 nooit
 minder dan maandelijks
 maandelijks
 wekelijks
 dagelijks of bijna dagelijks
7. Hoe vaak heeft u zich gedurende het afgelopen jaar schuldig gevoeld of zelfverwijt 
gehad over uw drankgebruik?
 nooit
 minder dan maandelijks
 maandelijks
 wekelijks
 dagelijks of bijna dagelijks
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8. Hoe vaak kon u zich in het afgelopen jaar gebeurtenissen van de dag daarvoor 
niet meer herinneren vanwege uw drankgebruik?
 nooit
 minder dan maandelijks
 maandelijks
 wekelijks
 dagelijks of bijna dagelijks
9. Heeft u uzelf of iemand anders wel eens verwond als gevolg van uw drankgebruik?
 nee, nog nooit
 ja, maar niet in het afgelopen jaar
 ja, in het afgelopen jaar
10. Heeft een familielid, vriend of een dokter of een hulpverlener in de gezondheidszorg 
zijn bezorgdheid geuit over uw drankgebruik en u gesuggereerd uw drankgebruik 
te minderen?
 nee, nog nooit
 ja, maar niet in het afgelopen jaar
 ja, in het afgelopen jaar
11. Vindt u dat u teveel drinkt?
 Ja
 Nee
12. Denkt u er wel eens over om te stoppen met drinken?
 Ja
 Nee
Denkt u dat het u lukt om te stoppen met drinken, als u dat zou willen?
 Ja
 Nee
13. Bent u van plan de komende maand te stoppen met drinken?
 Ja
 Nee






Tot slot nog één laatste vraag
Graag willen we u over een aantal maanden nogmaals een aantal vragen over leefstijl 




Dit is het einde van de vragenlijst.
Hartelijk dank voor uw medewerking!
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